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Abstract 
Part A of this Ph.D. thesis describes the construction and further transformations of 4-membered 
unsaturated ring systems like cyclobutenes, 2-azetines and thiete dioxides. Part B presents new boron-
mediated strategies in Zweifel olefinations and electrocoupling reactions. 
Part A 
Chapter I 
In contrast to cyclobutanes, the unsaturated variant of this important class of four-membered rings 
have been studied much less. Due to the strained ring structure, cyclobutenes have a unique reactivity 
and are therefore more difficult to access. Thus, part of this Ph.D. thesis aims to address the synthetic 
challenge of accessing cyclobutenes and cyclobutene-containing building blocks. Using a literature 
known first step, metallated cyclobutenes 0.02 could be easily accessed and were either engaged in 
palladium-mediated cross-coupling reactions (Suzuki-Miyaura-/Negishi cross-coupling) or converted 
to the corresponding iodo-cyclobutenes 0.03. With these convenient strategies in hands, a new library 
of functionalized cyclobutenes 0.04 was elaborated (> 49 examples).  
 
Next, a similar sequence towards vinyl-cyclobutenes 0.05 was examined. After having gained access to 
vinyl-cyclobutenes 0.05, a library of alkylidenecyclobutanes (ACBs, 0.07) was created, relying on a 
[4+2]-cycloaddition with activated dienophiles (0.06). Up to five consecutive stereocenters with great 
control over diastereoselectivity were constructed. Moreover, several ACBs were tested for their 
cytotoxicity against the leukemia cell line HL60, resulting in IC50 values between 14-120 M. 
XI 
  
 
 
Another part of this thesis focuses on an air promoted oxidative ring contraction of conjugated dienes 
such as 0.08 towards cyclopropyl ketones (CPKs, 0.09). Supported by mechanistical experiments and a 
computational analysis of the reaction between molecular oxygen and vinylcyclobutenes 0.08, a 
comprehensive overview of the mechanism was sketched. With this understanding, a universal 
oxidative ring contraction of cyclobutenes 0.10 with m-CPBA as oxidant was established and expanded 
to the formation of several biologically active compounds, containing the key-cyclopropyl ketone 
moiety.   
 
Finally, an unprecedented method for the formation of stable cyclobutene-organoborates as versatile 
and storable units for Suzuki-Miyaura cross-couplings was designed. 
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Chapter II 
In contrast to the important azetidine-based -lactams, 2-azetines have been scarcely explored, 
probably due to their intrinsicly higher reactivity. However, this reactivity, if used reasonably, can be 
exploited for the access to novel functionalized 2-azetine scaffolds. The first part of this chapter 
describes the straightforward synthesis of functionalized 2-azetines by an organometallic strategy.  
 
Two steps were required to access 0.14 from the commercially available 1-Boc-3-azetidinone (0.13). 
Key metallated 0.15 were obtained by simple treatment of 0.14 with two equivalents of s-BuLi and 
trapped with different electrophiles, coupled via palladium mediated Suzuki-Miyaura cross-coupling 
with various aromatic halides or engaged in a catalyst free Zweifel olefination. In summary, this led to 
a new library of more than 50 disubstituted 2-azetines (0.16-0.18). 
Next, a regiodivergent and stereoselective [4+2]-cycloaddition of vinyl-azetines 0.19/0.22 with suitable 
dienophiles 0.20 towards unprecedented fused alkylideneazetidines 0.21/0.23 was accomplished. In a 
high yielding one-pot process, 26 examples were isolated in great diastereoselectivity, expanding the 
class of known alkylideneazetidines.  
XIII 
  
 
 
Following the success of those cycloadditions, a straightforward access to isoxazoline azetidines was 
realized, employing (2+3)-cycloadditions. Disubstituted azetines 0.18 were converted to the 
corresponding isoxazoline azetidines 0.25 through stereoselective and regiocontrolled (2+3)-
cycloaddition with in-situ generated nitrile oxides 0.24. 
 
In the last part of this section, more stabilized 2-azetines were designed. The high reactivity of 2-
azetinyllithium species was tempered by derivatizing it into the corresponding organoboronates 0.26. 
These were stored for several months under different conditions and finally tested in Suzuki-Miyaura 
cross-coupling reactions. It was proven that they are most stable when kept in solution at -20 °C or 
neat at room temperature under inert atmosphere.   
 
Chapter III 
In this chapter, another class of 4-membered strained heterocycles was investigated, namely thiete 
dioxides. By using a literature known procedure based on organometallic reagents, monosubstituted 
thiete dioxides 0.27 were synthesized and utilized in the formation of fused, sophisticated isoxazoline 
thietanes. Via a (2+3)-cycloaddition strategy with nitrile oxides 0.24, a new library of elaborated 
architectures 0.28 with excellent regio- and stereoselectivity was assembled in up to 97% yield.  
 
XIV 
  
 
With the objective of developing an access to thiete-based atropisomers, C-H activation strategies – 
previously described in the group – were used. To reach this goal, the manipulation of the strength of 
-donor-acceptor interactions between the residues of disubstituted thiete dioxides 0.31 seemed to 
be inevitable. Therefore, different suitable aromatic linkers were introduced by C-H activation. The 
corresponding crystal structures of promising thiete dioxides 0.32/0.33 revealed the presence of axial 
chirality in the solid state at room temperature.  
 
Preliminary results on the behaviour of solvated functionalized thiete dioxides 0.31 showed, however, 
that the interactions responsible for atropisomerism are not strong enough to maintain chirality at 
ambient temperature or even at -50 °C.  
Finally, a C-H activation mediated macrocyclization of thiete dioxides is described. In this approach,  
C-H activation with similar congeners of mono-substituted thiete dioxides 0.34 resulted in 
unprecedented macrocycles 0.35 consisting of 3 thiete dioxide units. 
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Part B 
Chapter I 
While the Zweifel olefination is a well-developed and explored reaction, however, most of the 
literature-known procedures involve the use of expensive boron pinacol esters or have a lack of 
practical applicability. To overcome these issues, inexpensive boron alkoxides and different 
organometallic reagents were used in a convergent sequence.  A stoichiometrically controlled 
generation of bisorganoborinates 0.38 through a consecutive reaction of two different organometallic 
species with tri(n-butyl) borate led to a versatile and easily applicable new method in Zweifel 
olefinations.  
 
Chapter II 
In the last chapter of this Ph.D. thesis, the previously described Zweifel reaction of Chapter I (Part B) is 
revisited through an electrochemical approach. For this purpose, a new sequence towards mixed 
tetraorganoborates was engineered. Starting from commercially available potassium 
alkenyltrifluoroborates 0.40 followed by a treatment with various (hetero)aryl Grignard reagents 0.41, 
air and water stable potassium alkenyl(hetero)triarylborates 0.42 were obtained.  
 
After an electrochemical oxidation in acetonitrile, the coupled products 0.43 were isolated in 
moderate to good yields over two steps. It should be noted that no transition metal catalyst or any 
other additive is required in this unprecedented electrochemical coupling reaction. 
  
XVI 
  
 
  
XVII 
  
 
Table of Content  
Acknowledgments .................................................................................................................................. III 
Glossary ................................................................................................................................................. VII 
Abstract ................................................................................................................................................... X 
Table of Content .................................................................................................................................. XVII 
 
Part A 
 –  
Construction and Transformation of Unsaturated Four-Membered Carbo- and Heterocycles 
Chapter I - Cyclobutenes 
1 Introduction ................................................................................................................................... 23 
1.1 Synthesis of Cyclobutenes ..................................................................................................... 23 
1.2 Synthesis of Iodo-cyclobutenes ............................................................................................. 27 
1.3 Suzuki-Miyaura and Negishi Cross-Coupling Reactions ........................................................ 29 
1.4 Alkylidenecyclobutanes ......................................................................................................... 30 
1.5 [4+2]-Cycloadditions of Cyclobutenes ................................................................................... 32 
1.6 Ring Contraction Reactions ................................................................................................... 34 
2 Results ........................................................................................................................................... 36 
2.1 Unsaturated Four-Membered Rings: Efficient Strategies for the Construction of Cyclobutenes 
and Alkylidenecyclobutanes .............................................................................................................. 36 
2.2 Stereoselective Sequence toward Biologically Active Fused Alkylidenecyclobutanes ......... 48 
2.3 Oxidative Ring Contraction of Cyclobutenes: General Approach to Cyclopropylketones 
including Mechanistic Insights .......................................................................................................... 53 
3 Outlook .......................................................................................................................................... 71 
 Chapter II - Azetines 
4 Introduction ................................................................................................................................... 73 
4.1 Synthesis of 2-Azetines .......................................................................................................... 74 
4.2 Alkylideneazetidines .............................................................................................................. 76 
XVIII 
  
 
4.3 (2+3)-Cycloadditions of 2-Azetines ....................................................................................... 77 
5 Results ........................................................................................................................................... 78 
5.1 Methods for the Synthesis of Substituted Azetines .............................................................. 78 
5.2 One-Pot Preparation of Stable Organoboronate Reagents for the Functionalization of 
Unsaturated Four- and Five-Membered Carbo- and Heterocycles ................................................... 83 
5.3 Regiodivergent Stereoselective Access to Fused Alkylideneazetidines ................................ 96 
6 Outlook ........................................................................................................................................ 107 
 Chapter III – Thiete Dioxides 
7 Introduction ................................................................................................................................. 109 
7.1 Synthesis of Thiete Dioxides ................................................................................................ 110 
7.2 C-H Activation of Thiete Dioxides ........................................................................................ 111 
7.3 (2+3)-Cycloadditions of Thiete Dioxides .............................................................................. 112 
7.4 Atropisomerism ................................................................................................................... 113 
7.5 Spherands - Macrocyclic Receptors .................................................................................... 115 
8 Results ......................................................................................................................................... 117 
8.1 Chemodivergent and Stereoselective Access to Fused Isoxazoline Azetidines and Thietanes 
through [3+2]-Cycloadditions .......................................................................................................... 117 
8.2 Disubstituted Thiete Dioxides – Donor/Acceptor- Interactions towards Axial Chirality ..... 123 
8.3 Macrocyclic Thiete Dioxides ................................................................................................ 132 
9 Outlook ........................................................................................................................................ 135 
Chapter IV – Experimental Part 
10 General Consideration ............................................................................................................. 137 
11 Experimental for Chapter I ...................................................................................................... 139 
11.1 Unsaturated Four-Membered Rings: Efficient Strategies for the Construction of Cyclobutenes 
and Alkylidenecyclobutanes ............................................................................................................ 139 
11.2 Stereoselective Sequence toward Biologically Active Fused Alkylidenecyclobutanes ....... 147 
11.3 Oxidative Ring Contraction of Cyclobutenes: General Approach to Cyclopropylketones 
including Mechanistic Insights ........................................................................................................ 154 
12 Experimental for Chapter II ..................................................................................................... 156 
XIX 
  
 
12.1 Methods for the Synthesis of Substituted Azetines ............................................................ 156 
12.2 One-Pot Preparation of Stable Organoboronate Reagents for the Functionalization of 
Unsaturated Four- and Five-Membered Carbo- and Heterocycles ................................................. 165 
12.3 Chemodivergent and Stereoselective Access to Fused Isoxazoline Azetidines and Thietanes 
through [3+2]-Cycloadditions .......................................................................................................... 168 
13 Experimental for Chapter III .................................................................................................... 171 
13.1 Chemodivergent and Stereoselective Access to Fused Isoxazoline Azetidines and Thietanes 
through [3+2]-Cycloadditions .......................................................................................................... 171 
13.2 Disubstituted Thiete Dioxides – Donor/Acceptor- Interactions towards Axial Chirality ..... 176 
13.3 Macrocyclic Thiete Dioxides ................................................................................................ 190 
 
 Part B 
 –  
New Methods in Boron mediated Olefinations 
Chapter I – Zweifel Olefinations 
14 Introduction ............................................................................................................................. 209 
14.1 Zweifel Olefinations ............................................................................................................. 210 
15 Results ..................................................................................................................................... 212 
15.1 Single-Pot Access to Bisorganoborinates: Applications in Zweifel Olefination ................... 212 
16 Outlook .................................................................................................................................... 218 
Chapter II – Tetraorganoborates 
17 Introduction ............................................................................................................................. 220 
17.1 Synthesis of Tetraorganoborates ........................................................................................ 220 
17.2 Electrochemical Transformation of Tetraorganoborates .................................................... 223 
18 Results ..................................................................................................................................... 225 
18.1 Electrochemical Formation of Functionalized Alkenes using Tetraorganoborates ............ 225 
19 Outlook .................................................................................................................................... 233 
 
XX 
  
 
Chapter III – Experimental Part 
20 General Considerations ........................................................................................................... 235 
21 Experimental for Chapter I ...................................................................................................... 235 
21.1 Single-Pot Access to Bisorganoborinates: Applications in Zweifel Olefination ................... 235 
22 Experimental for Chapter II ..................................................................................................... 241 
22.1 Electrochemical Formation of Functionalized Alkenes using Tetraorganoborates ............ 241 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part A 
- 
Construction and Transformation of 
Unsaturated Four-Membered Carbo- and 
Heterocycles 
  
22 
 Part A - Chapter I 
 
 
 
 
 
 
 
 
 
Chapter I 
 
 
Cyclobutenes 
  
23 
 Part A - Chapter I 
 
1 Introduction 
Cyclobutenes are four-membered carbocyclic architectures containing a double bond within the ring. 
The inherent ring strain is a key characteristic feature of this compound class. Due to that peculiar 
framework, the cyclobutenyl moiety is barely found in natural compounds compared to the naturally 
occurring cyclobutanes (Figure 1). Nevertheless, several compounds have been reported. For instance, 
the sesquiterpene taynudol (1.01), was isolated from the essential oils of the liverworts Mylia taylorii 
and 4,5-dehydro-5-deoxyarmillol (1.02) is a constituent of the inky cap of the fungus Coprinus 
cinereus.1  
 
Figure 1: The cyclobutene moiety (highlighted in blue) in different natural compounds. 
Further examples containing a cyclobutene pattern are capillosanol (1.03), which possesses a unique 
bicyclo[7.2.0]undecane moiety and was isolated from the soft corals Sinularia capillosa, and finally, 
neofavelanone (1.04), extracted and characterized from the bark of Cnidoscolus phyllacanthus,  shows 
potential activity against the P-388 murine leukaemia cell line.2 
These rather complex cyclobutene-containing representatives of natural compounds clearly show the 
need for dependable and versatile synthetic methods toward their synthesis.  
1.1 Synthesis of Cyclobutenes 
Inheriting a strain-driven reactivity, cyclobutenes have served as versatile synthetic intermediates, 
whereupon their synthesis remain difficult.3 The most common strategies for gaining access to the 
core ring are [2+2]-cycloaddition reactions, either photochemically or through metal-catalysis.4 An 
 
1 S. H. Reuß; C.-L. Wu; H. Muhle; W. A. König, Phytochemistry 2004, 65, 2277; G. R. Pettit; Y. Meng; R. K. Pettit; 
D. L. Herald; F. Hogan; Z. A. Cichacz, Bioorg. Med. Chem. 2010, 18, 4879. 
2 S.-Y. Cheng; K.-J. Huang; S.-K. Wang; Z.-H. Wen; C.-H. Hsu; C.-F. Dai; C.-Y. Duh, Org. Lett. 2009, 11, 4830; Y. Endo; 
T. Ohta; S. Nozoe, Tetrahedron Lett. 1992, 33, 353.   
3 J. C. Namyslo; D. E. Kaufmann, Chem. Rev. 2003, 103, 1485. 
4 Y. Xu; M. L. Conner; M. K. Brown, Angew. Chem. Int. Ed. 2015, 54, 11918; T. Kang; S. Ge; L. Lin; X. Liu; X. Feng, 
Angew. Chem. Int. Ed. 2016, 55, 5541; B. M. Trost; M. Yanai; K. Hoogsteen, J. Am. Chem. Soc. 1993, 115, 5294. 
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example of a metal catalyzed [2+2]-cycloaddition was published by the group of Echavarren.5 Based 
on an intermolecular gold-(I)-catalyzed [2+2]-cycloaddition of alkenes and terminal alkynes, the 
enantioselective total synthesis of rumphellaone A (1.08) was demonstrated (Scheme 1). A Josiphos 
digold (I) complex served as adequate catalytic system to access cyclobutene 1.07 in high yield and 
good enantioselectivity. With further 8 steps that have been previously described by the group of 
Echavarren, rumphellaone A (1.08) is finally obtained.6 
 
Scheme 1: Intermolecular gold-(I)-catalyzed [2+2] cycloaddition towards rumphellaone A. 
A more recent example of an intermolecular metal-catalyzed [2+2]-cycloaddition was published by the 
group of Yoshikai in 2019.7 They described an original intermolecular [2+2]-cycloaddition between an 
alkyne 1.09 and an allene 1.10 using a cobalt(I)/bisphospine catalyst (Scheme 2). In this work, with the 
use of allenes (1.10) as cycloaddition partner, 3-alkylidenecyclobutene were accessed in good yields 
and high regioselectivities. A regioselective oxidative cyclization with the less substituted double bond 
of the allene 1.10 and the alkyne 1.09 with CoI was proposed as a reaction pathway. The 
alkylidenecobaltacyclopentene intermediate further undergoes a reductive elimination to afford the 
alkylidenecyclobutene adduct 1.11. 
 
Scheme 2: Cobalt catalyzed [2+2]-cycloaddition towards the synthesis of alkylidenecyclobutenes. 
In 1964 Corey and Streith investigated the internal photoaddition reaction of 2-pyrone (1.12), paving 
the way for further studies, in which the unstable and strained bicyclic lactone 1.13 was utilized 
(Scheme 3).8 One of the central arguments that initiated further investigations was the almost 
 
5 C. García-Morales; B. Ranieri; I. Escofet; L. López-Suarez; C. Obradors; A. I. Konovalov; A. M. Echavarren, J. Am. 
Chem. Soc. 2017, 139, 13628. 
6 B. Ranieri; C. Obradors; M. Mato; A. M. Echavarren, Org. Lett. 2016, 18, 1614.   
7 W. Ding; N. Yoshikai, Angew. Chem. Int. Ed. 2019, 58, 2500. 
8 E. J. Corey; J. Streith, J. Am. Chem. Soc. 1964, 86, 950. 
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quantitative photochemical isomerization of readily available 1.12 to the now storable 
cyclobutene 1.13.9 
 
Scheme 3: Internal photoaddition of 2-pyrone (1.12) towards the bicyclic cyclobutene 1.13. 
Especially the group of Maulide used this sensitive intermediate 1.13 as a starting building block in 
their research program.10 Employing different nucleophiles, new cyclobutene containing molecules 
(1.14) were accessed and utilized in further transformations, as in the total synthesis of (-)-
leodomycin D (1.22) (Scheme 4).11  
 
Scheme 4: Transformation of the bicyclic cyclobutene 1.13 and further synthetic steps based on this 
transformation. 
 
9 F. Frébault; M. Luparia; M. T. Oliveira; R. Goddard; N. Maulide, Angew. Chem. Int. Ed. 2010, 49, 5672. 
10 A. Misale; S. Niyomchon; N. Maulide, Acc. Chem. Res. 2016, 49, 2444. 
11 F. Frébault; M. Luparia; M. T. Oliveira; R. Goddard; N. Maulide, Angew. Chem. Int. Ed. 2010, 49, 5672; C. Souris; 
F. Frébault; A. Patel; D. Audisio; K.N. Houk; N. Maulide, Org. Lett. 2013, 15, 3242; C. Souris; M. Luparia; F. Frébault; 
D. Audisio; C.Farès; R. Goddard; N. Maulide, Chem. Eur. J. 2013, 19, 6566; C. Souris; A. Misale; Y. Chen; M. Luparia; 
N. Maulide, Org. Lett. 2015, 17, 4486. 
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Another elegant method for the preparation of cyclobutenes is the enlargement of existing cyclic 
systems.12 As described by the group of Fürstner, a platinum mediated rearrangement of 
methylenecyclopropanes can lead to mono- or disubstituted cyclobutenes (Scheme 5).13 
 
Scheme 5: Platinum mediated ring enlargement of methylenecyclopropanes towards cyclobutenes. 
In 1984, the group of Negishi employed a carbometallation strategy that allows not only the synthesis 
of a variety of functionalized cyclobutenes (1.31/1.35), but also represents the cornerstone for the 
synthesis of cyclobutene building blocks in this Ph.D. thesis (Scheme 6).14 The intermediary 
cyclobutene-metal species 1.34 was therefore utilized as a new starting point for cyclobutene 
functionalization. 
 
Scheme 6: Synthesis of substituted cyclobutenes by carbometalation. 
 
12 C.-W. Li; K. Pati; G.-Y. Lin; S. M. A. Sohel; H.-H. Hung; R.-S. Liu, Angew. Chem. Int. Ed. 2010, 49, 9891; R. Liu; M. 
Zhang; G. Winston-McPherson; W. Tang, Chem. Commun. 2013, 49, 4376; A. Masarwa; A. Fürstner; I. Marek, 
Chem. Commun. 2009, 38, 5760; H. Xu; W. Zhang; D. Shu; J. B. Werness; W. Tang, Angew. Chem. Int. Ed. 2008, 
47, 8933. 
13 A. Fürstner; C. Aïssa, J. Am. Chem. Soc. 2006, 128, 6306. 
14 L. D. Boardman; V. Bagheri; H. Sawada; E.-i. Negishi, J. Am. Chem. Soc. 1984, 106, 6105. 
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1.2 Synthesis of Iodo-cyclobutenes 
As described in the previous chapter, many reports focus on the formation of the cyclobutene core 
rather than using it, as a starting base of functionalization. Iodo-cyclobutenes are a promising source 
for new cyclobutene-functionalization and are already well known. Additionally, their synthesis can be 
found in several published work.15 Nevertheless, most of these reports lack of generality and simplicity, 
as many steps for their synthesis are necessary and/or too complex precursors are essential, 
preventing access to versatile building blocks. Inspirational is the work from Negishi between 1983 to 
1996, as it describes a way of getting access to metallated cyclobutenes by using organometallic 
chemistry.16  
 
Scheme 7: Synthesis of iodo-cyclobutenes by two different carbometalation pathways.  
In both sequences (Scheme 7), an initial lithiation on the most acidic C-H position of the bromo-alkyne 
1.32 occurs, followed by a syn-carbometalation that furnishes the metallated cyclobutenes 1.34/1.37. 
The corresponding iodo-cyclobutenes 1.36/1.38 were obtained after iodolysis.  
Concerning the use of a mixture of trimethylaluminium (1.40) and zirconocene dichloride (1.39), more 
details are given in Scheme 8.17 Starting with a transmetalation of one methyl group of the 
trimethylaluminium (1.40)  to the zirconium, followed by a chloride abstraction of the aluminium, the 
intermediary zwitterionic species 1.44 is formed. The alkyne coordinates to the cationic zirconium, 
 
15 H. Oda; K. Oshima; H. Nozaki, Chem. Lett. 1985, 53; K. Kasai; Y. Liu; R. Hara; T. Takahashi, Chem. Commun. 1998, 
18, 1989; K. Villeneuve; N. Riddell; R. W. Jordan; G. C. Tsui; W. Tam, Org. Lett. 2004, 6, 4543; E. B. Averina; R. R. 
Karimov; K. N. Sedenkova; Y. K. Grishin; T. S. Kuznetzova; N. S. Zefirov, Tetrahedron 2006, 62, 8814; A. Fürstner; 
A. Schlecker; C. W. Lehmann, Chem. Commun. 2007, 41, 4277; Y.-P. Wang; R. L. Danheiser, Tetrahedron Lett. 
2011, 52, 2111; Y. Li; X. Liu; H. Jiang; B. Liu; Z. Chen; P. Zhou, Angew. Chem. Int. Ed. 2011, 50, 6341; J. He; M. L. 
Snapper, Tetrahedron 2013, 69, 7831; B. Alcaide; P. Almendros; C. Lázaro-Milla, Adv. Synth. Catal. 2017, 359, 
2630; D. Kossler; F. G. Perrin; A. A. Suleymanov; G. Kiefer; R. Scopelliti; K. Severin; N. Cramer, Angew. Chem. Int. 
Ed. 2017, 56, 11490. 
16 E.-i. Negishi; L. D. Boardman; J. M. Tour; H. Sawada; C. L. Rand, J. Am. Chem. Soc. 1983, 105, 6344; L. D. 
Boardman; V. Bagheri; H. Sawada; E.-i. Negishi, J. Am. Chem. Soc. 1984, 106, 6105; E.-i. Negishi; L. D. Boardman; 
H. Sawada; V. Ragheri; A. T. Stoll; J. M. Tour; C. L. Rand, J. Am. Chem. Soc. 1988, 110, 5383; E.-i. Negishi; F. Liu; D. 
Choueiry; Mohamud; A. Silveira; M. Reeves, J. Org. Chem. 1996, 61, 8325; F. Liu; E.-i. Negishi, Tetrahedron Lett. 
1997, 38, 1149.   
17 S. Xu; E.-i. Negishi, Acc. Chem. Res. 2016, 49, 2158. 
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upon which a migratory insertion of the methyl group (bound to the zirconium) takes place. At last, a 
reversible transmetalation to aluminium occurs, forming the final syn-addition product 1.46.   
 
Scheme 8: Proposed mechanism of the carboalumination with zirconocene dichloride.17  
As proposed by Negishi, the carbometalation of metallated 4-halobut-1-ynes (1.47) leads to a gem-
bismetallated species 1.48 which can then undergo two different pathways for the ring closing step 
(Scheme 9). The two possible ways are differentiated by a σ- or π-type cyclization process, which after 
iodolysis of the metallated cyclobutene intermediate, give rise to two different regioisomers 
(1.50/1.54). 
 
Scheme 9: Proposed pathways for the carboalumination of 4-halobut-1-ynes to iodo-cyclobutenes. 
The σ-type pathway describes a SN2-type mechanism, where the electrons of the sigma-bond between 
carbon and lithium attack the carbon connected to the leaving halogen towards structure 1.49. In 
contrast, the π-type attack of the double bond leads intermediary to the cationic cyclopropane species 
1.51, whereupon two new routes can be described. In path a), the bond connected to the R-group 
undergoes a Wagner-Meerwein rearrangement, giving intermediate 1.52 and ultimately providing the 
same regioisomer 1.50 as for the σ-type mechanism. Path b) describes the other possibility of a 
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Wagner-Meerwein rearrangement and thus, after elimination of LiBr and iodolysis, leads to the 
formation of regioisomer 1.54. Negishi has shown that both pathways are possible. However, the 
application of such conditions in this thesis only led to one regioisomer 1.54, additionally confirmed 
by X-ray crystallographic data. With this robust and simple method in hands, the iodo-cyclobutene 
building block, as well as the metallated cyclobutene moiety have been extensively used and will be 
described thereafter.  
1.3 Suzuki-Miyaura and Negishi Cross-Coupling Reactions 
Over last decades, several cross-coupling reactions have been reported. It is remarkable however, that 
the first cross coupling reaction was already demonstrated in 1869 by Glaser, where the stoichiometric 
use of copper for the homocoupling of metal acetylides was reported.18 Since that early beginning, 
many more transition-metal-mediated cross-couplings have emerged, namely Stille, Heck, 
Sonogashira, Hiyama, Kumada and the two herein relevant methods, the Suzuki-Miyaura and Negishi 
cross-coupling reaction.19  
 
Scheme 10: General mechanism of palladium mediated cross-coupling.  
In most cases palladium complexes are used as pre-catalysts. The robustness of these systems in 
combination with high functional group tolerance made these protocols one of the cornerstones in 
creating new C-C bonds and was therefore rewarded with the Nobel Prize in 2010.20  The general 
accepted mechanism of a palladium mediated cross-coupling is depicted in Scheme 10. It consists of 
 
18 C. Glaser, Ber. Dtsch. Chem. Ges. 1869, 2, 422. 
19 D. Milstein; J. K. Stille, J. Am. Chem. Soc. 1978, 100, 3636; R. F. Heck; J. P. Nolley, J. Org. Chem. 1972, 37, 2320; 
K. Sonogashira; Y. Tohda; N. Hagihara, Tetrahedron Lett. 1975, 16, 4467; Y. Hatanaka; T. Hiyama, J. Org. Chem. 
1988, 53, 918; K. Tamao; K. Sumitani; M. Kumada, J. Am. Chem. Soc. 1972, 94, 4374; N. Miyaura; A. Suzuki, J. 
Chem. Soc., Chem. Commun. 1979, 19, 866; N. Miyaura; K. Yamada; A. Suzuki, Tetrahedron Lett. 1979, 20, 3437; 
A. O. King; N. Okukado; E.-i. Negishi, J. Chem. Soc., Chem. Commun. 1977, 19, 683. 
20 E.-i. Negishi, Angew. Chem. Int. Ed.  2011, 50, 6738; A. Suzuki, Angew. Chem. Int. Ed. 2011, 50, 6722. 
30 
 Part A - Chapter I 
 
three steps: oxidative addition, transmetalation and reductive elimination. For the Suzuki-Miyaura 
coupling, an organo-boron compound (1.61) and an organic halide (1.55) are combined in the presence 
of a base (Scheme 11). As a transition metal in the catalytic cycle, palladium and nickel are mainly 
described in the literature.21  
 
Scheme 11: General Suzuki-Miyaura cross coupling with palladium- or nickel-complexes.  
In the Negishi type coupling, organozinc compounds are used (Scheme 12). The reaction takes place 
between organic halides or triflates and organozinc compounds in the presence of palladium/nickel 
catalysts.22  
 
Scheme 12: General Negishi cross coupling with palladium- or nickel-complexes.  
As both cross-couplings show great advantages in terms of versatility and functional group tolerance, 
they were utilized in the sophistication of the cyclobutene ring, which can be found in Chapter I 
“Results”. 
1.4 Alkylidenecyclobutanes 
Alkylidenecyclobutanes have historically been in discussion since 1896, when Gustavson first 
debrominated erythrityl bromide with zinc and identified spiropentane (1.65) (“vinyltrimethylene” 
called to that time) from the product mixture (Scheme 13).23 Further studies revealed that an 
alkylidenecyclobutane was among the products in this mixture and methylenecyclobutane (1.66) could 
be identified for the first time.24   
 
Scheme 13: Compound mixture of the debromination of erythrityl bromide with zinc.  
 
21F.-S. Han, Chem. Soc. Rev. 2013, 42, 5270. 
22 S. Baba; E.-i. Negishi, J. Am. Chem. Soc.1976, 98, 6729. 
23 G. Gustavson, J. prakt. Chem. 1896, 54 (2), 97; G. Gustavson, J. prakt. Chem. 1896, 54 (1), 104. 
24 Philipov, J. prakt. Chem. 1916, 93 (2), 163; M. J. Murray, E. H. Stevenson, J. Am. Chem. Soc. 1944, 66, 812. 
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Despite this long history, alkylidenecyclobutanes have attracted much less attention than their 
homologous alkylidenecyclopropanes, mainly due to the lower reactivity of the cyclobutane core and 
the difficulty for their synthesis.25 Nevertheless, the methylenecyclobutane moiety can be found in 
several natural compounds (Figure 2).  
 
Figure 2: Natural occurring alkylidenecyclobutanes.   
For instance, the cytotoxin providencin (1.68) which was isolated from the Caribbean gorgonian 
octocoral Pseudopterogorgia kallos, and the female sex pheromone of the pink hibiscus mealylbug 
namely maconelliol (1.69) was isolated from Maconellicoccus hirsutus.26 The antibacterial illudosin 
(1.70) was isolated from the fungus Omphalotus olearius and belongs to the fomannosane-type 
sesquiterpene family.27 Another sesquiterpene, the repraesentin A (1.71 a protoilludane) was 
extracted from the fungus Lactarius repraesentaneus and was found to promote plant growth.28 The 
particular interest in the protoilludane family has been expressed in several total syntheses and is of 
primary importance in this work.29  
In general, alkylidenecyclobutanes are mainly formed by allene-alkene [2+2]-cycloaddition reactions 
and metal-catalyzed cyclizations.25 Starting from preformed four-membered ring compounds, the 
Wittig olefination of cyclobutanones 1.72 is one of the most versatile and efficient methods for the 
construction of alkylidenecyclobutanes 1.74 (Scheme 14).25  
 
 
25 A. Brandi; S. Cicchi; F. M. Cordero; A. Goti, Chem. Rev. 2014, 114, 7317. 
26 J. Marrero; A. D. Rodríguez; P. Baran; R. G. Raptis, Org. Lett. 2003, 5, 2551; A. Zhang; D. Amalin; S. Shirali; M. 
S. Serrano; R. A. Franqui; J. E. Oliver; J. A. Klun; J. R. Aldrich; D. E. Meyerdirk; S. L. Lapointe, Proc. Natl. Acad. Sci. 
U.S.A. 2004, 101, 9601. 
27 A. Arnone; R. Cardillo; G. Nasini; O. V. de Pava, J. Chem. Soc. Perkin. Trans. 1 1991, 1787; T. C. McMorris; R. 
Lira; P. K. Gantzel; M. J. Kelner; R. Dawe, J. Nat. Prod. 2000, 63, 1557. 
28 M. Hirota; Y. Shimizu; T. Kamo; H. Makabe; H. Shibata, Biosci. Biotechnol. Biochem. 2003, 67, 1597. 
29 M. Kögl; L. Brecker; R. Warrass; J. Mulzer, Angew. Chem. Int. Ed. 2007, 46, 9320; P. Siengalewicz; J. Mulzer; U. 
Rinner, Eur. J. Org. Chem. 2011, 35, 7041. 
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Scheme 14: Wittig olefination of cyclobutanones towards alkylidenecyclobutanes.  
Building on the previously described methodology (“Synthesis of Iodo-cyclobutenes”) on iodo-
cyclobutenes, the group of Didier engineered a sequence for the synthesis of alkylidenecyclobutanes, 
combining a boron-homologation and boron-allylation (Scheme 15).30 
 
Scheme 15: Boron-homologation/boron-allylation sequence towards alkylidenecyclobutanes.  
The objective was however to make this sequence more versatile and will be described in the next 
section of this thesis.  
1.5 [4+2]-Cycloadditions of Cyclobutenes 
Kurt Alder and Otto Diels described a concerted pericyclic [4+2]-cycloaddition for the first time in 1928, 
later called the Diels-Alder reaction.31 Forming six-membered rings, the Diels-Alder cycloaddition of a 
conjugated diene with a substituted dienophile is particularly useful for synthetic chemists as it 
provides the cycloadduct regio- and stereoselectively. In this type of cycloaddition, no intermediates 
are usually observed, as the reaction occurs via a single, cyclic transition state and therefore serves as 
an excellent example for a concerted pericyclic reaction (Scheme 16).32 In that cyclic transition state, 
the frontier p-orbitals of the diene 1.77 (HOMO - highest occupied molecular orbital) and of the alkene 
1.78 (LUMO - lowest unoccupied molecular orbital) are overlapping and finally forming two new 
carbon-carbon bonds. However, the reaction shown in Scheme 16 can only be regarded as schematic 
since the LUMO of the inactivated ethene (1.78) is too high in energy for the HOMO of 1,3-butadiene 
(1.77) to allow for reactivity. Only harsh reaction conditions would lead to the desired cycloadduct.33  
 
30 M. Eisold; D. Didier, Angew. Chem. Int. Ed. 2015, 54, 15884. 
31 O. Diels; K. Alder, Liebigs Ann. Chem. 1928, 460, 98; O. Diels; K. Alder, Ber. dtsch. Chem. Ges. A/B 1929, 62, 554. 
32 M. J. S. Dewar; S. Olivella; J. J. P. Stewart, J. Am. Chem. Soc. 1986, 108, 5771. 
33 L. M. Joshel; L. W. Butz, J. Am. Chem. Soc.1941, 63, 3350. 
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Scheme 16: [4+2]-cycloaddition of a diene and a dienophile illustrated with the involved p-orbitals (HOMO of 
the diene and LUMO of the dienophile). 
Although countless applications exist in literature, the [4+2]-cycloaddition of cyclobutenes was not 
given much attention, as only the use of the cyclobutene ring as a dienophile was reported by 
Danyshefsky.34 In contrast to cyclobutenes as dienophiles, Bäckvall’s group reported the use of 
vinylcyclobutenes 1.80 in [4+2]-cycloaddition strategies (Scheme 17).35 An activated dienophile, maleic 
anhydride (1.81), allowed access to fused alkylidenecyclobutanes 1.82. 
 
Scheme 17: [4+2]-cycloaddition of a substituted vinylcyclobutene 1.80 with maleic anhydride (1.82). 
With this example in mind, a synthesis towards unprecedented fused 5/6/4-ring systems containing 
an alkylidenecyclobutane moiety was reachable.  Worthy of note is the similarity with the 5/6/4-fused-
ring system of protoilludanes, especially the 6-protoilludane (1.83), which was a target in our research 
program (Figure 3).36 
 
Figure 3: One representative of the protoilludane family: 6-protoilludane.   
  
 
34 A. G. Ross; X. Li; S. J. Danishefsky, J. Am. Chem. Soc. 2012, 134, 16080; A. G. Ross; S. D. Townsend; S. J. 
DAnishefsky, J. Org. Chem. 2013, 78, 204. 
35 Y. Qiu; B. Yang; C. Zhu; J.-E. Bäckvall, Angew. Chem. Int. Ed. 2016, 55, 6520. 
36 W. Oppolzer; A. Nakao, Tetrahedron Lett. 1986, 27, 5471. 
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1.6 Ring Contraction Reactions 
Ring contraction reactions can be generally classified in three different categories based on their 
mechanism: anionic, cationic and carbenoid (Scheme 18).37  
 
Scheme 18: Three different types of ring contraction reactions classified by their inherent mechanism.  
In the anionic reaction pathway (Path A), a negative charge on a cyclic ring system (1.84) attacks a 
suitable leaving group resulting in a ring contraction (1.86). The cationic type (Path B) consists of a ring 
contraction triggered by an alkyl shift in conjunction with a carbonyl formation (1.88). The last one 
(Path C) contains an intermediate carbene or carbenoid 1.89 that rearranges and leads to a ring 
contraction. The Favorskii rearrangement on cyclic systems is a typical example of an anionic ring 
contraction and served as a successful tool in several natural product syntheses (Scheme 19).38 In the 
total synthesis of (+)-epoxydictymene (1.93), (-)-iridomyrmecin (1.94) and (+)-acoradiene (1.95), the 
anionic ring contraction of dibrominated (+)-pulegone (1.91) in the presence of a base is the key step. 
 
37 Ring Contraction Reactions in the Total Synthesis of Biologically Active Natural Products, L. F. Silva in 
Stereoselective Synthesis of Drugs and Natural Products (Eds.: V. Andrushko, N. Andrushko), John Wiley & Sons, 
Inc, Hoboken, NJ, USA, 2013, 1-20; L. F. Silva, Tetrahedron 2002, 58, 9137. 
38 A. E. Faworskii, J. Russ. Phys. Chem. 1894, 26, 559; T. F. Jamison; S. Shambayati; W. E. Crowe; S. L. Schreiber, J. 
Am. Chem. Soc. 1997, 119, 4353; J. Wolinsky; T. Gibson; D. Chan; H. Wolf, Tetrahedron 1965, 21, 1247; S. 
Kurosawa; M. Bando; K. Mori, Eur. J. Org. Chem. 2001, 23, 4395. 
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Scheme 19: The Favorskii rearrangement, applied in total syntheses of natural products.   
In 1959, Criegee and Noll described the ring contraction of a cyclobutane epoxide 1.96 in the presence 
of sulfuric acid (Scheme 20).39 They obtained a mixture of two different compounds from which a 
cyclopropyl ketone (1.98) was identified. Part of this Ph.D. thesis was devoted to the selective ring 
contraction of cyclobutenes by an oxidative ring contraction, as this rather unexplored reaction can 
give access to the pharmacologically important cyclopropyl ketone scaffold.40  
 
Scheme 20: Early example of an oxidative ring contraction of cyclobutane-epoxides. 
 
 
39 R. Criegee; N. Noll, Liebigs Ann. Chem. 1959, 627, 1; J. M. Conia, Angew. Chem. 1968, 80, 578. 
40 For some bioactive compounds see: J. X. Qiao; S. R. King; K. He; P. C. Wong; A. R. Rendina; J. M. Luettgen; B. 
Xin; R. M. Knabb; R. R. Wexler; P. Y. S. Lam, Bioorg. Med. Chem. Lett. 2009, 19, 462; C. E. Wainwright; J. S. Elborn; 
B. W. Ramsey; G. Marigowda; X. Huang; M. Cipolli; C. Colombo; J. C. Davies; K. De-Boeck; P. A. Flume; M. W. 
Konstan; S. A. McColley; K. McCoy; E. F. McKone; A. Munck; F. Ratjen; S. M. Rowe; D. Waltz; M. P. Boyle, N. Engl. 
J. Med. 2015, 373, 220; U. J. Ries; H. W. M. Priepke; N. H. Hauel; S. Handschuh; G. Mihm; J. M. Stassen; W. 
Wienen; H. Nar, Bioorg. Med. Chem. Lett. 2003, 13, 2297. 
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2  Results 
2.1 Unsaturated Four-Membered Rings: Efficient Strategies for the Construction of 
Cyclobutenes and Alkylidenecyclobutanes 
 
Reprinted with permission from A. N. Baumann, M. Eisold, G. M. Kiefl, S. T. Emmerling, D. Didier, 
Chem. Eur. J. 2017, 23, 1634. Copyright© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. 
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2.2 Stereoselective Sequence toward Biologically Active Fused Alkylidenecyclobutanes 
 
Reprinted with permission from A. N. Baumann, M. Eisold, D. Didier, Org. Lett. 2017, 19, 2114. 
Copyright© 2017 American Chemical Society.   
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2.3 Oxidative Ring Contraction of Cyclobutenes: General Approach to Cyclopropylketones 
including Mechanistic Insights 
 
Reprinted with permission from A. N. Baumann, F. Schüppel, M. Eisold, A. Kreppel, R. de Vivie-Riedle, 
D. Didier, J. Org. Chem. 2018, 83, 4905. Copyright© 2017 American Chemical Society. 
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3 Outlook 
Using previously described methods for the functionalization and transformation of the cyclobutenyl 
moiety, further applications are conceivable. For example, an asymmetric 1,4-addition of 
cyclobutenylketones with organocuprates in the presence of chiral ligands can lead to quaternary 
stereocenter-containing cyclobutanes 1.101 (Scheme 21). This method could ultimately give access to 
the enantioselective synthesis of grandisol (1.103) and fragranol (1.102), two naturally occurring 
pheromones. 
 
Scheme 21: 1,4-Addition of organocuprates onto cyclobutenylketone and  potential targets for total synthesis. 
A further transformation of iodo-cyclobutenes 1.104 could be achieved by an initial halogen-metal 
exchange, followed by an introduction of a boronic ester to form organoboronate 1.106 (Scheme 22). 
The latter can be engaged in a palladium-mediated reaction, leading after β-hydride elimination to 
different cyclobutene-containing boronic pinacol esters 1.109. Finally, a boron-allylation sequence 
with aldehydes or ketones would give access to a new library of functionalized cyclobutenes.  
 
Scheme 22: Palladium mediated functionalization of iodo-cyclobutenes followed by boron-allylation with 
different aldehydes.  
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4 Introduction 
2-Azetines are remarkable and expectedly reactive structures, possessing an intrinsic ring strain within 
a polarized 4-membered ring moiety. Only one natural occurring compound has been discovered so 
far.41 Isolated from the roots and stems of Cleistanthus gracilis, a 2-azetine fused with a 7-membered 
ring connected to a glucose moiety, was identified (Figure 4). 
 
Figure 4: The only natural occurring compound (+)-gracicleistanthoside, containing a 2-azetine moiety.  
(+)-Gracicleistanthoside (2.01) was found to possess a down regulation of the TNF--induced synthesis 
of interleikin-6 in HaCaT cells without any cytotoxicity and can therefore be referred to as anti-
inflammatory.42 Additionally, 2-azetines are well suited as precursors for the synthesis of 
pharmacological important classes of azetidines and -lactams. Some representative examples are 
depicted in Figure 5. For instance, the two azetidines BRD0026 (2.02) and BRD3444 (2.03) are novel 
antimalarial inhibitors with the potential to cure and prevent the further transmission of the disease.43  
 
Figure 5: Examples of pharmacologically important azetidines and -lactams. 
 
41 P. M. Pinho; W- Naengchomnong; A. Kijjoa; N. Nazareth; A. M. S. Silva; G. Eaton; W. Herz, Phytochemistry 2006, 
67, 1789. 
42 J. Ahn; H.-S. Chae; Y.-W. Chin; J. Kim, Nat. Prod. Res. 2018, 12, 1691. 
43 N. Kato; E. Comer; T. Sakata-Kato; A. Sharma; M. Sharma; M. Maetani; J. Bastien; N. M. Brancucci; J. A. Bittker; 
J. Corey; D. Calrke; E. Derbyshire; G. Dornan; S. Duffy; S. Eckley; M. A. Itoe; K. M. J. Koolen; T. Lewis; P. S. Lui; 
A. K. Lukens; E. Lund; S. March; E. Meibalan; J. McPhail; B. Meier; B. Mitasev; E. Moss; M. Sayes; Y. VanGessel; 
M. Wawer; T. Yoshinaga; Z.-M. Zeeman; V. M. Avery; S. N. Bhatia; J. E. Burke; F. Catteruccia; J. C. Clardy; P. A. 
Clemons; K. Dechering; J. R. Duvall; M. A. Foley; F. Gusovsky; C. H. Kocken; M. Marti; M. Morningstar; B. Munoz; 
D. Neafsey; A. Sharma; E. A. Winzeler; D. F. Wirth; C. A. Scherer; S. L. Schreiber, Nature 2016, 538, 344. 
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Cefradin (2.04) is a representative member of antibiotic cephalosporines, a huge class of -lactam 
antibiotics.  
However, methods for the formation and transformation of 2-azetines into important saturated 
derivatives are rather rare. This certainly originates from the difficulty of their synthesis.44 To overcome 
this methodological gap, new ways are inevitable to provide access to highly substituted azetidines. 
Some relevant and known synthetic pathways will be described in the following section.   
4.1 Synthesis of 2-Azetines 
The synthesis of 2-azetines was pioneered by Henery-Logan and Rodricks in 1963. In their work on 
azetinone (2.05), the unsaturated -lactam 2.06 was synthesized via a boron trifluoride triggered  
-elimination (Scheme 23). The -elimination approach is one of the most common methods for the 
formation of 2-azetines and double bonds in general and can be found in several reports.45 
 
Scheme 23: One of the first reported synthesis of a 2-azetine by -elimination. 
More recently, Hodgson and his group engaged the commercially available N-Boc-3-methoxyazetidine 
(2.07) in an -lithiation/-elimination sequence towards 2-substituted 2-azetines such as 2.12  
(Scheme 24).46 For the -lithiation step, two equivalents of the organometallic compound s-BuLi, were 
used. Following the first -lithiation, lithium methoxide is eliminated through -elimination 
mechanism, whereupon the second equivalent of s-BuLi subsequently deprotonates the 2-azetine 2.09 
to finally form the 2-lithiated azetine 2.10. In this general approach, a large diversity of different 
electrophiles could be added to 2.10. However, their attempt to perform a Negishi coupling through 
transmetalation with zinc only gave poor yields of desired coupling products. 
 
 
44 For a short review see: D. Didier; A. N. Baumann; M. Eisold, Tetrahedron Lett. 2018, 59, 3975; T. W. Reidl; L. L. 
Anderson, Asian J. Org. Chem. 2019, 8, 931. 
45 F. Effenberger; R. Maier, Angew. Chem. Int. Ed. 1966, 5, 416; M. E. Jung; Y. M. Choi, J. Org. Chem. 1991, 56, 
6729; P.R. Dave, R. Duddu, J. Li, R. Surapaneni, R. Gilardi, Tetrahedron Lett. 1998, 39, 5481; A. P. Marchand; D. 
Rajagopal; S. G. Bott; T. G. Archibald, J. Org. Chem. 1994, 59, 1608. 
46 D. M. Hodgson; C. I. Pearson; A. L. Thompson, J. Org. Chem. 2013, 78, 1098; D. M. Hodgson; C. I. Pearson; M. 
Kazmi, Org. Lett. 2014, 16, 856. 
75 
 Part A - Chapter II 
 
 
Scheme 24: Hodgson`s approach towards the synthesis of 2-azetines.  
A different method for getting access to 2-azetines was described by the group of Barluenga, where a 
copper-catalyzed [3+1]-cycloaddition of alkenyldiazoacetates (2.15) and iminoiodinanes (2.16) was 
used (Scheme 25).47 In the first catalytic step, the cycloaddition towards the aziridine 2.17 occurs, 
followed by extrusion of molecular nitrogen and formation of a copper-carbene complex which then 
undergoes a ring-enlargement of the aziridine moiety towards the final 2-azetine 2.18.  
 
Scheme 25: [3+1]-cycloaddition of alkenyldiazoacetates and iminoiodinanes towards 2-azetines. 
Considering the different methods for the synthesis of 2-azetines, the -elimination approach, 
especially the one investigated by Hodgson, was selected as a perfect headstone for the synthesis of 
2-azetine building blocks and for further manipulation. Starting with a species similar to  
lithiated 2.10 (Scheme 24), various paths were developed, such as Suzuki cross couplings  
(see Chapter I “Suzuki-Miyaura and Negishi Cross-Coupling Reactions” ) or Zweifel-olefinations (see 
Part B/Chapter I “Zweifel Olefinations“).  
 
 
 
47 J. Barluenga; L. Riesgo; G. Lonzi; M. Tomás; L. A. López, Chem. Eur. J. 2012, 18, 9221. 
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4.2 Alkylideneazetidines 
Alkylideneazetidines represent a unique class of strained cyclic azetidines. Due to their difficulty of 
formation, only little is known about their chemistry and properties.48 Apart from the well-known -
lactams (cephalosporines and penicillins), a few biologically active alkylideneazetidines are already 
known. Two of them are depicted in Figure 6. Polyoxin O (2.19) has shown antifungal activity, while 2-
alkylideneazetidine 2.20 possesses inhibiting properties against leukocyte elastase and gelatinase.49  
 
Figure 6: Some pharmacologically important alkylideneazetidines. 
In 2006 Li and Lu described a well thought-through strategy for the synthesis of 2-alkylideneazetidines 
by employing a copper-catalyzed intramolecular N-vinylation (Scheme 26).50 Several  
2-alkylideneazetidines such as 2.22 could be accessed with remarkably high yields, and finally 
converted into the -lactams 2.23 through ozonolysis.  
 
Scheme 26: Copper-catalyzed intramolecular N-vinylation towards alkylideneazetidines. 
As already described in Chapter I “[4+2]-Cycloadditions of Cyclobutenes”, the Diels-Alder reaction 
represents a powerful tool for further transformations with cyclobutenes, in getting access to the 
important class of alkylidenecyclobutanes. This cycloaddition strategy was therefore applied to 
convert 2-azetines into fused alkylideneazetidines.  
 
48 For recent examples see: D. K. Tiwari; A. Y. Shaikh; L. S. Pavase; V. K. Gumaste; A. R. A. S. Deshmukh Tetrahedron 
2007, 63, 2524; K. Tehrani; N. De Kimpe, Curr. Org. Chem. 2009, 13, 854; S. Stanković; M. D’hooghe; T. 
Vanderhaegen; K. A. Tehrani; N. De Kimpe, Synlett 2014, 25, 75. 
49 J. Li; L. Li; Y. Chen; H. Tan, Microb. Cell Fact. 2012, 11, 135; G. Cainelli; P. Galletti; S. Garbisa; D. Giacomini; L. 
Sartor; A. Quintavalla, Bioorg. Med. Chem. 2003, 11, 5391. 
50 H. Lu; C. Li, Org. Lett. 2006, 8, 5365. 
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In an approach similar to the [4+2]-cycloaddition, the use of 1,3-dipoles for the derivatization of  
2-azetines will be described thereafter.  
4.3 (2+3)-Cycloadditions of 2-Azetines 
(2+3)-Cycloaddition reactions or 1,3-dipolar cycloadditions, are widely applied in organic syntheses 
and are useful in opening the pathway towards more complex molecules.51 However, the utilization of 
2-azetines in 1,3-dipolar cycloaddition strategies has only been reported once in the literature 
(Scheme 27).52 In that work, a 1,3-dipolar cycloaddition of different nitrones 2.24 with 2-azetine (2.09) 
was described. Furthermore, the cycloaddition adduct 2.25 was directly converted into 2,3-
disubstituted quinolines 2.26 by a silver-catalyzed ring opening-/ring-closing-sequence. 
 
Scheme 27: 1,3-Dipolar cycloaddition of 2-azetine and different nitrones followed by a silver-catalyzed ring 
opening- and closing-sequence. 
On the one hand, this clearly demonstrates the applicability of azetines. On the other hand, a general 
method for their use in 1,3-dipolar cycloadditions is still not provided. Therefore, a more versatile and 
general approach in 1,3-dipolar cycloadditions was designed and combined with the sulfur analogues 
of azetines (thiete dioxides). This results will be presented in Chapter III “Chemodivergent and 
Stereoselective Access to Fused Isoxazoline Azetidines and Thietanes through [3+2]-Cycloadditions”. 
  
 
51 For an overview on 1,3-dipolar cycloadditons see: L.-Y. Wang; Y. Tang, Intermolecular 1,3-Dipolar 
Cycloadditions of Alkenes, Alkynes, and Allenes. In Comprehensive Organic Synthesis II; Elsevier, 2014; 
1342−1383; T. Hashimoto; K. Maruoka, Chem. Rev. 2015, 115, 5366; M. S. Singh; S. Chowdhury; S. Koley, 
Tetrahedron 2016, 72, 1603. 
52 H. Yan; X. Li; C. Wang; B. Wan, Org. Chem. Front. 2017, 4, 1833. 
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5 Results 
5.1 Methods for the Synthesis of Substituted Azetines 
 
Reprinted with permission from A. N. Baumann, M. Eisold, A. Music, G. Haas, Y. M. Kiw, D. Didier, Org. 
Lett. 2017, 19, 5681. Copyright© 2017 American Chemical Society. 
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5.2 One-Pot Preparation of Stable Organoboronate Reagents for the Functionalization of 
Unsaturated Four- and Five-Membered Carbo- and Heterocycles 
 
Reprinted with permission from A. N. Baumann, M. Eisold, A. Music, D. Didier, Synthesis 2018, 50, 
3149. Copyright© 2018 Georg Thieme Verlag KG Stuttgart · New York. 
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5.3 Regiodivergent Stereoselective Access to Fused Alkylideneazetidines  
 
Reprinted with permission from A. N. Baumann, A. Music, M. Eisold, D. Didier, J. Org. Chem. 2018, 83, 
783. Copyright© 2018 American Chemical Society. 
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6 Outlook 
With those new methods in hands, a further diversification of 2-azetine building blocks is imaginable, 
exemplified in two different pathways, both starting with the key intermediate 2.27 (Scheme 28). In 
the first, the azetinyllithium species 2.27 is trapped by a CO2-source followed by an asymmetric 
hydrogenation and deprotection. This would ultimately lead to a new class of chiral amino acid 
azetidines 2.28.   
 
Scheme 28: Possible sequences towards a new library of functionalized azetidine-containing moieties.  
The other pathway for the transformation of 2-azetines could be based on boron-related strategies, 
which were recently developed in the group of Didier (Scheme 28).53 The previously formed 
azetinyllithium species 2.27 would undergo a stereospecific boron-homologation to form the 
azetinylmethylboronic ester 2.29. In the next step, two routes towards the synthesis of functionalized 
alkylideneazetidines would be plausible. These two different approaches could open a wide library of 
unique structures such as 2.30/2.31 and allow access to further methods for the synthesis and 
transformation of this very important class of N-containing four-membered ring systems.  
 
 
 
 
 
53 M. Eisold; D. Didier, Angew. Chem. Int. Ed. 2015, 54, 15884; M. Eisold; D. Didier, Org. Lett. 2017, 19, 4046. 
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7 Introduction 
The four-membered analogues to cyclobutenes and 2-azetines, containing a fully oxidized sulfur atom 
are called thiete dioxides (3.01) (Figure 7). Just like for the other unsaturated four-membered rings, 
the inherent ring strain is one of the key properties of this structure. Moreover, the sp2-carbon next to 
the sulfur is polarized and therefore activated for further transformations. Not only the difference in 
electronegativity between sulfur and carbon, but also the presence of oxygen atoms as directing group, 
plays a role in this unique reactivity. Nevertheless, thiete dioxides are difficult to access and therefore 
scarcely examined. To the best of our knowledge, no thiete dioxide structure can be found in natural 
occurring compounds and the only bioactive thiete dioxide was synthesized by the group of Didier.54 
However, some of their functionalized saturated derivatives occur in nature or demonstrate their 
interesting properties in life-science.   
 
Figure 7: Thiete dioxide and some relevant structures with S-containing four-membered rings.  
For instance, the synthetic thietane dioxide 3.02 shows high antidepressant activity in combination 
with low toxicity.55 The naturally occurring alkylidenethietane 3.03 was isolated in 1975 from the roots 
of Cullumia squarrossa.56 Unfortunately, no bioactivity experiments have been conducted so far. The 
saturated and volatile thietane 3.04 was found in the gland secretions of a mink and is believed to be 
used in communication across species, sex and age.57  Thietane 3.05 is known as a pesticide and the 
 
54 M. Eisold; A. Müller-Deku; F. Reiners; D. Didier, Org. Lett. 2018, 20, 4654. 
55 E. E. Klen; I. L. Nikitina; N. N. Makarova; A. F. Miftakhova; O. A. Ivanova; F. A. Khaliullin; E. K. Alekhin, Pharm. 
Chem. J. 2017, 50, 642. 
56 F. Bohlmann; A. Suwita, Chem. Ber. 1975, 108, 515. 
57 J.-X. Zhang; L. Sun; Z.-B. Zhang; Z.-W. Wang; Y. Chen; R. Wang, J. Chem. Ecol. 2002, 28, 1287. 
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highly substituted thietane 3.06 is used as a sweetener.58 Thiete dioxides can be suitable precursors in 
the formation of new and diverse thietane-containing molecules although their compound class is 
underrepresented in the literature. Therefore, new tools for their formation are required, as well as 
their implication in drug discovery.  
7.1 Synthesis of Thiete Dioxides 
One of the first reported synthesis of the thiete dioxide core was achieved by Dittmer and Christy in 
1962 (Scheme 29).59 Their route disclose the use of epichlorohydrin (3.07) as a starting material, that 
was treated with a basic saturated hydrogen sulfide solution to get to 3-thietanol (3.08). After an 
oxidation with hydrogen peroxide the 3-thietanol dioxide (3.09) was converted into the corresponding 
chloride 3.10 with thionyl chloride. A final elimination step with triethylamine afforded the desired 
thiete dioxide 3.01 in good yield.  
 
Scheme 29: First reported synthesis of thiete dioxide 3.01 in 1962 by Dittmer and Christy. 
In the 1960s, many publications appeared with different or similar attempts for the synthesis of thiete 
dioxides.60 One year after the first discovery of Dittmer in 1962, Hasek and his group used a [2+2]-
cycloaddition strategy, where they used in situ generated sulfenes and ketene O,N- or N,N-acetals for 
the formation of thiete dioxides (Scheme 30).61   
 
Scheme 30: [2+2]-Cycloaddition between in situ generated sulfenes and ketene O,N-acetal towards the 
formation of thiete dioxides.  
 
58 P. Renold; W. Zambach; P. Maienfisch; M. Muehlebach, PCT Int. Appl. WO2009080250; T. M. Brennan; M. E. 
Hendrick, U.S. 4411925. 
59 D. C. Dittmer; M. E. Christy, J. Org. Chem. 1961, 26, 1324. 
60 W. E. Truce; J. R. Norell; J. E. Richman; J. P. Walsh, Tetrahedron Lett. 1963, 25, 1677; G. Opitz; H. Schempp, 
Liebigs Ann. Chem. 1965, 684, 103; W. E. Truce; D. J. Abraham; P. N. Son, J. Org. Chem. 1967, 32, 990; J. N. Wells; 
F. S. Abbott, J. Med. Chem. 1966, 9, 489.  
61 R. H. Hasek; P. G. Gott; R. H. Meen; J. C. Martin, J. Org. Chem. 1963, 28, 2496; R. H. Hasek; R. H. Meen; J. C. 
Martin, J. Org. Chem. 1965, 30, 1495. 
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The in situ generated sulfene can be easily prepared by the treatment of methansulfonylchloride with 
triethylamine. In the example of Hasek, depicted in Scheme 30, a ketene O,N-acetal (3.11) was used 
for the intermediary formation of the thietane 3.13. Following a final -elimination, the desired thiete 
dioxide 3.14 was obtained in moderate yield. 
For the synthesis of several grams of thiete dioxides, the robust procedure of Dittmer and co-worker 
for the synthesis of thiete 1,1-dioxide and 3-chlorothiete 1,1-dioxide should be considered.62 In this 
work, a halogenation with elemental chlorine of thietane dioxide followed by an elimination step with 
triethylamine produces the aforementioned thiete dioxides in good to high yields.  
More recently, Burkhard demonstrated a straightforward synthesis of 3-aryl-thiete dioxides (3.18) 
(Scheme 31).63 In his work, Burkhard used the commercially available thietan-3-one (3.15) and treated 
the latter with different lithiated arenes. These generated thietanoles 3.16 were then converted into 
the corresponding sulfones 3.17 by using m-CPBA as an oxidant. Finally, the desired 3-aryl-
thiete dioxides 3.18 were obtained by a consecutive mesylation/-elimination sequence using 
triethylamine and mesylchloride.  
 
Scheme 31: Straightforward synthesis of 3-aryl-thiete dioxides by Burkhard. 
As each step is high yielding, this procedure was adopted and expanded for the synthesis of 
functionalized thiete dioxides as well as for their further transformations in this work. 
7.2 C-H Activation of Thiete Dioxides 
The well-known and extensively applied strategy of C-H activation has become a key concept for 
synthetic chemists all over the world.64 Especially its use in late state functionalization drives a 
continuous interest in C-H activation.65 For a replacement of a carbon-hydrogen bond with a new bond 
(for example to another carbon),  the C-H bond needs to be activated, as this type of bond is known to 
be quite unreactive. As C-H bonds are ubiquitous in organic molecules, the control of the 
 
62 T. C. Sedergran; D. C. Dittmer, Org. Synth. 1984, 62, 210. 
63 J. A. Burkhard, New Opportunities for Four- Membered Heterocycles: From Synthetic Studies to Unique 
Applications in Drug Discovery. PhD Thesis, ETH Zürich, 2011, DOI: 10.3929/ethz-a-006834147.   
64 For a review see: J. F. Hartwig, Nature 2008, 455, 314; K. Godula; D. Sames, Science 2006, 5770, 67; R. Giri; B.-
F. Shi; K. M. Engle; N. Maugel; J.-Q. Yu, Chem. Soc. Rev. 2009, 38, 3242. 
65 P. A. Wender; M. K. Hilinski; A. V. W. Mayweg, Org. Lett. 2005, 7, 79; D. J. Abrams; P. A. Provencher; E. J. 
Sorensen, Chem. Soc. Rev. 2018, 47, 8925; M. S. Chen; M. C. White, Science 2007, 5851, 783. 
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regioselectivity plays the major role and therefore, has to be controlled using directing groups attached 
to the target molecule.66 In most cases, directed C-H-bond activation is catalyzed by transition metals.67 
Recently, the group of Didier performed a palladium catalyzed C-H activation on thiete dioxides (3.18), 
in which the unique structural properties of polarization in combination with the directing group (SO2) 
were exploited (Scheme 32).68 This led to the unprecedented bis-functionalized structures 3.19. 
 
Scheme 32: C-H Activation of thiete dioxides towards disubstituted thiete dioxides by Didier. 
This robust tool was further used to expand the scope of this transformation, but also to show possible 
applications of disubstituted thiete dioxides. 
7.3 (2+3)-Cycloadditions of Thiete Dioxides 
Cycloadditions can be the right choice to enhance the complexity of an existing system. Particularly, 
(2+3)-cycloadditions were extensively applied in organic chemistry and will be described more detailed 
in Chapter II “(2+3)-Cycloadditions of 2-Azetines”.  
1,3-Dipolar cycloadditions of thiete dioxides are rarely described in literature. One of these studies 
describes the crystal structure of an isoxazoline thietane.69 Another pioneer work was done by the 
research groups of Rastelli and Micheli, as they reported for the first time 1,3-dipolar cycloadditions 
of nitrones, nitrile oxides and diazoalkanes with thiete 1,1-dioxide (3.01) (Scheme 33).70 A special focus 
was set on the regiochemical behaviour of the unsubstituted thiete 1,1-dioxide. When nitrile oxides or 
nitrones were used as 1,3-dipoles only one regioisomer (3.21) was observed, whereas a mixture of 
3.20 and 3.21 (approximately 1:1) was detected, conducting the cycloaddition reaction with 
diazoalkanes. 
 
66 For a review on bidentate directing groups see: G. Rouquet; N. Chatani, Angew. Chem. Int. Ed. 2013, 52, 11726; 
S. D. Sarkar; W. Liu; S. I. Kozhushkov; L. Ackermann, Adv. Synth. Catal. 2014, 356, 1461; J. Liu; G. Chen; Z. Tan, 
Adv. Synth. Catal. 2016, 358, 1174; L. M. Chapman; J. C. Beck; L. Wu; S. E. Reisman, J. Am. Chem. Soc. 2016, 138, 
9803; A. Biafora; B. A. Khan; J. Bahri; J. M. Hewer; L. J. Goossen, Org. Lett. 2017, 19, 1232. H. M.-F. Viart; A. 
Bachmann; W. Kayitare; R. Sarpong, J. Am. Chem. Soc. 2017, 139, 1325. 
67 L. Ackermann; J. Pospech, Org. Lett. 2011, 13, 4153; Z.-Y. Gu; C.-G. Liu; S.-Y. Wang; S.-J. Ji, J. Org. Chem. 2017, 
82, 2223; T. Yamamoto; A. Ishibashi; M. Suginome, Org. Lett. 2017, 19, 886. 
68 M. Eisold; A. Müller-Deku; F. Reiners; D. Didier, Org. Lett. 2018, 20, 4654. 
69 G. J. Gainsford; A. D. Woolhouse, Acta Crystallogr., Sect. E: Struct. Rep. Online 2002, 58, o715. 
70 P. G. De Benedetti; S. Quartieri; A. Rastelli; M. de Amici; C. de Micheli; R. Gandolfi; P. J. Gariboldi, Chem.Soc., 
Perkin Trans.2 1982, 95 
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Scheme 33: Different 1,3-dipolar cycloadditions with thiete 1,1-dioxide and the imaginable regiochemical 
outcome. 
Consequently, some questions arose for this work: Can this method open the access to a new group 
of thietane dioxides? What is the regiochemical outcome of such reaction? Is there any application for 
fused thietane dioxides? These questions will be addressed in the result section “Chemodivergent and 
Stereoselective Access to Fused Isoxazoline Azetidines and Thietanes through [3+2]-Cycloadditions”. 
7.4 Atropisomerism 
Atropisomerism is a type of stereochemistry in a molecular system that is caused by a significantly 
reduced free rotation around a single bond. This rotational hindrance results in axial chirality, allowing 
two different stereoisomers to be isolated at a given temperature.71 Remarkably, atropisomers are 
often found in natural products or in drugs and are therefore of great importance in medicinal 
chemistry and in the development of new drugs.72 Several representative examples are depicted in 
Figure 8. For instance, murrastifoline F (3.22), an alkaloidal component of Murraya koenigii shows that 
this type of stereochemistry is not limited to carbon-carbon bonds.73 Another compound is knipholone 
(3.23), which was isolated from Kniphofia foliosa, with varying degrees of enantiomeric purity.74  
 
71 G. H. Christie; J. Kenner, J. Chem. Soc., Trans. 1922, 121, 614; P. Llody-Williams; E. Giralt, Chem. Soc. Rev. 2001, 
30, 145; M. Ōki in Topics in Stereochemistry (Eds.: N. L. Allinger, E. L. Eliel, S. H. Wilen), John Wiley & Sons, Inc, 
Hoboken, NJ, USA, 1983, 1-81. 
72 For a short review see: J. Clayden; W. J. Moran; P. J. Edwards; S. R. LaPlante, Angew. Chem. Int. Ed. 2009, 48, 
6398; S. R. LaPlante; P. J. Edwards; L. D. Fader; A. Jakalian; O. Hucke, ChemMedChem 2011, 6, 505; A. Zask; J. 
Murphy; G. A. Ellestad, Chirality 2013, 25, 265; J. E. Smyth; N. M. Butler; P. A. Keller, Nat. Prod. Rep. 2015, 32, 
1562; P. W. Glunz, Bioorg. Med. Chem. Lett. 2018, 28, 53; S. T. Toenjes; J. L. Gustafson, Future Med.Chem. 2018, 
10, 409. 
73 C. Ito; Y. Thoyama; M. Omura; I. Kajiura; H. Furukawa, Chem. Pharm. Bull. 1993, 41, 2096. 
74 E. Dagne; W. Steglich, Phytochemistry 1984, 23, 1729; J. Mutanyatta; M. Bezabih; B. M. Abegaz; M. Dreyer; R. 
Brun; N. Kocher; G. Bringmann, Tetrahedron 2005, 61, 8475. 
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Figure 8: Atropisomerism in selected naturally occurring compounds and drugs.  
The not naturally occurring BMS-76778 (3.24) can efficiently inhibit the dipeptidyl  
peptidase-4 (DPP4).75 Atropisomers not only occur in drug discovery, they are also widely used as chiral 
catalysts.76 Certainly, the most famous example are the atropisomers of the 1,1′-binaphthyl series, 
with a racemization half-life of 14.5 minutes at 50 °C (∆Gǂ = 23.5 kcal/mol) (Scheme 34).77 
 
Scheme 34: Isomerization reaction of (S) to (R)-1,1′-binaphthyl. 
Many different methods exist for the synthesis of catalysts with inherent axial chirality.78 The key 
requirement for axially chiral molecules is, of course, a strong steric hindrance between two groups 
connected by an axis. Nevertheless, some other interactions, especially the non-covalent -
 
75 R. P. Brigance; H. J. Chao; A. Fura; T. Harrity; J. Marcinkeviciene; S. P. O`Conner; J. K. Tamura; D. Xie; Y. Zhang; 
H. E. Klei; K. Kish; C. A. Weigelt; H. Turdi; A. Wang; R. Zahler; M. S. Kirby; L. G. Hamann; W. Meng, J Med Chem. 
2010, 53, 5620; Y. Wang; L. M. Simpkins; R. P. Brigance; W. Meng; A. Wang; M. S. Kirby; C. A. Weigelt; L. G. 
Hamann; S. P. O´Conner, Bioorg. Med. Chem. Lett. 2010, 20, 6273; Y. Wang; W. Wang; J. Fevig; J. Feng; A. Wang; 
T. Harrity; D. Egan; N. Morgan; M. Cap; A. Fura; H. E. Klei; K. Kish; C. Weigelt; L. Sun; P. Levesque; F. Moulin; Y.-X. 
Li; R. Zahler; M. S. Kirby; L. G. Hamann; P. Devasthale, J. Med. Chem. 2013, 56, 7343. 
76 L. Pu, Chem. Rev. 1998, 98, 2405; A. Joncour; A. Décor, S. Thoret; A. Chiaroni; O. Baudoin, Angew. Chem. Int. 
Ed. 2006, 45, 4149. Y.-B. Wang; P. Yu; Z.-P. Zhou; J. Zhang; J. J. Wang; S.-H. Luo; Q.-S. Gu; K. N. Houk; B. Tan, Nat. 
Catal. 2019, 2, 504; 
77 A. S. Cooke; M. M. Harris, J. Chem. Soc. 1963, 0, 2365; 
78 For a review on the synthesis of chiral biaryls see: G. Bringmann; A. J. P. Mortimer; P. A. Keller; M. J. Gresser; 
J. Garner; M. Breuning, Angew. Chem. Int. Ed. 2005, 44, 5384; Y.-S. Jang; Ł. Woźniak; J. Pedroni; N. Cramer, 
Angew. Chem. Int. Ed. 2018, 57, 12901; C. G. Newton, E. Braconi, J. Kuziola, M. D. Wodrich, N. Cramer, Angew. 
Chem. Int. Ed. 2018, 57, 11040; S. Song; J. Zhou; C. Fu; S. Ma, Nat. Commun. 2019, 10, 507. 
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interactions, play an important role.79 This usually weak interaction can be used for host guest systems 
like molecular tweezers.80  
In summary, the importance of axial chirality can be found in many areas of chemistry and is not limited 
to the synthesis of novel catalysts but can also applied to drug synthesis. With this in mind, one of the 
objectives was the synthesis of disubstituted thiete dioxides possessing chirality through 
atropisomerism. 
7.5 Spherands - Macrocyclic Receptors 
Spherands can be classified as macrocyclic ligands with limited conformational flexibility. One of the 
few spherands ever described is shown in Figure 9. The first synthesis of this spherand (3.26) was 
reported by Donald Cram in 1979.81 This pioneering work was later rewarded with a Nobel prize for 
Chemistry in 1987 with Charles Pedersen and Jean-Marie Lehn. Spherands present a high rigidity, 
preorganization and an electron-pair-lined cavity.82 Consequently, they are strong complexation 
receptors for ions, such as lithium, sodium or potassium. Indeed, the binding constant for lithium ions 
is one of the strongest known so far. However, no organic molecule can be trapped, due to the small 
cavity of the host system.83 
 
Figure 9: Prototypical spherand.  
The typical synthesis of spherand 3.26 was described by Cram and it involves three steps, starting from 
p-cresol (3.27), with an overall yield of 6.3% (Scheme 35). In the first step, p-cresol was oxidatively 
 
79 For a review on non-covalent -interactions see: A. J. Neel; M. J. Hilton; M. S. Sigman; F. D. Toste, Nature 2017, 
543, 637. 
80 For review see: J. Leblond; A. Petitjean, ChemPhysChem 2011, 12, 1043 and F.-G. Klärner; T. Schrader, Acc. 
Chem. Res. 2013, 46, 967; M. Bosquez; A. Cambray; A. Miralrio; R.-M. del Castillo; R. Salcedo, Comput. Theor. 
Chem. 2017, 1115, 335. 
81 D. J Cram; T. Kaneda; R. C. Helgeson; G. M. Lein, J. Am. Chem. Soc. 1979, 101, 6752. 
82 D. J. Cram, Angew. Chem. Int. Ed. 1986, 25, 1039; L. F. Lindoy; K.-M. Park; S. S. Lee in Supramolecular Chemistry 
(Eds.: P. A. Gale, J. W. Steed), John Wiley & Sons, Ltd, Chichester, UK, 2012, 7017. 
83 G. M. Lein; D. J. Cram, J. Chem. Soc. Chem. Commun. 1982, 5, 301; D. J. Cram; G. M. Lein; T. Kaneda; R. C. 
Helgeson; C. B. Knobler; E. Maverick; K. N. Trueblood, J. Am. Chem. Soc. 1981, 103, 6228. 
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coupled in the presence of iron to the triphenoxy moiety 3.28. In the second step, an ortho-
bromination was carried out, followed by a methylation of the free alcohol groups. A lithiation of 
structure 3.29 followed by reaction with Fe(acac)3 led to the desired spherand 3.26. Due to the use of 
s-BuLi, the spherand had to be treated with EDTA-solution to get rid of remaining lithium ions.  
 
Scheme 35: Synthesis of spherand 3.26 (see Figure 9). 
Following these early findings, several other spherands were synthesized and characterized with 
respect to host-guest interactions with different ions.84 Motivated by these unusual structures, the 
synthesis of thiete based spherand analogues such as 3.30 was envisioned (Scheme 36). The previously 
described C-H activation of thiete dioxides was chosen as the appropriate tool for this purpose.  
 
Scheme 36: Possible C-H activation of thiete dioxides towards thiete based spherand analogues.  
  
 
84 D. J. Cram; T. Kaneda; G. M. Lein; R. C. Helgeson, J. Chem. Soc. Chem. Commun. 1979, 21, 948b; D. J. Cram; R. 
A. Carmack; M. P. DeGrandpre; G. M. Lein; I. Goldberg; C. B. Knobler; E. F. Maverick; K. N. Trueblood, J. Am. Chem. 
Soc. 1987, 109, 7068; D. J. Cram, R. A. Carmack; R. C. Helgeson, J. Am. Chem. Soc. 1988, 110, 571. 
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8 Results 
8.1 Chemodivergent and Stereoselective Access to Fused Isoxazoline Azetidines and 
Thietanes through [3+2]-Cycloadditions 
 
Reprinted with permission from A. N. Baumann, F. Reiners, T. Juli, D. Didier, Org. Lett. 2018, 20, 6736. 
Copyright© 2018 American Chemical Society. 
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8.2 Disubstituted Thiete Dioxides – Donor/Acceptor- Interactions towards Axial Chirality 
For axial chirality, appropriate substituents on thiete dioxides are necessary. Therefore, the optimized 
procedure of Burkhard was utilized to access mono substituted thiete dioxides 3.18 (Scheme 38). 
 
Scheme 38: Three-step sequence towards mono substituted thiete dioxides.  
Using commercially available 3-thietanone (3.15) in a three-step sequence led to the mono substituted 
thiete dioxides in moderate to good yields over three steps. In most cases, organomagnesium reagents 
led to an increased yield compared to organolithium species (Table 1). 3-Phenyl-2H-thiete 1,1-dioxide 
3.18-a was synthesized via phenylmagnesium bromide giving the desired product in a high yield of 78% 
over three steps. On the contrary, using anthracen-9-yllithium provided thiete dioxide 3.18-c in only 
25%.  
Table 1: Overview of various mono substituted thiete dioxides.  
Entry Electrophile Organometallic reagent Product Yield[a] 
1 
 
 
 
3.18-a, 78% 
2 
 
  
3.18-b, 70% 
3 
 
 
3.18-c, 25% 
4 
 
 
3.18-d, 48% 
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Entry Electrophile Organometallic reagent Product Yield[a] 
5 
 
 
 
3.18-e, 37% 
6 
 
 
3.18-f, 60% 
7 
 
 
3.18-g, 61% 
8 
  
3.18-h, 60% 
9 
 
 
3.18-i, 32% 
10 
 
 
3.18-j, 68% 
11[b] 
 
 
3.18-k, 24% 
[a] Yield of isolated, analytically pure product; [b] for the elimination step DAST and BF3.OEt was used. 
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In the next step, the previously described C-H activation was chosen as the key step for the 
manipulation of mono substituted thiete dioxide 3.18 towards conceivable atropisomerism.85  
 
Scheme 39: C-H activation of mono substituted thiete dioxides towards disubstituted. 
Different mono substituted thiete dioxides 3.18 were engaged in a pivalate-assisted palladium 
catalyzed C-H activation with a variety of aromatic halogenates (Table 2). This led to 23 disubstituted 
thiete dioxides 3.19 in up to 95%.  
Table 2: Overview of various bis-substituted thiete dioxides.  
Entry 3.18 Ar-X Product Yield[a] 
1 
  
 
3.19-a, 62% 
2 
 
 
 
3.19-b, 70% 
3 
 
 
3.19-c, 70% 
4 
 
 
3.19-d, 62% 
5 
 
 
3.19-e, 95% 
 
85 M. Eisold; A. Müller-Deku; F. Reiners; D. Didier, Org. Lett. 2018, 20, 4654. 
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Entry 3.18 Ar-X Product Yield[a] 
6 
 
 
 
3.19-f, 85% 
7 
 
 
 
3.19-g, 43% 
8 
 
 
 
3.19-h, 71% 
9 
 
 
R3.05-i, 95% 
10 
 
 
 
3.19-j, 41% 
11 
 
 
 
3.19-k, 41% 
12 
 
 
 
3.19-l, 93% 
13 
 
 
3.19-m, 69% 
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Entry 3.18 Ar-X Product Yield[a] 
14 
 
 
 
3.19-n, 40% 
15 
  
3.19-o, 53% 
16 
 
 
3.19-p, 61% 
17 
 
 
3.19-q, 88% 
18 
 
 
3.19-r, 67% 
19 
 
 
 
3.19-s, 60% 
20 
 
 
3.19-t, 50% 
21 
 
 
3.19-u, 57% 
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Entry 3.18 Ar-X Product Yield[a] 
22 
 
 
 
3.19-v, 58% 
23 
 
 
3.19-w, 46% 
[a] Yield of isolated, analytically pure product. 
The proposed mechanism is depicted in Scheme 40. Experiments were conducted to determine the 
mechanism type of the reaction.86 The investigations suggested that a “BIES” (base-assisted internal 
substitution) fits better the reaction path than the “CMD” (concerted-metalation-deprotonation) 
mechanism. Potassium carbonate has to be added to regenerate the pivalate by deprotonation of the 
corresponding acid.  
 
Scheme 40: Proposed catalytic cycle of the pivalate-assisted palladium catalyzed C-H activation. 
It is worth noting, that when using 4-(2-bromophenyl)pyridine as the coupling partner, analytical data 
revealed a palladium crossover, according to the oxidative insertion step towards 3.33 (Scheme 41). 
 
86 M. Eisold; A. Müller-Deku; F. Reiners; D. Didier, Org. Lett. 2018, 20, 4654. 
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This migration equilibrium is already well known,87 however, it is still surprising, that only one isomer 
was ever obtained after successful C-H activation.  
 
Scheme 41: 1,4-Metal shift according to the oxidative insertion of 4-(2-bromophenyl)pyridine. 
To detect atropisomerism, we tried to crystalize different disubstituted thietes 3.19 in diverse solvent 
ratios (hexane/dichloromethane). X-ray crystal structures are depicted in Table 3. First observations of 
axial chirality in the solid state was detected for the bi-naphthyl thiete dioxide 3.19-b. The structure 
shows evident --interactions between the two aromatic residues. With this results in hands, we set 
out to explore different moieties containing a naphthyl group on the starting material. Structures  
3.19-e/f exhibited promising interactions, whereupon in structure 3.19-d the distance among the 
naphthyl and anthryl moiety was increased. Consequently, the compounds 3.19-b/e/f were measured 
on a chiral HPLC at different temperatures (20 °C, -20 °C, -50 °C) to test for atropisomerism in the liquid 
state. Unfortunately no separation was detected as the rotational barrier is probably too low to 
stabilize enantiomers at the given temperature.  
Table 3: Crystal structures of some disubstituted thiete dioxides.  
Entry 3.19 Crystal Structure 
1 
 
3.19-b  
2 
  
3.19-d 
 
 
87 G. Karig; M.-T. Moon; N. Thasana; T. Gallagher, Org. Lett. 2002, 4, 3115. 
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Entry 3.19 Crystal Structure 
3 
  
3.19-e  
4 
  
3.19-f  
5 
  
3.19-i 
 
6 
  
3.19-k  
7 
  
3.19-l  
8 
  
3.19-m 
 
9 
  
3.19-q  
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Entry 3.19 Crystal Structure 
10 
  
3.19-u  
11 
  
3.19-v  
12 
  
3.19-w  
 
In order to increase --interactions between the residues, we set out to modulate the electron-
donating/electron-withdrawing nature of the substituents. Therefore, the electron rich thiete dioxide 
3.18-j (Table 1) was engaged in the coupling reaction with the electron deficient 4-(2-
bromophenyl)pyridine. This led to the crystal structure of 3.19-k. Nevertheless, the distance and 
arrangement of the residues did not give promising results. Electron rich biaryl- or naphthyl derivatives 
were further used in C-H activation with electron deficient aromatic groups. However, compounds 
3.19-l/m clearly demonstrate that a linker between the residues increases the - electrostatic 
interactions. Indeed, the next thiete dioxides 3.19-(n-w) showed stronger interactions. Especially 
compound 3.19-w, with strong electron deficient NO2-groups in close distance to the methoxy-
naphthyl group, revealed strong donor/acceptor interactions. With nearly face-centred stacking and 
an approximate average distance of 3.5 Å an optimum for this kind of interactions was achieved.88 As 
a consequence, several structures with promising axial chirality in the solid state were further studied 
in solution by chiral HPLC. Unfortunately, even at temperatures of -50 °C, no de-coalescence of the 
measured signal peak was ever observed. In conclusion, with this optimized --interactions, stable 
 
88 C. R. Martinez; B. L. Iverson, Chem. Sci. 2012, 3, 2191. 
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axial chirality was found in the solid state at room temperature, but no atropisomerism could be 
detected in solution.  
With this early findings, further explorations could lead to a new scaffold of thiete dioxide containing 
molecules with unknown properties.    
8.3 Macrocyclic Thiete Dioxides 
Based on the C-H activation strategy, discussed in detail in Chapter III “Disubstituted Thiete Dioxides 
– Donor/Acceptor- Interactions towards Axial Chirality”, macrocyclic ring systems containing the 
thiete dioxide moiety were synthesized. Therefore, mono substituted thiete dioxides bearing a halogen 
on the aromatic residue had to be prepared (Scheme 42).  
 
Scheme 42: Three-step sequence towards mono substituted thiete dioxides. 
Compared to former obtained thiete dioxides 3.18, the yields drastically dropped (Table 4). The first 
step is probably crucial, as a selective mono-exchange reaction of the double halogenated aromatic 
must be performed.  
Table 4: Overview of some mono substituted thiete dioxides bearing a bromide on the aromatic residue.  
Entry Electrophile Organometallic reagent Product Yield[a] 
1 
 
 
 
3.18-l, 62% 
2 
 
 
3.18-m, 42% 
3 
 
 
3.18-n, 35% 
133 
 Part A - Chapter III 
 
Entry Electrophile Organometallic reagent Product Yield[a] 
4 
 
 
 
3.18-o, 22% 
5 
 
 
3.18-p, 7% 
[a] Yield of isolated, analytically pure product. 
Acceptable yields were observed considering the three-step procedure. With this method in hands, a 
new scaffold of halogen bearing mono substituted thiete dioxides were synthesized, opening a new 
route to further transformations. Palladium-catalyzed C-H activation led to compounds 3.30 (Scheme 
43).  
 
Scheme 43: C-H activation of mono substituted thiete dioxides towards thiete dioxide macrocycles. 
Cyclic thiete dioxides containing three thiete units were obtained in up to 45% (3.30-c) yield (Table 5). 
Considering procedures for the synthesis of related macrocyclic spherands, the yields between 20 and 
45% are quite good. Moreover, a gram scale procedure of macrocycle 3.30-b was successful conducted 
in similar yield of 41%.  Unfortunately, the C-H activation of the thiete dioxide 3.18-p, which would 
offer a coordination site in the ring cavity due to the inwards pointing sulfur atoms of the thiophene 
moiety, remains unsuccessful. As these structures are proved insoluble in many organic solvents as 
well as in water, resulting in unsatisfactory characterization by NMR. Instead, X-ray measurements 
and/or high-resolution mass analysis were used for characterization. 
Table 5: Cyclic thiete dioxide containing macrocycles and crystal structure.   
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Entry 3.18 Product  Yield[a] 
1 
 
  
3.30-a, 37% 
2 
 
 
 
3.30-b, 42% 
3 
 
 
 
3.30-c, 45% 
4 
 
 
 
3.30-d, 20% 
[a] Yield of isolated, analytically pure product. 
Crystal structures confirm the cyclic structures, consisting of three thiete dioxide units. In summary, 
further studies are needed to deepen the knowledge about properties and applications of these cyclic 
structures. 
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9 Outlook 
Mono- or disubstituted thiete dioxides are now readily available building blocks. However, many more 
transformations are imaginable. Therefore, a synthesis of chiral thiete mono-oxides could open new 
routes for diversification and transformation towards new properties and use in drug 
design/modification. For the generation of chiral thiete mono-oxides a similar approach will be used 
as for the previously synthesized thiete dioxides (see Chapter III “Synthesis of Thiete Dioxides”). The 
only difference and challenge would be the use of a chiral oxidant to mono-oxidize the sulfur atom 
(3.34) without obtaining overoxidation products or mixtures (Scheme 44).89  
 
Scheme 44: Synthesis of mono substituted chiral thiete mono oxides by a chiral oxidizer.  
The next step would involve the C-H activation, as demonstrated for thiete dioxides, in Chapter III  
“C-H Activation of Thiete Dioxides”, to grant access to disubstituted chiral thiete mono oxides (3.36) 
(Scheme 45).  
 
Scheme 45: C-H activation of mono substituted chiral thiete mono oxides towards disubstituted thietes. 
The generation of quaternary stereocenter-containing thietanones, could be done by 1,2-addition of 
organometallic species to chiral thiete mono-oxides (3.36), followed by electrophilic trapping 
(Scheme 46). By coordination of the metal from the metallic reagent by the oxygen, the 
carbometalation could be diastereoselectivly controlled in a syn-addition. This would ultimately lead 
to a new library of chiral thietanes 3.37. 
 
Scheme 46: 1,2-Addition of organometallic species to chiral thiete mono-oxides towards chiral thietanes.
 
89 For a review on chiral sulfoxides see: J. Han; V. A. Soloshonok; K. D. Klika; J. Drabowicz; A. Wzorek, Chem. Soc. 
Rev. 2018, 47, 1307. 
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Part A, Chapter IV, contains typical experimental procedures and selected examples for each topic 
discussed in this part. The full supporting information can be downloaded free of charge on the 
corresponding website of the publishing company. For unpublished results, the entire analytical data 
is shown.  
10 General Consideration 
Commercially available starting materials were used without further purification unless otherwise 
stated. All reactions were carried out under N2 atmosphere in flame-dried glassware. Syringes used to 
transfer anhydrous solvents or reagents were purged with nitrogen prior to use. CH2Cl2 was pre-dried 
over CaCl2 and distilled from CaH2. THF was refluxed and distilled from sodium benzophenone ketyl 
under nitrogen. Et2O was pre-dried over CaCl2 and passed through activated Al2O3 (the solvent 
purification system SPS-400-2 from Innovative Technologies Inc.). MeCN was purchased in HPLC 
gradient grade (>=99.9%) from Fisher Scientific. Chromatography purifications were performed using 
silica gel (SiO2, 0.040-0.063 mm, 230-400 mesh ASTM) from Merck or Florisil (MgSiO3, 60-100 mesh) 
from APOLLO. Some samples were purified with preparative-layer plates using Merck PLC silica gel 
60 F254 (2 mm). The spots were visualized under UV (254 nm) or by staining the TLC plate with KMnO4 
solution (3.0 g KMnO4, 300 mL H2O, 5 drops conc. H2SO4), p-anisaldehyde solution (4 mL p-
anisaldehyde, 200 mL ethanol, 3 mL acetic acid, 10 mL conc. H2SO4) and/or “curcumin” stain (100 mg, 
100 mL ethanol, 2 M HCl (99:1 v/v). Diastereoisomeric ratios were determined by 1H NMR and 13C NMR. 
NMR spectra were recorded on Mercury 200, Varian NMR-Systtem 600 or Bruker Avance III HD 
400 MHz equipped with a CryoProbe™ spectrometers. Chemical shifts are reported as δ values in ppm 
relative to residual solvent peak (1H NMR) or solvent peak (13C NMR) in deuterated chloroform (CDCl3: 
δ 7.26 ppm for 1H NMR and δ 77.16 ppm for 13C NMR) or deuterated acetonitrile (CD3CN: δ 1.94 ppm 
for 1H-NMR and δ 118.69 and δ 1.39 ppm for 13C-NMR). Further used deuterated solvent: benzene-d6. 
Abbreviations for signal coupling are as follows: s (singlet), d (doublet), t (triplet), q (quartet), quint 
(quintet), m (multiplet), app (apparent) and br (broad). Reaction endpoints were determined by gas 
chromatography with n-undecane as an internal standard or TLC monitoring of the reactions. Gas 
chromatography was performed with machines of Agilent Technologies 7890, using a column of type 
HP 5 (Agilent 5% phenylmethylpolysiloxane; length: 15 m; diameter: 0.25 mm; film thickness: 0.25 μm) 
or Hewlett-Packard 6890 or 5890 series II, using a column of type HP 5 (HewlettPackard, 5% 
phenylmethylpolysiloxane; length: 15 m; diameter: 0.25 mm; film thickness: 0.25 μm). High-resolution 
mass spectra (HRMS) and low-resolution mass spectra (LRMS) were recorded on Finnigan MAT 95Q or 
Finnigan MAT 90 instrument or JEOL JMS-700. Infrared spectra were recorded on a Perkin 281 IR 
spectrometer and samples were measured neat (ATR, Smiths Detection DuraSample IR II Diamond 
ATR). The absorption bands were reported in wave numbers (cm−1) and abbreviations for intensity are 
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as follows: vs (very strong; maximum intensity), s (strong; above 75% of max. intensity), m (medium; 
from 50% to 75% of max. intensity), w (weak; from 25% to 50% of max. intensity), vw (very weak; 
below 25%) and br (broad). Melting points were determined on a Büchi B-540 apparatus and are 
uncorrected. Single crystals were grown in small vials with a volume of 5.0 mL from slow evaporation 
of dichloromethane/hexanes mixtures at room temperature. Suitable single crystals were then 
introduced into perfluorinated oil and mounted on top of a thin glass wire.  
Structure Determinations: The intensity data of 3.19-b, 3.19-d, 3.19-e, 3.19-f, 3.19-i, 3.19-k, 3.19-l, 
3.19-m, 3.19-q, 3.19-u, 3.19-w, 3.19-v, 3.30-a and 3.30-b was collected at a temperature of 293 K 
(3.19-b), 103 K (3.19-d), 100 K (3.19-e), 299 K (3.19-f), 100 K (3.19-i), 100 K (3.19-k), 143 K (3.19-l), 
143 K (3.19-m), 100 K (3.19-q), 100 K (3.19-u), 143 K (3.19-w), 298 K (3.19-v), 296 K (3.30-a), 110 K 
(3.30-b) on a Bruker D8 Venture TXS diffractometer with a Spellman generator (50 kV, 40 mA)  using 
Mo-K radiation (λ = 0.71073 Å). The structures were solved by direct methods (SHELXT)90 and refined by 
full-matrix least squares techniques against Fo2 (SHELXL-2014/7)91.  
Supporting Information available: Crystallographic data have been deposited at the Cambridge 
Crystallographic Data Centre: CCDC-1955894 for 3.19-b; CCDC-1955895 for 3.19-d; CCDC-1955896 for 
3.19-e; CCDC- 1955897 for 3.19-f; CCDC-1955902 for 3.19-i; CCDC- 1956145 for 3.19-k; CCDC- 1955898 
for 3.19-l; CCDC-1955899 for 3.19-m; CCDC-1955900 for 3.19-q; CCDC-1955901 for 3.19-u; CCDC-
1955903 for 3.19-w; CCDC-1955904 for 3.19-v; CCDC-1955905 for 3.30-a; CCDC-1955906 for 3.30-b. 
Copies of the data can be obtained free of charge: https://www.ccdc.cam.ac.uk/structures/. 
The concentration of organometallic reagent from commercially purchased and synthesized reagents 
was determined either by titration of isopropyl alcohol using the indicator 1,10-phenanthrolinein in 
THF or by using iodine dissolved in THF. 
  
 
90 G. M. Sheldrick, Acta Cryst. 2015, A71, 3. 
91 G. M. Sheldrick, Acta Cryst. 2015, C71, 3. 
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11 Experimental for Chapter I 
11.1 Unsaturated Four-Membered Rings: Efficient Strategies for the Construction of 
Cyclobutenes and Alkylidenecyclobutanes 
Synthesis of cyclobutenyl aluminium species and further trapping towards iodo-cyclobutenes 
 
To a solution of 4-bromobutyne 4.01 (10 mmol, 1.0 equiv.) in pentane (0.5 M) a solution of n-
butyllithium (10 mmol, 1.0 equiv.) in hexane at −78 °C was added dropwise and stirred for 30 minutes. 
A second flask was charged with Cp2ZrCl2 (10 mmol, 1.0 equiv.) in CH2Cl2 (0.5 M) and a solution of 
trimethylaluminium (20 mmol, 2.0 equiv.) in hexane was added at room temperature and stirred for 
30 minutes. The second solution was transferred to the first one at −78 °C via cannula. The resulting 
mixture was then allowed to stir at room temperature for 2 hours to form the metallated cyclobutenyl 
derivative 4.02. The suspension was cooled to -78 °C and a solution of iodine in THF (15 mmol, 
1.5 equiv.) was added slowly. After stirring for 30 mins at aforesaid temperature, the mixture was 
slowly poured onto ice-cold hydrochloric acid (10 equiv., 0.5 M HCl), while stirring vigorously. The 
aqueous phase was extracted with hexanes (3 × 50 mL). The combined organic phases were washed 
with saturated aqueous sodium hydrogen carbonate solution (50 mL) and brine (50 mL). The washed 
solution was dried over magnesium sulfate, filtrated and concentrated under reduced pressure at 10 °C 
(careful, as some products 4.03 are quite volatile). The crude cyclobutyl iodide 4.03 was purified by 
flash column chromatography over silica using pentanes as an eluent.  
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(2-(3-Iodo-2-methylcyclobut-2-en-1-yl)ethyl)benzene (selected example) 
Using (3-bromohex-5-yn-1-yl)benzene provided the product (3.38 g, 62%) as a colourless oil. 
Rf = 0.58 (hexane, UV, KMnO4). 1H NMR (400 MHz, CDCl3): δ: 7.31-7.25 (m, 2H), 7.22-7.14 (m, 3H), 2.96 
(dtt, J = 9.2, 4.7, 1.4 Hz, 1H), 2.87 (ddq, J = 12.3, 4.5, 2.3 Hz, 1H), 2.64 (dd, J = 8.8, 6.9 Hz, 2H), 2.42-2.32 
(m, 1H), 1.95 (dddd, J = 13.3, 8.4, 7.3, 4.9 Hz, 1H), 1.73-1.62 (m, 1H), 1.59 ppm (td, J = 2.3, 1.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3): δ: 157.9, 142.2, 128.5 (2 13C signals overlapping), 126.0, 83.3, 48.3, 43.1, 
34.6, 33.8, 14.9 ppm. LRMS (DEP/EI-Orbitrap): m/z [%]: 298.0 (3), 171.1 (16), 143.1 (24), 129.1 (12), 
117.1 (82), 91.1 (100). HRMS (EI-Orbitrap): m/z: [M+] Calcd for C13H15I+: 298:0218, found 298:0214. IR 
(Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 3085 (vw) 3062 (vw) 3026 (w) 2923 (m) 2847 (w) 1648 (w) 1603 (w) 
1496 (m) 1453 (m) 1436 (w) 1371 (w) 1319 (vw) 1239 (m) 1181 (w) 1094 (w) 1057 (w) 1029 (w) 
1022 (w) 1002 (w) 977 (m) 902 (w) 863 (w) 840 (w) 744 (m) 696 (vs) 661 cm-1 (m). 
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1H NMR (400 MHz, CDCl3)  
 
13C NMR (101 MHz, CDCl3) 
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Synthesis of cyclobutenyl zinc species and further trapping towards iodo-cyclobutenes or in-situ 
Negishi cross-coupling 
 
To a stirred solution of 4-bromobut-1-yne 4.04 (1 mmol, 1.0 equiv.) in THF (0.2 M) was added dropwise 
n-butyllithium (1 mmol, 1.0 equiv.) at -78 °C. After 15 min the cooling bath was exchanged to an -30 °C 
one. This temperature was maintained for 5 min before adding dropwise the allyl-zinc-species 4.05 
(1 mmol, 1.0 equiv.). After 10 min the cooling bath was removed, and the colourless solution was 
warmed to room temperature over 1 h. The colour changed from colourless to pale yellowish. 
a) Formation of iodo-cyclobutenes 
The reaction mixture was treated with iodine (1 mmol, 1.0 equiv.) followed by a small amount of 
water. The crude mixture was extracted three times with diethyl ether and dried over dry magnesium 
sulfate. filtrated and concentrated under reduced pressure at 10 °C. The crude cyclobutyl iodide 4.07 
was purified by flash column chromatography over silica using hexanes as an eluent. 
b) In-situ Negishi cross-coupling 
Pd(dba)2 (4 mol%) and TFP (8 mol%) were dissolved in THF in a second flask. After 10-20 min the red 
solution turned to yellow. The aryl-iodide 4.08 (0.95 mmol, 0.95 equiv.) was added in THF (0.15 M) to 
the yellow solution of the catalytic-system and stirred for 10 min. Finally, the cyclobutenyl-zinc-species 
4.06 was quickly added to the second flask with the aryl-iodide 4.08 and stirred for 1 h. After treatment 
with water, the crude mixture was extracted three times with diethyl ether and dried over dry 
magnesium sulfate. The solvent was removed under reduced pressure and the crude was purified by 
column chromatography or preparative-layer plates with appropriate solvent mixture to obtain aryl-
cyclobutene derivatives 4.09. 
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Negishi cross-coupling of iodo-cyclobutenes 
 
Pd(dba)2 (4 mol%) and TFP (8 mol%) was dissolved in THF in a flask. After 10-20 min the red solution 
turned to yellow. The iodo-cyclobutene 4.10 (0.95 mmol, 0.95 equiv.) was added in THF (0.15 M) to the 
yellow solution of the catalytic-system and stirred for 10 min. Finally, the alkenyl-zinc-species 4.11 
(1 mmol, 1.0 equiv.) was quickly added to the second flask with the cyclobutene-iodide 4.10 and stirred 
for 1 h. After treatment with water, the crude mixture was extracted three times with diethyl ether 
and dried over dry magnesium sulfate. The solvent was removed under reduced pressure and the 
crude was purified by column chromatography or preparative-layer plates with appropriate solvent 
mixture to obtain the cross-coupling product 4.12. 
 
2,4-Dibromo-6-(2-methyl-3-octylcyclobut-1-en-1-yl)pyridine (selected example) 
Using 1-iodo-2-methyl-3-octylcyclobut-1-ene provided the product (67 mg, 54%) as slightly yellow oil. 
Rf = 0.33 (hexane, UV, KMnO4). 1H NMR (400 MHz, CDCl3): δ: 7.42-7.40 (m, 1H), 7.17 (d, J = 1.4 Hz, 1H), 
2.83-2.70 (m, 1H), 2.70-2.59 (m, 1H), 2.24-2.14 (m, 1H), 2.11 (q, J = 1.9 Hz, 3H), 1.74-1.61 (m, 1H), 1.44-
1.16 (m, 13H), 0.88 ppm (t, J = 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ: 156.2, 154.1, 141.9, 133.6, 
133.6, 127.1, 121.8, 42.6, 32.5, 32.4, 31.9, 29.9, 29.6, 29.3, 27.5, 22.7, 14.6, 14.2 ppm. LRMS (DEP/EI-
Orbitrap): m/z [%]: 417.1 (8), 415.2 (14), 413,3 (8), 334.2 (14), 316,0 (20), 302.0 (100). HRMS (EI-
Orbitrap): m/z: [M+] Calcd for C18H2579Br2N+: 413.0345, found 413.0345. IR (Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 
3098 (vw), 2954 (w), 2921 (m), 2852 (m), 1654 (m), 1554 (vs), 1520 (s), 1465 (w), 1430 (w), 1380 (w), 
1368 (m), 1352 (m), 1300 (w), 1240 (vw), 1184 (w), 1151 (s), 1122 (w), 1081 (m), 974 (vw), 867 (w), 
839 (m), 773 (m), 746 (vs), 722 (w), 675 cm-1 (w). 
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1H NMR (400 MHz, CDCl3)  
 
13C NMR (101 MHz, CDCl3) 
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Suzuki cross-coupling of iodo-cyclobutenes 
 
To a stirred solution of cyclobutene-iodide 4.10 (1 mmol, 1.0 equiv.) in dioxane/H2O (2:1) (0.05 M) 
arylboronic acid 4.13 (1.33 mmol, 1.33 equiv.) and K2CO3 (2.7 equiv.) was added at room temperature. 
The reaction mixture was stirred for 10 min before adding the Pd(PPh3)4 (4 mol%). The cross-coupling 
was performed at 50 °C for 1 h. The colour of the reaction mixture turned after completion to red or 
black. Finally, the reaction was treated with a small amount of water, extracted three times with 
diethyl ether and dried over dry magnesium sulfate. The solvent was removed under reduced pressure 
and the crude was purified by column chromatography or preparative-layer plates with appropriate 
solvent mixture to obtain aryl-cyclobutene derivatives 4.14. 
 
N,N-Dimethyl-4-(2-(2-methylallyl)cyclobut-1-en-1-yl)aniline (selected example) 
Using 1-iodo-2-(2-methylallyl)cyclobut-1-ene provided the product (32 mg, 56%) as yellow oil. 
Rf = 0.7 (9:1 hexane/EtOAc, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 7.24-7.21 (m, 2H), 6.71-6.66 
(m, 2H), 4.79-4.76 (m, 2H), 3.05-3.02 (m, 2H), 2.93 (s, 6H), 2.62-2.57 (m, 2H), 2.42-2.38 (m, 2H), 
1.76 ppm (s, 3H). 13C NMR (101 MHz, CDCl3) δ 149.5, 143.2, 139.1, 135.6, 126.7, 125.2, 112.5, 111.2, 
77.2, 40.7, 39.1, 28.2, 26.1, 23.0 ppm. LRMS (DEP/EI-Orbitrap): m/z [%]: 226.2 (100), 212.2 (95), 197.1 
(35), 183.1 (90), 170.1 (45), 155.1 (35), 141.1 (50), 128.1 (65). HRMS (EI-Orbitrap): m/z: [M+] Calcd for 
C16H21N+: 227.1674, found 227.1660. IR (Diamond-ATR, neat) 𝜈max: 3075 (w), 2966 (w), 2911 (m), 
2835 (m), 1609 (s), 1520 (vs), 1480 (w), 1461 (w), 1444 (m), 1428 (w), 1353 (s), 1265 (w), 1224 (m), 
1194 (m), 1167 (m), 1128 (w), 1061 (w), 946 (m), 889 (m), 820 (m), 796 (m), 598 cm-1 (w). 
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1H NMR (400 MHz, CDCl3)  
 
13C NMR (101 MHz, CDCl3) 
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11.2 Stereoselective Sequence toward Biologically Active Fused Alkylidenecyclobutanes 
Synthesis of cyclobutenyl zinc species and further in-situ Negishi cross-coupling 
 
To a stirred solution of 4-bromobut-1-yne 4.04 (1 mmol, 1.0 equiv.) in THF (0.2 M) n-butyllithium 
(1 mmol, 1.0 equiv.) was added dropwise at -78 °C. After 15 min the cooling bath was exchanged to an 
-30 °C one. This temperature was maintained for 5 min before adding dropwise the allyl-zinc-species 
4.05 (1 mmol, 1.0 equiv.). After 10 min the cooling bath was removed, and the colourless solution was 
warmed to room temperature over 1 h. The colour changed from colourless to pale yellowish. During 
that time, Pd(dba)2 (4 mol%) and TFP (8 mol%) were dissolved in THF in a second flask. After 10-20 min 
the red solution turned to yellow. The iodo-alkene 4.15 (0.95 mmol, 0.95 equiv.) was added in THF 
(0.15 M) to the yellow solution of the catalytic-system and stirred for 10 min. Finally, the cyclobutenyl-
zinc-species 4.06 was quickly added to the second flask with the iodo-alkene 4.15 and stirred for 1 h. 
After treatment with water, the crude mixture was extracted three times with diethyl ether and dried 
over dry magnesium sulfate. The solvent was removed under reduced pressure and the crude was 
purified by column chromatography or preparative-layer plates with appropriate solvent mixture to 
obtain vinyl-cyclobutene derivative 4.16. 
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(E)-1-(6-Chlorohex-1-en-1-yl)-2-(2-methylallyl)cyclobut-1-ene (selected example) 
Using 4-bromobut-1-yne provided the product (0.59 mmol, 132 mg, 98%) as colorless oil. 
Rf = 0.65 (hexane, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 6.13 (d, J = 15.5, 1H), 5.55 (dt, J = 
14.8, 7.0 Hz, 1H), 4.76-4.71 (m, 2H), 3.54 (t, J = 6.7 Hz, 2H), 2.80 (s, 2H), 2.44-2.38 (m, 2H), 2.35-2.32 
(m, 2H), 2.13 (q, J = 7.2 Hz, 2H), 1.84-1.75 (m, 2H), 1.72 (s, 3H), 1.59-1.50 ppm (m, 2H). 13C NMR (101 
MHz, CDCl3) δ 143.4, 139.5, 139.3, 129.8, 123.6, 111.5, 45.1, 37.9, 32.2, 32.0, 28.2, 26.8, 25.6, 
22.8 ppm. LRMS (DEP/EI-Orbitrap): m/z [%]: 224.1 (10), 209.0 (10), 147.1 (10), 133.0 (90), 119.0 (40), 
105.0 (100), 91.0 (100). HRMS (EI-Orbitrap): m/z: [M+] Calcd for C14H21Cl [M]+: 224.1332, found 
224.1333. IR (Diamond-ATR, neat) max: 3076 (vw), 2937 (m), 2917 (m), 2869 (m), 2839 (w), 2361 (vw), 
1722 (m), 1714 (m), 1694 (m), 1679 (m), 1650 (m), 1631 (m), 1614 (w), 1444 (m), 1434 (m), 1374 (m), 
1302 (m), 1269 (m), 1222 (m), 1191 (m), 1174 (m), 1073 (m), 1060 (m), 1027 (m), 962 (vs), 891 (vs), 
800 (m), 740 (m), 725 cm-1 (s). 
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1H NMR (400 MHz, CDCl3)  
 
13C NMR (101 MHz, CDCl3) 
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Suzuki cross-coupling of iodo-cyclobutenes 
 
To a stirred solution of iodo-cyclobutene 4.10 (1 mmol, 1.0 equiv.) in THF (0.7 M) was added alkenyl 
boronic acid 4.17 (1.5 mmol, 1.5 equiv.), Pd(dppf)Cl2·CH2Cl2 (4 mol%) and NaOH (1.5 equiv.) (1.0 M) at 
room temperature. The reaction mixture was stirred for 1-4 h. The colour of the reaction mixture 
turned after completion to black. Finally, the reaction was treated with a small amount of water, 
extracted three times with diethyl ether and dried over magnesium sulfate. The solvent was removed 
under reduced pressure and the crude was purified by column chromatography with appropriate 
solvent mixture to obtain vinylcyclobutene 4.18. 
 
(E)-(2-(2-(2-Methylallyl)cyclobut-1-en-1-yl)vinyl)cyclohexane (selected example) 
Using 1-iodo-2-(2-methylallyl)cyclobut-1-ene provided the product (0.49 mmol, 106 mg, 98%) as 
colorless oil. 
Rf = 0.80 (hexane, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 6.10 (d, J = 15.6 Hz, 1H), 5.54 (dd, J = 
15.7, 6.9 Hz, 1H), 4.76 (s, 1H), 4.73 (s, 1H), 2.81 (s, 2H), 2.44-2.40 (m, 2H), 2.36-2.31 (m, 2H), 2.06-1.96 
(m, 1H), 1.75 (s, 2H), 1.72 (s, 4H), 1.69-1.61 (m, 1H), 1.34-1.04 ppm (m, 6H). 13C NMR (101 MHz, CDCl3) 
δ 143.4, 139.9, 138.9, 136.7, 120.3, 111.4, 40.9, 37.9, 33.1, 28.2, 26.3, 26.2, 25.6, 22.8 ppm. LRMS 
(DEP/EI-Orbitrap): m/z [%]: 216.2 (15), 201.2 (5), 187.2 (2), 173.2 (5), 159.2 (10), 145.1 (15), 133.1 (75), 
119.1 (40), 105.1 (85), 91.1 (100).  HRMS (EI-Orbitrap): m/z: [M+] Calcd for C16H24 [M]+: 216.1878, found 
216.1873. IR (Diamond-ATR, neat) max: 2927 (vs), 2853 (m), 1715 (m), 1697 (m), 1676 (m), 1648 (w), 
1627 (w), 1450 (m), 1374 (w), 1260 (w), 1188 (w), 1149 (w), 1077 (m), 1061 (w), 1022 (w), 971 (m), 
892 cm-1 (m). 
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1H NMR (400 MHz, CDCl3)  
  
13C NMR (101 MHz, CDCl3) 
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[4+2]-Cycloaddition reaction of isolated vinyl-cyclobutenes with suitable dienophiles 
 
Vinyl-cyclobutene 4.19 (1 mmol, 1.0 equiv.) and the corresponding cyclopentenedione derivative 4.20 
(2 mmol, 2.0 equiv.) were filled into a pressure tube and dissolved in toluene (1.0 M). The tube was 
sealed, slowly heated to 90 °C in an oil bath and stirred for 10-48 h. The progress was monitored by 
gas- and by thin-layer chromatography. The reaction was stopped after complete conversion, the 
solvent removed under reduced pressure and the crude product was purified by column 
chromatography with appropriate solvent mixture to obtain fused alkylidenecyclobutanes 4.21. 
 
(3aR*,4R*,7R*,7aR*,7bR*)-2,7a-Dimethyl-7-phenethyl-4-phenyl-3a,4,6,7,7a,7b-hexahydro-1H-
cyclobuta[e]isoindole-1,3(2H)-dione (selected example) 
Using (E)-(2-(2-(2-methylallyl)cyclobut-1-en-1-yl)vinyl)benzene provided the product (0.23 mmol, 
89 mg, 51%) as colourless solid. 
Rf = 0.30 (8:2 hexane/EtOAc, UV, KMnO4). 1H NMR (400 MHz, CDCl3) δ 7.35-7.29 (m, 4H), 7.24-7.20 (m, 
3H), 7.17-7.11 (m, 3H), 5.88 (s, 1H), 3.65 (d, J = 4.2 Hz, 1H), 3.33 (dd, J = 8.1, 4.6 Hz, 1H), 2.97 (d, J = 8.1 
Hz, 1H), 2.71 (s, 3H), 2.63-2.56 (m, 2H), 2.53-2.44 (m, 1H), 2.38-2.29 (m, 1H), 2.00-1.88 (m, 2H), 1.76-
1.67 (m, 1H), 1.35 ppm (s, 3H). 13C NMR (101 MHz, CDCl3) δ 177.3, 177.1, 145.7, 142.2, 140.6, 128.7, 
128.5, 128.4, 128.2, 126.8, 125.9, 116.2, 50.9, 49.7, 46.9, 42.8, 38.3, 33.7, 33.6, 31.7, 24.3, 21.0 ppm. 
LRMS (DEP/EI-Orbitrap): m/z [%]: 385.4 (45), 308.3 (5), 300.3 (10), 294.3 (90), 209.2 (35), 183.9 (40), 
167.1 (55), 131.1 (30), 117.1 (100). HRMS (EI-Orbitrap): m/z: [M+] Calcd for C26H27NO2 [M]+: 385.2042, 
found 385.2038. IR (Diamond-ATR, neat) max: 2929 (w), 1703 (vs), 1496 (w), 1452 (w), 1432 (w), 
1381 (w), 1280 (w), 1044 (w), 979 (w), 761 (w), 749 (w), 700 cm-1 (w). Melting point = 150 °C. 
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1H NMR (400 MHz, CDCl3)  
 
13C NMR (101 MHz, CDCl3) 
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11.3 Oxidative Ring Contraction of Cyclobutenes: General Approach to Cyclopropylketones 
including Mechanistic Insights 
Oxidative ring contraction of cyclobutenes with m-CPBA  
 
To cyclobutenes 4.22 (1 mmol, 1.0 equiv.) in CH2Cl2 (0.1 M) m-CPBA in CH2Cl2 (0.3 M, 1 mmol, 
1.0 equiv.) was added at 0 °C. The reaction was checked after 10 min by TLC, and another portion of 
m-CPBA (0.5 mmol, 0.5 equiv.) was added if the reaction was not complete. This step was repeated 
until full conversion of the substrates. The reaction was then treated by addition of NaOH (1 M) and 
extracted with CH2Cl2 (3 × 20 mL). Volatiles were removed under reduced pressure and the crude 
product purified by column chromatography with appropriate solvent mixture to obtain 
cyclopropylketones or -aldehydes 4.23. 
 
3-(1-Acetylcyclopropyl)benzaldehyde (selected example) 
Using 3-(2-methylcyclobut-1-en-1-yl)benzaldehyde provided the product (0.15 mmol, 27 mg, 58%) as 
colourless oil.  
Rf = 0.2 (hexane/EtOAc 9:1, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 10.03 (s, 1H), 7.89 (t, J = 1.7 
Hz, 1H), 7.82 (dt, J = 7.6, 1.5 Hz, 1H), 7.65 (ddd, J = 7.7, 1.9, 1.2 Hz, 1H), 7.54 (t, J = 7.6 Hz, 1H), 2.00 (s, 
3H), 1.67 (dd, J = 6.8, 4.2 Hz, 2H), 1.22 ppm (dd, J = 7.1, 3.7 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 207.7, 
192.2, 142.4, 137.1, 136.9, 131.5, 129.6, 129.4, 37.5, 29.2, 18.7 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 
188.1 (100). HRMS (EI-Orbitrap): m/z: [M+] Calcd for C12H12O2+: 188.0837; found: 188.0831. IR 
(Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 3010 (w), 1758 (w), 1720 (m), 1692 (vs), 1604 (w), 1586 cm
-1 (w). 
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13C NMR (101 MHz, CDCl3) 
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12 Experimental for Chapter II 
12.1 Methods for the Synthesis of Substituted Azetines 
Synthesis of 3-substituted 1-Boc-3-methoxyazetidines 
 
Commercially available tert-butyl 3-oxoazetidine-1-carboxylate 4.24 (5.0 mmol, 1.0 equiv.) was 
dissolved in THF (0.25 M) and cooled to -30 °C. The corresponding Grignard reagent (6.5 mmol, 
1.3 equiv.) was added dropwise and the solution stirred for one hour before warming to room 
temperature. The reaction mixture was treated with saturated NH4Cl and extracted twice with diethyl 
ether (2 x 20 mL). The combined organic layers were dried over magnesium sulfate and the solvents 
were evaporated under vacuum. The crude alcohol was then redissolved in THF (0.5 M) and cooled to 
0 °C. After adding sodium hydride (6.5 mmol, 1.3 equiv.) portion-wise, the reaction mixture was 
allowed to reach room temperature and stirred for one hour. Methyl iodide (6.5 mmol, 1.3 equiv.) was 
then added and the mixture stirred for two more hours at room temperature. The reaction was treated 
with methanol and the solvents were evaporated. The crude product was purified by column 
chromatography with appropriate solvent mixture to obtain 3-substituted 1-Boc-3-methoxyazetidines 
4.25. 
  
157 
 Part A - Chapter IV 
 
 
tert-Butyl 3-methoxy-3-(4-methoxyphenyl)azetidine-1-carboxylate (selected example) 
Using tert-butyl 3-oxoazetidine-1-carboxylate provided the product (3.75 mmol, 1.100 g, 75%) as 
colourless oil. 
Rf = 0.5 (hexane/EtOAc 9:1, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 7.25 (d, J = 8.5 Hz, 2H), 6.88 
(d, J = 8.5 Hz, 2H), 4.11 (s, 4H), 3.77 (s, 3H), 3.00 (s, 3H), 1.41 ppm (s, 9H). 13C NMR (101 MHz, CDCl3) δ 
159.3, 156.5, 131.7, 127.5, 113.9, 79.6, 76.3, 60.4, 58.4, 55.2, 51.3, 28.3 ppm. LRMS (ESI-quadrupole): 
m/z (%): 294.2 (85), 279.1 (45), 206.1 (100), 162.1 (5). HRMS (ESI-quadrupole): m/z: Calcd for 
C16H24NO4+: 294.1700, found 294.1702. IR (Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 2974 (w), 2938 (w), 2882 (w), 
2836 (vw), 1698 (vs), 1612 (m), 1584 (w), 1514 (m), 1456 (m), 1390 (vs), 1366 (s), 1304 (m), 1276 (m), 
1246 (vs), 1166 (s), 1148 (s), 1104 (vs), 1070 (s), 1034 (s), 1016 (m), 1002 (m), 930 (w), 860 (m), 830 (s), 
808 (m), 770 (m), 732 cm-1 (w). 
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1H NMR (400 MHz, CDCl3)  
 
13C NMR (101 MHz, CDCl3) 
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Synthesis of 2,3-substituted 1-Boc-2-azetines 
 
Azetidines 4.25 (0.5 mmol, 1.0 equiv.) were dissolved in THF (0.1 M) and the solution was cooled down 
to -78 °C. After the addition of TMEDA (1.3 mmol, 2.5 equiv.), sec-BuLi (1.3 mmol, 2.5 equiv.) was 
added dropwise and the mixture was stirred for one hour. The reaction was then treated with the 
corresponding electrophile 4.27 (1.0 mmol, 1.0 equiv.), stirred for 30 minutes and warmed up to room 
temperature. After workup with saturated NH4Cl and extraction with diethyl ether (2 x 10 mL), the 
organic phases were combined and dried over sodium sulfate. The solvents were evaporated, and the 
crude product was purified by column chromatography on preneutralized silica gel (1% NEt3) to obtain 
2,3-substituted 1-Boc-2-azetines 4.28. 
 
tert-Butyl 4-(hydroxy(4-(methylthio)phenyl)methyl)-3-phenylazete-1(2H)-carboxylate(selected 
example) 
Using tert-butyl 3-methoxy-3-phenylazetidine-1-carboxylate provided the product (0.30 mmol, 
115 mg, 60%) as yellow oil. 
Rf = 0.55 (hexane/EtOAc 8:2, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 8.2 Hz, 2H), 
7.33-7.27 (m, 2H), 7.25-7.17 (m, 3H), 7.16-7.12 (m, 2H), 6.18 (s, 1H), 5.81 (d, J = 10.3 Hz, 1H), 4.60 (d, J 
= 11.3 Hz, 1H), 4.56 (d, J = 11.2 Hz, 1H), 2.47 (s, 3H), 1.46 ppm (s, 9H). 13C NMR (101 MHz, CDCl3) δ 
144.0, 139.5, 137.9, 137.9, 131.7, 128.9, 127.3, 126.8, 126.7, 125.1, 121.0, 81.9, 68.2, 56.2, 28.4, 
16.0 ppm. LRMS (ESI-quadrupole): 367.2 (10), 366.2 (75), 310.0 (100), 266.1 (10). HRMS (ESI-
quadrupole): m/z: Calcd for C22H24NO2S+[M-OH]+: 366.1528, found 366.1525. IR (Diamond-ATR, neat) 
𝜈𝑚𝑎𝑥: 3334 (w), 2974 (w), 2922 (w), 2874 (w), 1672 (s), 1598 (w), 1492 (m), 1478 (m), 1448 (s), 1412 
(vs) cm-1(s). 
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Synthesis of 2,3-substituted 1-Boc-2-azetines through Suzuki cross-coupling  
 
Azetidines 4.25 (0.5 mmol, 1.0 equiv.) were dissolved in THF (0.1 M) and the solution was cooled down 
to -78 °C. After the addition of TMEDA (1.3 mmol, 2.5 equiv.), sec-BuLi (1.3 mmol, 2.5 equiv.) was 
added dropwise and the mixture stirred for one hour. B(Oi-Pr)3 (1.0 mmol, 2.0 equiv.) was then added 
and the resulting mixture was stirred for 10 min at -78 °C before being warmed to 0 °C and stirred for 
another hour. Pd(dppf)Cl2 · CH2Cl2 (4 mol%), the corresponding aryl halide 4.30 (1.0 mmol, 2.0 equiv.) 
and an aqueous solution of sodium hydroxide (1.5 mmol, 3.0 equiv., 1 M) were consecutively added. 
The reaction mixture was then stirred for 48 h at ambient temperature. After aqueous workup and 
extraction with diethyl ether (2 x 10 mL), the organic phases were combined and dried over sodium 
sulfate. The solvents were evaporated, and the crude product was purified by column chromatography 
on preneutralized silica gel (1% NEt3) obtain 2,3-substituted 1-Boc-2-azetines 4.31. 
 
tert-Butyl 4-(2,6-dimethoxypyrimidin-4-yl)-3-phenylazete-1(2H)-carboxylate (selected example) 
Using tert-butyl 3-methoxy-3-phenylazetidine-1-carboxylate provided the product (0.40 mmol, 
146 mg, 79%) as yellow oil. 
Rf = 0.5 (hexane/EtOAc 8:2, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 7.81 (d, J = 7.3 Hz, 2H), 7.27-
7.16 (m, 3H), 6.78 (s, 1H), 4.60 (s, 2H), 3.99 (s, 3H), 3.91 (s, 3H), 1.38 ppm (s, 9H). 13C NMR (101 MHz, 
CDCl3) δ 172.1, 165.1, 157.0, 153.9, 140.4, 131.6, 129.9, 128.5, 128.4, 127.1, 101.9, 81.3, 56.9, 55.2, 
54.2, 28.3 ppm. LRMS (ESI-quadrupole): m/z 369.3 (15), 301.2 (5), 296.2 (10), 268.2 (100), 254.1 (10), 
196.1 (15), 166.0 (40), 140.0 (55). HRMS (ESI-quadrupole): Calcd for C20H23N3O4+: 369.1689, found 
369.1684. IR (Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 2978 (w), 2954 (w), 2856 (vw), 1742 (w), 1706 (s), 1626 (w), 
1578 (s), 1556 (s), 1496 (w), 1476 (m), 1456 (m), 1390 (s), 1354 cm-1 (vs). 
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1H NMR (400 MHz, CDCl3)  
 
13C NMR (101 MHz, CDCl3) 
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Synthesis of 2,3-substituted 1-Boc-2-azetines through Zweifel reaction 
 
Azetidines 4.25 (0.5 mmol, 1.0 equiv.) were dissolved in THF (0.1 M) and the solution was cooled down 
to -78 °C. After the addition of TMEDA (1.3 mmol, 2.5 equiv.), sec-BuLi (1.3 mmol, 2.5 equiv.) was 
added dropwise and the mixture was stirred for one hour. The corresponding pinacol arylboronate 
4.32 was added in THF (0.5 mmol, 1.0 equiv., 0.25 M) and the resulting mixture was stirred at -78 °C 
and then 0 °C for 15 min each. The mixture was then cooled back to -78 °C and a solution of iodine in 
THF (0.5 mmol, 1.0 equiv., 0.25 M) was added dropwise, followed by the addition of a suspension of 
sodium methoxide in methanol (5.0 mmol, 10 equiv., 2.5 M). The mixture was then stirred at 0 °C for 
30 min and subsequently at ambient temperature overnight. After aqueous workup and extraction 
with diethyl ether (2 x 10 mL), the organic phases were combined and dried over sodium sulfate. The 
solvents were evaporated, and the crude product was purified by column chromatography on 
preneutralized silica gel (1% NEt3) obtain 2,3-substituted 1-Boc-2-azetines 4.31. 
 
tert-Butyl 3-(phenylethynyl)-4-(pyridin-2-yl)azete-1(2H)-carboxylate (selected example) 
Using tert-butyl 3-methoxy-3-(phenylethynyl)azetidine-1-carboxylate provided the product 
(0.34 mmol, 111 mg, 67%) as orange oil. 
Rf = 0.7 (hexane/EtOAc 8:2, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 8.70 (ddd, J = 4.8, 1.8, 1.0 Hz, 
1H), 7.88 (d, J = 7.9 Hz, 1H), 7.72 (td, J = 7.8, 1.8 Hz, 1H), 7.53-7.43 (m, 2H), 7.36-7.29 (m, 3H), 7.23 
(ddd, J = 7.5, 4.8, 1.2 Hz, 1H), 4.58 (s, 2H), 1.45 ppm (s, 9H). 13C NMR (101 MHz, CDCl3) δ 152.7, 151.7, 
149.7, 148.2, 136.0, 131.7, 128.5, 128.4, 123.5, 123.2, 105.4, 96.6, 82.5, 81.4, 59.3, 28.3 ppm.  LRMS 
(EI-Orbitrap): m/z 332.3 (20), 259.2 (5), 232.2 (100), 204.1 (10), 127.0 (5), 105.0 (15). HRMS (EI-
Orbitrap): m/z: [M+] Calcd for C21H20N2O2+: 332.1525, found 332.1520.  IR (Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 
2978 (w), 2944 (vw), 2934 (vw), 1708 (vs), 1654 (vw), 1646 (vw), 1628 (w), 1580 (w), 1560 (vw), 
1506 cm-1 (vw). 
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1H NMR (400 MHz, CDCl3)  
 
13C NMR (101 MHz, CDCl3) 
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12.2 One-Pot Preparation of Stable Organoboronate Reagents for the Functionalization of 
Unsaturated Four- and Five-Membered Carbo- and Heterocycles 
Synthesis of stable azetine-containing-borates and further stability tests via Suzuki-Miyaura cross-
coupling 
 
Azetidines 4.25 (10 mmol, 1.0 equiv.) were dissolved in THF (0.1 M) and the solution was cooled down 
to -78 °C. After the addition of TMEDA (13 mmol, 2.5 equiv.), sec-BuLi (13 mmol, 2.5 equiv.) was added 
dropwise and the mixture was stirred for one hour. B(Oi-Pr)3 (10 mmol, 2.0 equiv.) was then added 
and the resulting mixture was stirred for 10 min at -78 °C before being warmed to room temperature 
and stirred for another 1 h. The so obtained tetraorganoborates 4.29 were stored under different 
conditions and, regarding to stability, tested over several month via Suzuki-Miyaura cross-coupling 
reactions: 
Pd(dppf)Cl2 · CH2Cl2 (4 mol%), the corresponding aryl halide 4.30 (1.0 mmol, 2.0 equiv.) and an aqueous 
solution of sodium hydroxide (1.5 mmol, 3.0 equiv., 1 M) were consecutively added to the dissolved 
tetraorganoborate 4.29 in THF (0.5 mmol, 1.0 equiv.). The reaction mixture was then stirred for 48 h at 
ambient temperature. After aqueous workup and extraction with diethyl ether (2 x 10 mL), the organic 
phases were combined and dried over sodium sulfate. The solvents were evaporated, and the crude 
product was purified by column chromatography on preneutralized silica gel (1% NEt3) obtain 2,3-
substituted 1-Boc-2-azetines 4.31. 
Synthesis of stable cyclobutene-containing-borates and further stability tests via Suzuki-Miyaura cross-
coupling 
 
To a solution of 1-iodo-2-methylcyclobut-1-ene 4.32 (10 mmol, 1.0 equiv.) in Et2O (0.5 M) a solution of 
n-BuLi (11 mmol, 1.1 equiv.) was slowly added at -78 °C. After stirring for 30 min at the aforementioned 
temperature, B(Oi-Pr)3 (11.5 mmol, 1.15 equiv.) and THF (total concn 0.25 M) were added and the 
resulting mixture was stirred for an additional 1 h at room temperature. Then obtained 
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tetraorganoborate 4.33 was stored under different conditions and, regarding to stability, tested over 
several month via Suzuki-Miyaura cross-coupling reactions: 
Pd(dppf)Cl2 · CH2Cl2 (4 mol%), the corresponding aryl halide 4.30 (1.0 mmol, 2.0 equiv.) and an aqueous 
solution of sodium hydroxide (1.5 mmol, 3.0 equiv., 1 M) were consecutively added to the dissolved 
tetraorganoborate 4.33 in THF (0.5 mmol, 1.0 equiv.). The reaction mixture was then stirred for 48 h at 
ambient temperature. After aqueous workup and extraction with diethyl ether (2 x 10 mL), the organic 
phases were combined and dried over sodium sulfate. The solvents were evaporated, and the crude 
product was purified by column chromatography on silica gel to obtain functionalized cyclobutenes 
4.35. 
 
1-(2-Methylcyclobut-1-en-1-yl)isoquinoline (selected example) 
Using 1-iodo-2-methylcyclobut-1-ene provided the product (0.13 mmol, 25 mg, 64%) as a colorless oil. 
Rf = 0.3 (hexane/EtOAc 9:1, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ = 8.52 (d, J = 5.6 Hz, 1H), 
8.30 (d, J = 8.5 Hz, 1H), 7.80 (d, J = 7.0 Hz, 1H), 7.67-7.63 (m, 1H), 7.56 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H), 
7.50 (d, J = 5.6 Hz, 1H), 3.11-3.06 (m, 2H), 2.63-2.57 (m, 2H), 2.02 ppm (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 155.3, 147.5, 142.5, 137.8, 136.8, 129.9, 127.1, 126.9, 126.7, 126.6, 119.2, 31.1, 29.9, 17.2 
ppm. LRMS (EI-Orbitrap): m/z 194 [M-H]+ (100), 180 (100), 167 (30), 154 (20). HRMS (EI-Orbitrap): m/z: 
[M+] Calcd for C14H12N: 194.0970 [M-H]+; found: 194.0962. 
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1H NMR (400 MHz, CDCl3)  
 
13C NMR (101 MHz, CDCl3) 
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12.3 Chemodivergent and Stereoselective Access to Fused Isoxazoline Azetidines and 
Thietanes through [3+2]-Cycloadditions 
Synthesis of fused isoxazoline azetidines with mono-substituted azetines 
 
Azetidines 4.25 (1 mmol, 1.0 equiv.) were dissolved in THF (0.1 M) and the solution was cooled down 
to -78 °C. After the addition of TMEDA (1.3 mmol, 2.5 equiv.), sec-BuLi (1.3 mmol, 2.5 equiv.) was 
added dropwise and the mixture was stirred for one hour. The reaction was then treated with water 
(2.0 mmol, 2 equiv.), stirred for 30 minutes and warmed up to room temperature. The solvents were 
evaporated and the crude azetines 4.36 were dissolved in dichloromethane (0.25 M) and transferred 
in a BIOTAGE Microwave reaction vessel equipped with a magnetic stirring bar. Triethylamine (3 mmol, 
6.0 equiv.) was added at once at room temperature followed by the corresponding chlorooxime 4.37 
(1 mmol, 1 equiv.). The vial was sealed and heated in a BIOTAGE Initiator+ Robot Sixty microwave 
synthesizer to 100 °C (measured by the vertically focused IR temperature sensor) for 30 min. The 
reaction cycle was repeated another two times, each time adding additionally 1.0-2.0 equiv. of 
chlorooxime 4.37 (2.0-3.0 equiv. in total). The completion of the cycloaddition reaction was monitored 
by thin layer chromatography. After the reaction was complete, the crude mixture was extracted three 
times with dichloromethane. The combined organic layers were dried over magnesium sulfate, filtered 
and concentrated under reduced pressure. Purification of the crude products by flash column 
chromatography with appropriate solvent mixtures afforded the desired cycloaddition reaction 
products 4.38. 
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tert-Butyl-(1S*,5R*)-5-(4-(dimethylamino)phenyl)-4-(4-methoxyphenyl)-2-oxa-3,7-
diazabicyclo[3.2.0]hept-3-ene-7-carboxylate (selected example) 
Using tert-Butyl 3-(4-(dimethylamino)phenyl)-3-methoxyazetidine-1-carboxylate provided the product 
(0.22 mmol, 91 mg, 44%) as yellowish oil.  
Rf = 0.5 (hexane/EtOAc 7:3, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 7.50-7.46 (m, 2H), 7.12-7.07 
(m, 2H), 6.80-6.75 (m, 2H), 6.72-6.65 (m, 2H), 5.99 (s, 1H), 4.66 (d, J = 8.0 Hz, 1H), 4.30 (d, J = 8.0 Hz, 
1H), 3.76 (s, 3H), 2.94 (s, 6H), 1.47 ppm (s, 9H). 13C NMR (101 MHz, CDCl3) δ 161.1, 155.4, 150.1, 129.4, 
127.5, 121.9, 119.8, 114.3, 112.8, 99.7, 81.1, 61.7, 55.4, 53.7, 40.5, 28.4 ppm.  LRMS (DEP/EI-Orbitrap): 
m/z (%): 423.5 (15), 323.3 (90), 294.2 (100). HRMS (EI-Orbitrap): m/z: [M+] Calcd for C24H29N3O4+: 
423.2158; found: 423.2152. IR (Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 2976 (w), 2934 (vw), 2897 (vw), 2838 (vw), 
2251 (vw), 1703 (m), 1610 (m), 1524 (m), 1514 cm-1 (m).  
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1H NMR (400 MHz, CDCl3)  
 
13C NMR (101 MHz, CDCl3) 
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13 Experimental for Chapter III 
13.1 Chemodivergent and Stereoselective Access to Fused Isoxazoline Azetidines and 
Thietanes through [3+2]-Cycloadditions 
Synthesis of mono-substituted thiete dioxides 
 
A flask was charged with thietan-3-one 4.39 (10.0 mmol, 1.0 equiv.) and THF (0.5 M) was added. The 
reaction mixture was cooled to -78 °C and a solution of organolithium reagent (1.30 equiv.) was added 
dropwise.  Alternatively, the reaction mixture was cooled to -30 °C and a solution of organomagnesium 
reagent (1.30 equiv.) was added dropwise. After stirring for 60 min the mixture was brought to 
ambient temperature and treated with a solution of saturated aqueous NH4Cl. The aqueous phase was 
extracted with dichloromethane (3 × 50 mL) and washed with a solution of saturated aqueous sodium 
chlorid (1 × 50 mL). The combined organic phases were dried over magnesium sulfate and 
concentrated in vacuo. The residue, containing the thietanol 4.40, was dissolved in dichloromethane 
(50 mL), cooled to 0 °C and m-CPBA (20.0 mmol, 2.0 equiv., 77%) was added portion wise. After TLC 
showed full conversion of the thietanol 4.40 (approx. 10 min) water was added. The aqueous phase 
was extracted with dichloromethane (3 × 50 mL) and washed with a solution of saturated aqueous 
sodium chloride (1 × 50 mL). The combined organic phases were dried over magnesium sulfate, filtered 
and concentrated in vacuo. The residue, containing the thietanol dioxide 4.41, was dissolved in 
dichloromethane (50 mL) and triethylamine (30 mmol, 3.0 equiv.) was added. Mesylchlorid (30 mmol, 
3.0 equiv.) was subsequently added dropwise and the mixture was stirred until TLC indicated full 
conversion of the starting thietanol dioxide 4.41 (approx. 30 min) water was added. The aqueous 
phase was extracted with dichloromethane (3 × 50 mL) and washed with a solution of saturated 
aqueous sodium chloride (1 × 50 mL). The combined organic phases were dried over magnesium 
sulfate, filtered and concentrated in vacuo. The crude thiete dioxides 4.42 were purified by flash 
column chromatography with appropriate solvent mixtures. 
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3-(4'-Methoxy-[1,1'-biphenyl]-2-yl)-2H-thiete 1,1-dioxide (selected example) 
Using (4'-methoxy-[1,1'-biphenyl]-2-yl)lithium provided the product (1.37 g, 4.8 mmol, 48%) as a 
yellowish solid.  
Rf = 0.25 (hexane/EtOAc 8:2, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 7.52 (td, J = 7.4, 1.6 Hz, 
1H), 7.46-7.37 (m, 2H), 7.34 (dd, J = 7.6, 1.3 Hz, 1H), 7.22-7.17 (m, 2H), 7.01-6.95 (m, 2H), 5.98 (s, 1H), 
4.47 (s, 2H), 3.87 ppm (s, 3H). 13C NMR (101 MHz, CDCl3) δ 159.9, 147.2, 143.2, 139.6, 132.4, 131.7, 
131.5, 129.9, 129.3, 128.0, 127.9, 114.4, 71.5, 55.5 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 286.1 (5), 
237.1 (5), 221.0 (100), 207.0 (25). HRMS (EI-Orbitrap): m/z: [M]+ Calcd for C16H14O332S+: 286.0664; 
found: 286.0658. IR (Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 2961 (w), 2958 (w), 2934 (w), 2929 (w), 2919 (w), 1610 
(m), 1598 (w), 1574 (w), 1558 (w), 1516 cm-1 (m). Melting point: 120 (±2) °C. 
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1H NMR (400 MHz, CDCl3)  
 
13C NMR (101 MHz, CDCl3) 
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Synthesis of fused isoxazoline thietanes with mono-substituted thiete dioxides 
 
A 0.5-2.0 mL BIOTAGE Microwave reaction vessel equipped with a magnetic stirring bar was charged 
with the respective mono-substituted thiete dioxide 4.42 (0.2 mmol, 1.0 equiv.) followed by the 
corresponding chlorooxime 4.37 (0.2 mmol, 1.0 equiv.). The mixture was dissolved in dichloromethane 
(0.1 M) before triethylamine (1.2 mmol, 6.0 equiv.) was added at once at room temperature. The vial 
was sealed and heated in a BIOTAGE Initiator+ Robot Sixty microwave synthesizer to 100 °C (measured 
by the vertically focused IR temperature sensor) for 30 min. The reaction cycle was repeated another 
two times, each time adding additionally 1.0-2.0 equiv. of chlorooxime 4.37 (2.0-3.0 equiv. in total). 
The completion of the cycloaddition reaction was monitored by thin layer chromatography. After the 
reaction was complete, the crude mixture was extracted three times with dichloromethane. The 
combined organic layers were dried over magnesium sulfate, filtered and concentrated under reduced 
pressure. Purification of the crude products by flash column chromatography with appropriate solvent 
mixtures afforded the desired cycloaddition reaction products 4.43.  
 
(1S*,5S*)-1-(naphthalen-1-yl)-4-phenyl-2-oxa-6-thia-3-azabicyclo[3.2.0]hept-3-ene 6,6-dioxide 
(selected example) 
Using 3-(naphthalen-1-yl)-2H-thiete 1,1-dioxide provided the product (0.16 mmol, 56 mg, 80%) as 
white solid.  
Rf = 0.5 (hexane/EtOAc 8:2, UV, KMnO4). 1H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 8.4 Hz, 1H), 7.97 (d, J 
= 8.0 Hz, 2H), 7.83-7.76 (m, 2H), 7.68-7.57 (m, 3H), 7.54-7.47 (m, 4H), 6.59 (dd, J = 3.8, 1.3 Hz, 1H), 5.33 
(dd, J = 14.3, 1.2 Hz, 1H), 4.98 ppm (dd, J = 14.4, 3.8 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 151.9, 134.8, 
131.5, 131.5, 129.9, 129.8, 129.6, 129.3, 127.6, 127.4, 126.8, 124.9, 124.8, 124.3, 91.5, 82.8, 81.6 ppm. 
LRMS (DEP/EI-Orbitrap): m/z (%): 349.3 (10), 271.1 (100), 254.1 (5), 242.1 (3), 207.0 (30). HRMS (EI-
Orbitrap): m/z: [M+] Calcd for C20H15NO3S+: 349.0773; found: 349.0768. IR (Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 
3053(w), 3037(vw), 3021(w), 3018(w), 2992(vw), 2953(w), 2923(w), 2920(w), 1600(w), 1511 cm-1 (w). 
Melting point: 220 (±2) °C. 
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1H NMR (400 MHz, CDCl3)  
 
13C NMR (101 MHz, CDCl3) 
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13.2 Disubstituted Thiete Dioxides – Donor/Acceptor- Interactions towards Axial Chirality 
General procedure: C-H Functionalization of 2H-thiete 1,1- dioxides 
 
A pressure tube was charged with 2H-thiete 1,1- dioxides derivative 3.18 (0.2 mmol, 1 equiv.) and 2 mL 
toluene was added. Subsequently, K2CO3 (55 mg, 0.4 mmol, 2.0 equiv.), Pd(Oak)2 (1.8 mg, 8 μmol, 
4 mol%), tricyclohexylphosphane (PCy3) (4.5 mg, 16 μmol, 8 mol%), the corresponding arylbromide 
(0.3 mmol, 1.5 equiv.) and a few drops of pivalic acid (~7 μL, 30 mol%) were added. The mixture was 
stirred at 100 °C in the sealed pressure tube until TLC showed consumption of the starting 2H-thiete 
1,1- dioxides (approx. 16 hours). After cooling to ambient temperature, the tube was opened and a 1:1 
mixture of H2O:Et2O (4 mL) was added. The aqueous phase was extracted with Et2O (3 x 20 mL). The 
combined organic phases were dried over magnesium sulfate, filtrated, concentrated in vacuo and 
purified by flash-column chromatography on silica gel with the appropriate solvent mixture to obtain 
pure 3.19. 
 
3-Phenyl-4-(4-phenylpyridin-3-yl)-2H-thiete 1,1-dioxide (3.19-a) (selected example) 
Using 4-(2-bromophenyl)pyridine according to general procedure, provided 3.19-a (41 mg, 0.12 mmol, 
62%) as a white solid.  
Rf = 0.2 (hexane/EtOAc 7:3, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 8.90 (s, 1H), 8.77 (d, J = 5.1 
Hz, 1H), 7.50-7.30 (m, 4H), 7.26 (s, 5H), 7.01 (d, J = 7.6 Hz, 2H), 4.74 ppm (s, 2H). 13C NMR (101 MHz, 
CDCl3) δ 151.5, 150.5, 150.1, 146.4, 141.9, 137.1, 131.8, 129.2, 129.0, 128.8, 128.6, 128.5, 128.2, 124.7, 
122.3, 69.5 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 333.1 (2), 268.1 (100), 191.1 (30). HRMS (EI-
Orbitrap): m/z: [M-HSO2]+ Calcd for C20H14N+: 268.1126; found: 268.1129. IR (Diamond-ATR, neat) 
𝜈𝑚𝑎𝑥: 2970 (w), 2909 (w), 1582 (w), 1576 (w), 1476 (w), 1447 (w), 1405 (w), 1334 (w), 1293 (s), 1278 
(m), 1262 (w), 1203 (m), 1189 (w), 1180 (w), 1132 (vs), 1104 (w), 1076 (m), 1064 (w), 1041 (w), 1022 
(w), 988 (w), 958 (w), 910 (w), 851 (m), 836 (w), 780 (m), 761 cm-1 (s).  Melting point: 216 (±2) °C.  
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1H NMR (400 MHz, CDCl3)  
 
13C NMR (101 MHz, CDCl3) 
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3,4-Di(naphthalen-1-yl)-2H-thiete 1,1-dioxide (3.19-b) 
Using 1-bromonaphthalene according to general procedure, provided 3.19-b (0.50 g, 1.4 mmol, 70%) 
as a brownish solid.  
Rf = 0.4 (hexane/EtOAc 8:2, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 8.12 (dd, J = 8.5, 1.1 Hz, 1H), 
7.91-7.74 (m, 5H), 7.59 (dd, J = 7.2, 1.2 Hz, 1H), 7.52 (dd, J = 7.2, 1.3 Hz, 1H), 7.47-7.30 (m, 5H), 7.21 
(ddd, J = 8.4, 6.9, 1.3 Hz, 1H), 5.16 ppm (s, 2H). 13C NMR (101 MHz, CDCl3) δ 153.7, 141.2, 133.7, 133.6, 
131.5, 131.1, 130.8, 129.7, 128.9, 128.6, 128.5, 128.3, 127.4, 127.3, 127.2, 126.7, 126.6, 125.5, 125.3, 
125.3, 125.2, 124.7, 72.3 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 356.2 (10), 339.1 (2), 308.2 (60), 291.1 
(100), 276.1 (95). HRMS (EI-Orbitrap): m/z: [M]+ Calcd for C23H16O2S+: 356.0871; found: 356.0863. IR 
(Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 2364 (m), 2358 (m), 2344 (w), 1312 (w), 1296 (m), 1287 (s), 1276 (m), 1260 
(m), 1251 (m), 1235 (m), 1218 (m), 1204 (m), 1183 (s), 1138 (s), 1114 (m), 1087 (m), 1057 (w), 981 (m), 
803 cm-1 (m).  Melting point: 170 (±2) °C. 
 
4-(Isoquinolin-4-yl)-3-(naphthalen-1-yl)-2H-thiete 1,1-dioxide (3.19-c) 
Using 4-bromoisoquinoline according to general procedure, provided 3.19-c (50 mg, 0.14 mmol, 70%) 
as a white solid.  
Rf = 0.2 (hexane/EtOAc 7:3, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 9.17 (s, 1H), 8.43 (s, 1H), 
8.24 (d, J = 8.4 Hz, 1H), 7.96 (d, J = 8.1 Hz, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.82 (d, J = 8.2 Hz, 1H), 7.70 (t, J 
= 8.3 Hz, 2H), 7.62 (t, J = 7.5 Hz, 1H), 7.54 (d, J = 7.1 Hz, 1H), 7.49-7.44 (m, 1H), 7.40 (t, J = 7.3 Hz, 1H), 
7.21 (t, J = 7.7 Hz, 1H), 5.18 ppm (s, 2H). 13C NMR (101 MHz, CDCl3) δ 154.7, 151.3, 144.4, 143.0, 133.8, 
133.3, 132.1, 131.7, 129.5, 129.1, 128.4, 128.3, 128.3, 127.6, 127.4, 127.2, 126.8, 125.3, 124.7, 124.5, 
119.9, 72.6 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 357.1 (40), 309.1 (90), 292.1 (100), 266.1 (30). 
HRMS (EI-Orbitrap): m/z: [M]+ Calcd for C22H15NO2S+: 357.0823; found: 357.0816. Melting point: 165 
(±2) °C. 
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4-(Anthracen-9-yl)-3-(naphthalen-1-yl)-2H-thiete 1,1-dioxide (3.19-d) 
Using 9-bromoanthracene according to general procedure, provided 3.19-d (50 mg, 0.12 mmol, 62%) 
as a brownish solid.  
Rf = 0.5 (hexane/EtOAc 7:3, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 8.49 (s, 1H), 8.39 (d, J = 8.8 
Hz, 2H), 7.98 (d, J = 8.4 Hz, 3H), 7.74 (t, J = 8.3 Hz, 2H), 7.52 (ddd, J = 8.6, 6.6, 1.4 Hz, 2H), 7.48 – 7.43 
(m, 3H), 7.41 – 7.35 (m, 1H), 7.29 – 7.23 (m, 2H), 5.36 ppm(s, 2H). 13C NMR (101 MHz, CDCl3) δ 153.5, 
145.8, 133.7, 131.4, 131.2, 131.0, 130.4, 130.1, 129.0, 128.9, 127.9, 127.6, 127.2, 127.1, 126.6, 125.8, 
125.6, 125.2, 124.4, 120.8, 72.3 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 406.2 (15), 341.2 (100), 326.1 
(20). HRMS (EI-Orbitrap): m/z: [M]+ Calcd for C27H18O2S+: 406.1028; found: 406.1023. IR (Diamond-
ATR, neat) 𝜈𝑚𝑎𝑥: 1300 (s), 1205 (m), 1180 (m), 1160 (m), 1134 (vs), 1114 (m), 898 (m), 804 (m), 781 (s), 
733 cm-1 (vs).  Melting point: 185 (±2) °C. 
 
3-(Naphthalen-1-yl)-4-(4-phenylpyridin-3-yl)-2H-thiete 1,1-dioxide (3.19-e) 
Using 4-(2-bromophenyl)pyridine according to general procedure, provided 3.19-e (73 mg, 0.19 mmol, 
95%) as a white solid.  
Rf = 0.2 (hexane/EtOAc 7:3, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 9.14 (s, 1H), 8.61 (d, J = 5.1 
Hz, 1H), 7.75 (t, J = 8.2 Hz, 2H), 7.42 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.20 (ddd, J 
= 8.3, 6.8, 1.3 Hz, 1H), 7.17-7.13 (m, 1H), 7.00 (d, J = 5.1 Hz, 1H), 6.95-6.86 (m, 3H), 6.80 (dd, J = 7.2, 
1.2 Hz, 1H), 6.67-6.63 (m, 2H), 4.92 ppm (s, 2H). 13C NMR (101 MHz, CDCl3) δ 151.2, 150.1, 149.7, 149.0, 
142.6, 136.9, 133.4, 131.3, 129.2, 128.7, 128.2, 128.1, 127.8, 127.7, 126.9, 126.5, 126.4, 124.7, 124.6, 
124.6, 122.8, 72.3 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 383.1 (10), 354.9 (1), 335.1 (25), 318.1 (30), 
304.1 (50). HRMS (EI-Orbitrap): m/z: [M]+ Calcd for C24H17NO2S+: 383.0980; found: 383.0974. IR 
(Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 1708 (vs), 1435 (w), 1418 (m), 1360 (s), 1320 (m), 1221 (s), 1132 (w), 1093 
(w), 777 cm-1 (m).  Melting point: 215 (±2) °C. 
 
180 
 Part A - Chapter IV 
 
 
(2-(3-(Naphthalen-1-yl)-1,1-dioxido-2H-thiet-4-yl)phenyl)(phenyl)methanone (3.19-f) 
Using (2-bromophenyl)(phenyl)methanone according to general procedure, provided 3.19-f (70 mg, 
0.17 mmol, 85%) as a white solid.  
Rf = 0.2 (hexane/EtOAc 8:2, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 7.92 (dd, J = 7.7, 1.1 Hz, 1H), 
7.67 (dd, J = 8.3, 1.2 Hz, 1H), 7.63-7.53 (m, 3H), 7.46-7.34 (m, 3H), 7.29 (ddd, J = 8.3, 6.8, 1.4 Hz, 1H), 
7.25-7.17 (m, 3H), 7.10 (t, J = 7.8 Hz, 2H), 7.04 (dd, J = 8.3, 1.5 Hz, 2H), 4.87 (s, 2H). 13C NMR (101 MHz, 
CDCl3) δ 194.4, 151.0, 141.3, 139.0, 135.0, 133.6, 132.9, 131.3, 131.2, 129.9, 129.8, 129.6, 129.3, 129.3, 
128.9, 127.9, 127.5, 127.2, 127.1, 126.5, 126.5, 125.0, 124.8, 72.5 ppm. LRMS (DEP/EI-Orbitrap): m/z 
(%): 346.1 (30), 331.1 (15), 239.1 (60). HRMS (EI-Orbitrap): m/z: [M-SO2]+ Calcd for C26H18O+: 346.1358; 
found: 346.1359. IR (Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 1656 (s), 1299 (s), 1286 (m), 1266 (m), 1256 (m), 1184 
(m), 1135 (s), 1114 (m), 927 (m), 799 (m), 777 (s), 761 (m), 704 cm-1 (vs).  Melting point: 181 (±2) °C. 
 
3-(Anthracen-9-yl)-4-(isoquinolin-4-yl)-2H-thiete 1,1-dioxide (3.19-g) 
Using 4-bromoisoquinoline according to general procedure, provided 3.19-g (35 mg, 0.09 mmol, 43%) 
as a white solid.  
Rf = 0.2 (hexane/EtOAc 7:3, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 8.57 – 8.47 (m, 2H), 8.14 (d, 
J = 8.5 Hz, 2H), 8.03 (dd, J = 8.6, 1.4 Hz, 2H), 7.93 (d, J = 8.6 Hz, 1H), 7.68 (d, J = 8.3 Hz, 1H), 7.60 – 7.41 
(m, 6H), 7.07 (ddd, J = 8.4, 6.9, 1.3 Hz, 1H), 5.19 ppm (s, 2H). 13C NMR (101 MHz, CDCl3) δ 157.4, 147.1, 
143.4, 143.1, 136.4, 131.2, 130.5, 129.6, 129.2, 128.4, 128.1, 127.7, 127.3, 126.7, 125.9, 125.1, 124.7, 
124.7, 122.4, 74.0 ppm. HRMS (EI-Orbitrap): m/z: [M]+ Calcd for C26H17NO2S+: 407.0980; found: 
407.0973. Melting point: 180 (±2) °C. 
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(2-(3-Mesityl-1,1-dioxido-2H-thiet-4-yl)phenyl)(phenyl)methanone (3.19-h) 
Using (2-bromophenyl)(phenyl)methanone according to general procedure, provided 3.19-h (57 mg, 
0.14 mmol, 71%) as a white solid.  
Rf = 0.4 (hexane/EtOAc 8:2, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 7.96 (d, J = 7.2 Hz, 1H), 7.63 
(td, J = 7.6, 1.3 Hz, 1H), 7.54-7.40 (m, 4H), 7.33-7.24 (m, 3H), 6.43 (s, 2H), 4.74 (s, 2H), 2.00 ppm (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 193.7, 153.3, 142.8, 139.6, 138.7, 135.8, 134.9, 132.7, 130.9, 130.1, 129.4, 
129.2, 129.0, 128.8, 127.9, 127.0, 125.6, 72.2, 21.0, 20.1 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 338.1 
(70), 323.1 (40), 305.1 (20). HRMS (EI-Orbitrap): m/z: [M-SO2]+ Calcd for C24H19O2+: 338.1671; found: 
338.1680. IR (Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 1654 (m), 1447 (w), 1440 (w), 1314 (w), 1303 (vs), 1287 (m), 
1269 (m), 1203 (m), 1184 (s), 1166 (w), 1156 (w), 1128 (s), 926 (m), 846 (m), 830 (w), 804 (w), 760 (s), 
701 cm-1 (vs).  Melting point: 162 (±2) °C. 
 
3-Mesityl-4-(4-phenylpyridin-3-yl)-2H-thiete 1,1-dioxide (3.19-i) 
Using 4-(2-bromophenyl)pyridine according to general procedure, provided 3.19-i (71 mg, 0.19 mmol, 
95%) as a white solid.  
Rf = 0.25 (hexane/EtOAc 7:3, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 8.91 (s, 1H), 8.60 (d, J = 5.1 
Hz, 1H), 7.36-7.22 (m, 3H), 7.13 (d, J = 5.1 Hz, 1H), 7.10-7.07 (m, 2H), 6.61 (s, 2H), 4.66 (s, 2H), 2.19 (s, 
3H), 1.75 ppm (s, 6H). 13C NMR (101 MHz, CDCl3) δ 152.3, 150.7, 149.9, 149.7, 145.1, 139.6, 137.6, 
135.6, 128.8, 128.7, 128.6, 128.1, 125.8, 125.1, 123.2, 72.3, 21.1, 20.3 ppm. LRMS (DEP/EI-Orbitrap): 
m/z (%): 375.1 (10), 327.1 (5), 311.1 (10), 296.1 (100).  HRMS (EI-Orbitrap): m/z: [M]+ Calcd for 
C23H21NO2S+: 375.1293; found: 375.1294. IR (Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 1580 (m), 1478 (w), 1396 (m), 
1303 (vs), 1289 (m), 1262 (m), 1244 (m), 1193 (s), 1177 (s), 1156 (m), 1128 (s), 1065 (w), 1036 (w), 982 
(w), 848 (s), 825 (w), 780 (m), 764 (m), 749 (m), 734 (m), 706 cm-1 (s).  Melting point: 196 (±2) °C. 
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3-(4-Methoxyphenyl)-4-(4-phenylpyridin-3-yl)-2H-thiete 1,1-dioxide (3.19-j) 
Using 4-(2-bromophenyl)pyridine according to general procedure, provided 3.19-j (30 mg, 0.08 mmol, 
41%) as a white solid.  
Rf = 0.1 (hexane/EtOAc 7:3, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 8.88 (s, 1H), 8.76 (d, J = 5.2 
Hz, 1H), 7.50-7.38 (m, 3H), 7.32-7.23 (m, 3H), 6.98 (d, J = 8.9 Hz, 2H), 6.71 (d, J = 8.8 Hz, 2H), 4.69 (s, 
2H), 3.78 ppm (s, 3H). 13C NMR (101 MHz, CDCl3) δ 162.4, 151.3, 150.7, 150.2, 143.5, 141.3, 137.2, 
130.2, 129.1, 128.6, 128.6, 124.7, 122.6, 121.8, 114.3, 69.3, 55.6 ppm. LRMS (DEP/EI-Orbitrap): m/z 
(%): 363.1 (5),315.1 (5), 298.1 (10), 268.1 (20). HRMS (EI-Orbitrap): m/z: [M]+ Calcd for C21H17NO3S+: 
363.0929; found: 363.0919. IR (Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 2967 (w), 2909 (w), 1601 (s), 1581 (m), 1571 
(m), 1516 (s), 1476 (w), 1463 (w), 1427 (m), 1397 (w), 1336 (m), 1313 (m), 1289 (s), 1267 (s), 1200 (m), 
1178 (s), 1127 (vs), 1118 (vs), 1080 (m), 1073 (m), 1045 (m), 1018 (s), 988 (w), 982 (w), 958 (m), 926 
(w), 853 (m), 838 (s), 814 (m), 790 (m), 778 (m), 762 (m), 746 cm-1 (s).  Melting point: 223 (±2) °C. 
 
4-(4-Phenylpyridin-3-yl)-3-(3,4,5-trimethoxyphenyl)-2H-thiete 1,1-dioxide (3.19-k) 
Using 4-(2-bromophenyl)pyridine according to general procedure, provided 3.19-k (35 mg, 0.08 mmol, 
41%) as a white solid. 
Rf = 0.05 (hexane/EtOAc 7:3, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 8.89 (s, 1H), 8.75 (d, J = 5.1 
Hz, 1H), 7.45-7.37 (m, 3H), 7.34-7.27 (m, 3H), 6.17 (s, 2H), 4.71 (s, 2H), 3.82 (s, 3H), 3.62 ppm (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 153.2, 151.5, 150.7, 150.1, 145.8, 142.0, 141.3, 137.0, 129.1, 128.7, 128.5, 
124.5, 124.5, 122.3, 105.6, 69.5, 61.1, 56.2 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 423.1 (30), 375.1 
(10), 359.1 (20), 328.1 (40). HRMS (EI-Orbitrap): m/z: [M]+ Calcd for C23H21NO5S+: 423.1140; found: 
423.1144. IR (Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 1579 (m), 1508 (m), 1499 (w), 1452 (m), 1414 (m), 1400 (w), 
1358 (m), 1296 (s), 1241 (m), 1194 (m), 1126 (vs), 1104 (m), 1079 (m), 1004 (m), 963 (w), 947 (w), 922 
(m), 914 (m), 858 (m), 829 (m), 798 (w), 782 (m), 760 (m), 743 cm-1 (s).  Melting point: 208 (±2) °C. 
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3-([1,1'-Biphenyl]-2-yl)-4-phenyl-2H-thiete 1,1-dioxide (3.19-l) 
Using bromobenzene according to general procedure, provided 3.19-l (62 mg, 0.19 mmol, 93%) as a 
white solid.  
Rf = 0.5 (hexane/EtOAc 8:2, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 7.57-7.48 (m, 5H), 7.44-7.33 
(m, 9H), 4.06 ppm (s, 2H). 13C NMR (101 MHz, CDCl3) δ 152.6, 141.8, 139.8, 139.2, 130.8, 130.7, 130.4, 
129.7, 129.2, 129.0, 129.0, 128.7, 128.5, 127.9, 127.2, 126.9, 71.7 ppm. LRMS (DEP/EI-Orbitrap): m/z 
(%): 267.1 (100), 252.1 (30), 239.0 (10). HRMS (EI-Orbitrap): m/z: [M]+ Calcd for C21H16O2S+: 332.0871; 
found: 332.0859. IR (Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 3059 (w), 3027 (w), 1964 (w), 1953 (w), 1711 (m), 1595 
(w), 1493 (w), 1473 (m), 1448 (m), 1435 (w), 1362 (w), 1327 (m), 1304 (vs), 1221 (w), 1194 (s), 1176 
(vs), 1130 (vs), 1076 (w), 1031 (w), 1025 (w), 1009 (w), 963 (w), 917 (w), 850 (w), 761 cm-1 (vs).  Melting 
point: 146 (±2) °C. 
 
3-([1,1'-Biphenyl]-2-yl)-4-(4-methoxyphenyl)-2H-thiete 1,1-dioxide (3.19-m) 
Using 1-bromo-4-methoxybenzene according to general procedure, provided 3.19-m (50 mg, 
0.14 mmol, 69%) as a white solid.  
Rf = 0.2 (hexane/EtOAc 9:1, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 7.61-7.31 (m, 11H), 6.87 (d, 
J = 8.9 Hz, 2H), 4.02 (s, 2H), 3.83 ppm (s, 3H). 13C NMR (101 MHz, CDCl3) δ 161.2, 152.4, 141.8, 139.8, 
136.2, 130.7, 130.4, 130.0, 129.0, 129.0, 128.8, 128.7, 128.5, 127.9, 119.4, 114.7, 71.5, 55.5 ppm. LRMS 
(DEP/EI-Orbitrap): m/z (%): 362.2 (5), 298.2 (40), 267.1 (40), 239.1 (20). HRMS (EI-Orbitrap): m/z: [M]+ 
Calcd for C22H18O3S+: 362.0977; found: 362.0971. IR (Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 1603 (m), 1511 (m), 
1474 (w), 1454 (w), 1420 (w), 1298 (s), 1256 (s), 1185 (vs), 1176 (s), 1127 (s), 1075 (w), 1064 (w), 1048 
(w), 1025 (s), 1007 (m), 998 (w), 985 (w), 961 (w), 925 (w), 856 (w), 831 (s), 815 (w), 786 (w), 765 (vs), 
743 (s), 726 (m), 716 (m), 704 cm-1 (vs).  Melting point: 152 (±2) °C. 
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(E)-3-([1,1'-Biphenyl]-2-yl)-4-(4-(phenyldiazenyl)phenyl)-2H-thiete 1,1-dioxide (3.19-n) 
Using (E)-1-(4-iodophenyl)-2-phenyldiazene according to general procedure, provided 3.19-n (35 mg, 
0.08 mmol, 40%) as a red solid.  
Rf = 0.5 (hexane/EtOAc 8:2, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 7.98-7.87 (m, 4H), 7.67 (d, J 
= 8.5 Hz, 2H), 7.62-7.49 (m, 6H), 7.48-7.33 (m, 6H), 4.12 ppm (s, 2H). 13C NMR (101 MHz, CDCl3) δ 153.2, 
152.6, 152.0, 142.0, 140.5, 139.7, 131.7, 130.9, 130.9, 129.5, 129.3, 129.1, 129.0, 129.0, 128.8, 128.6, 
128.1, 128.0, 123.7, 123.2, 71.9 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 436.1 (20), 388.1 (5), 371.1 
(10), 252.1 (50). HRMS (EI-Orbitrap): m/z: [M]+ Calcd for C27H20N2O2S+: 436.1245; found: 436.1240. IR 
(Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 1481 (w), 1432 (w), 1408 (w), 1324 (w), 1301 (vs), 1278 (w), 1262 (w), 1221 
(w), 1191 (m), 1172 (s), 1164 (m), 1132 (s), 1123 (m), 1106 (w), 1071 (w), 1041 (w), 1027 (w), 1020 (w), 
1012 (w), 1006 (w), 1000 (w), 961 (w), 916 (w), 859 (m), 835 (m), 765 (vs), 750 (m), 740 cm-1 (s).  
Melting point: 160 (±2) °C. 
 
3-([1,1'-Biphenyl]-2-yl)-4-(4-nitrophenyl)-2H-thiete 1,1-dioxide (3.19-o) 
Using 1-bromo-4-nitrobenzene according to general procedure, provided 3.19-o (40 mg, 0.11 mmol, 
53%) as a white solid.  
Rf = 0.5 (hexane/EtOAc 8:2, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 8.19 (d, J = 8.8 Hz, 2H), 7.64-
7.57 (m, 3H), 7.54-7.44 (m, 3H), 7.43-7.35 (m, 3H), 7.32-7.27 (m, 2H), 4.23 ppm (s, 2H). 13C NMR 
(101 MHz, CDCl3) δ 150.2, 148.3, 143.5, 142.1, 139.4, 132.8, 131.5, 131.2, 129.1, 128.8, 128.8, 128.7, 
128.2, 128.1, 124.4, 72.4 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 358.2 (10), 313.2 (50), 296.1 (5), 283.1 
(10), 266.1 (100). HRMS (EI-Orbitrap): m/z: [M]+ Calcd for C21H15NO4S+: 377.0722; found: 377.0713. IR 
(Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 3095 (w), 1569 (m), 1559 (m), 1432 (w), 1292 (vs), 1212 (s), 1186 (s), 1142 
(m), 1127 (vs), 854 (m), 792 cm-1 (s).  Melting point: 210 (±2) °C. 
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3-([1,1'-Biphenyl]-2-yl)-4-(pyridin-4-yl)-2H-thiete 1,1-dioxide (3.19-p) 
Using 4-bromopyridine according to general procedure, provided 3.19-p (40 mg, 0.11 mmol, 61%) as a 
yellow oil.  
Rf = 0.1 (hexane/EtOAc 7:3, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 8.61 (d, J = 5.9 Hz, 2H), 7.58 
(td, J = 7.5, 1.5 Hz, 1H), 7.53-7.48 (m, 2H), 7.46-7.36 (m, 4H), 7.35-7.27 (m, 4H), 4.18 ppm (s, 2H). 13C 
NMR (101 MHz, CDCl3) δ 150.6, 150.0, 144.4, 142.0, 139.4, 134.1, 131.4, 131.1, 129.1, 128.8, 128.8, 
128.7, 128.1, 120.9, 72.4 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 268.1 (100), 239.1 (10), 226.1 (5). 
HRMS (EI-Orbitrap): m/z: [M]+ Calcd for C20H15NO2S+: 333.0823; found: 333.0827.  
 
3-([1,1'-Biphenyl]-2-yl)-4-(4-phenylpyridin-3-yl)-2H-thiete 1,1-dioxide (3.19-q) 
Using 4-(2-bromophenyl)pyridine according to general procedure, provided 3.19-q (72 mg, 0.18 mmol, 
88%) as white solid.  
Rf = 0.2 (hexane/EtOAc 7:3, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 8.58 (d, J = 5.1 Hz, 1H), 8.47 
(s, 1H), 7.36-7.17 (m, 7H), 7.16-7.09 (m, 4H), 7.05 (td, J = 7.6, 1.3 Hz, 1H), 6.79-6.69 (m, 3H), 4.22 ppm 
(s, 2H). 13C NMR (101 MHz, CDCl3) δ 150.6, 149.7, 149.6, 148.9, 143.7, 141.9, 139.5, 137.4, 130.4, 130.4, 
128.6, 128.5, 128.5, 128.4, 128.3, 128.2, 127.4, 124.5, 122.3, 71.3 ppm. LRMS (DEP/EI-Orbitrap): m/z 
(%): 409.1 (5), 345.1 (50), 330.1 (20). HRMS (EI-Orbitrap): m/z: [M]+ Calcd for C26H19NO2S+: 409.1136; 
found: 409.1139. IR (Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 1709 (m), 1581 (m), 1481 (m), 1444 (w), 1436 (w), 
1400 (w), 1362 (m), 1327 (w), 1301 (s), 1221 (m), 1192 (m), 1173 (s), 1130 (s), 1076 (w), 850 (m), 778 
(m), 766 (m), 756 cm-1 (s).  Melting point: 210 (±2) °C. 
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3-([1,1'-Biphenyl]-2-yl)-4-(pyrimidin-5-yl)-2H-thiete 1,1-dioxide (3.19-r) 
Using 5-bromopyrimidine according to general procedure, provided 3.19-r (45 mg, 0.13 mmol, 67%) as 
a yellow oil.  
Rf = 0.4 (hexane/EtOAc 6:4, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 9.13 (s, 1H), 8.62 (s, 2H), 
7.62-7.51 (m, 1H), 7.52-7.41 (m, 3H), 7.37-7.30 (m, 3H), 7.25-7.20 (m, 2H), 4.46 ppm (s, 2H). 13C NMR 
(101 MHz, CDCl3) δ 158.9, 154.6, 146.2, 143.5, 141.9, 139.2, 131.6, 131.3, 129.0, 128.8, 128.7, 128.5, 
128.3, 128.2, 122.4, 77.2, 72.7 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 334.2 (2), 269.2 (100), 215.1 
(10). HRMS (EI-Orbitrap): m/z: [M]+ Calcd for C19H14N2O2S+: 334.0776; found: 334.0774.  
 
3-(4'-Methoxy-[1,1'-biphenyl]-2-yl)-4-(4-nitrophenyl)-2H-thiete 1,1-dioxide (3.19-s) 
Using 1-bromo-4-nitrobenzene according to general procedure, provided 3.19-s (49 mg, 0.12 mmol, 
60%) as a yellow oil.  
Rf = 0.5 (hexane/EtOAc 7:3, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 8.19 (d, J = 8.8 Hz, 2H), 7.63 
(d, J = 8.8 Hz, 2H), 7.56 (td, J = 7.5, 1.5 Hz, 1H), 7.51-7.45 (m, 2H), 7.40 (td, J = 7.5, 1.4 Hz, 1H), 7.22 (d, 
J = 8.7 Hz, 2H), 6.92 (d, J = 8.6 Hz, 2H), 4.27 (s, 2H), 3.82 ppm (s, 3H). 13C NMR (101 MHz, CDCl3) δ 160.0, 
150.0, 148.3, 143.7, 141.8, 132.9, 131.6, 131.5, 131.1, 130.0, 128.8, 128.6, 128.0, 127.7, 124.4, 114.5, 
72.3, 55.5 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 355.1 (5), 343.1 (50), 326.9 (5), 313.1 (10). HRMS 
(EI-Orbitrap): m/z: [M]+ Calcd for C22H17NO5S+: 407.0827; found: 407.0821.  
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3-(4'-Methoxy-[1,1'-biphenyl]-2-yl)-4-(pyren-1-yl)-2H-thiete 1,1-dioxide (3.19-t) 
Using 1-bromopyrene according to general procedure, provided 3.19-t (49 mg, 0.10 mmol, 50%) as a 
yellow oil.  
Rf = 0.5 (hexane/EtOAc 8:2, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 8.23-8.15 (m, 3H), 8.11 (d, J 
= 8.9 Hz, 1H), 8.06-7.99 (m, 4H), 7.96 (d, J = 7.9 Hz, 1H), 7.37 (td, J = 7.5, 1.3 Hz, 1H), 7.32 (dd, J = 7.9, 
1.2 Hz, 1H), 7.25 (d, J = 6.8 Hz, 1H), 7.15 (td, J = 7.6, 1.4 Hz, 1H), 6.99 (d, J = 8.6 Hz, 2H), 6.60 (d, J = 8.6 
Hz, 2H), 4.56 (s, 2H), 3.54 ppm (s, 3H). 13C NMR (101 MHz, CDCl3) δ 159.2, 153.0, 142.3, 141.9, 132.6, 
132.2, 131.2, 131.1, 130.8, 130.7, 129.8, 129.5, 129.4, 129.3, 128.9, 128.7, 127.3, 127.2, 127.0, 126.4, 
126.0, 126.0, 124.8, 124.7, 124.3, 122.1, 113.9, 71.0, 55.0 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 486.1 
(5), 480.1 (60). HRMS (EI-Orbitrap): m/z: [M]+ Calcd for C32H22O3S+: 486.1290; found: 486.1291.  
 
3-(4'-Methoxy-[1,1'-biphenyl]-2-yl)-4-(4-phenylpyridin-3-yl)-2H-thiete 1,1-dioxide (3.19-u) 
Using 4-(2-bromophenyl)pyridine according to general procedure, provided 3.19-u (50 mg, 0.11 mmol, 
57%) as white solid.  
Rf = 0.3 (hexane/EtOAc 6:4, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 8.64-8.54 (m, 2H), 7.33-7.22 
(m, 4H), 7.20-7.09 (m, 4H), 7.03 (td, J = 7.5, 1.3 Hz, 1H), 6.77 (td, J = 7.0, 1.7 Hz, 3H), 6.66 (d, J = 8.7 Hz, 
2H), 4.19 (s, 2H), 3.84 ppm (s, 3H). 13C NMR (101 MHz, CDCl3) δ 159.6, 150.7, 149.8, 149.7, 148.7, 143.9, 
141.7, 137.5, 131.7, 130.5, 129.8, 128.7, 128.6, 128.5, 128.5, 128.4, 126.9, 124.6, 124.5, 122.4, 114.0, 
71.3, 55.5 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 439.1 (80), 389.1 (5), 375.1 (85), 360.1 (30). HRMS 
(EI-Orbitrap): m/z: [M]+ Calcd for C27H21NO3S+: 439.1242; found: 439.1238. IR (Diamond-ATR, neat) 
𝜈𝑚𝑎𝑥: 1711 (m), 1611 (m), 1517 (m), 1483 (m), 1442 (m), 1302 (vs), 1246 (s), 1222 (m), 1192 (s), 1176 
(s), 1132 (vs), 1035 (m), 834 (m), 761 (m), 755 (m), 700 cm-1 (m).  Melting point: 220 (±2) °C. 
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3-(2-Methoxynaphthalen-1-yl)-4-(4-phenylpyridin-3-yl)-2H-thiete 1,1-dioxide (3.19-v) 
Using 4-(2-bromophenyl)pyridine according to general procedure, provided 3.19-v (52 mg, 0.13 mmol, 
63%) as yellowish solid.  
Rf = 0.5 (hexane/EtOAc 6:4, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 9.16 (s, 1H), 8.54 (d, J = 5.1 
Hz, 1H), 7.71 (d, J = 9.1 Hz, 1H), 7.67 (d, J = 7.3 Hz, 1H), 7.23 (d, J = 7.6 Hz, 2H), 7.13 (ddd, J = 8.3, 6.7, 
1.4 Hz, 1H), 7.09-7.03 (m, 1H), 6.97 (t, J = 7.6 Hz, 2H), 6.91 (d, J = 5.1 Hz, 1H), 6.85 (d, J = 9.1 Hz, 1H), 
6.66-6.62 (m, 2H), 5.00 (s, 2H), 3.70 ppm (s, 3H). 13C NMR (101 MHz, CDCl3) δ 155.1, 151.0, 150.7, 149.7, 
149.3, 140.8, 137.0, 132.7, 130.2, 128.4, 128.3, 127.6, 127.5, 127.5, 127.5, 124.8, 124.0, 123.5, 123.5, 
111.8, 111.6, 72.9, 55.5 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 413.1 (10), 349.1 (10), 318.1 (30). 
HRMS (EI-Orbitrap): m/z: [M]+ Calcd for C25H19NO3S+: 413.1086; found: 413.1087. IR (Diamond-ATR, 
neat) 𝜈𝑚𝑎𝑥: 1592 (m), 1580 (m), 1510 (m), 1467 (m), 1294 (s), 1267 (s), 1249 (m), 1223 (w), 1176 (m), 
1165 (vs), 1136 (s), 1106 (m), 1079 (s), 1026 (m), 998 (w), 969 (m), 909 (w), 869 (m), 856 (m), 812 (s), 
778 (s), 762 (s), 748 cm-1 (s).  Melting point: 190 (±2) °C. 
 
4-(3',5'-Dinitro-[1,1'-biphenyl]-2-yl)-3-(2-methoxynaphthalen-1-yl)-2H-thiete 1,1-dioxide (3.19-w) 
Using 2-bromo-3',5'-dinitro-1,1'-biphenyl according to general procedure, provided 3.19-w (46 mg, 
0.09 mmol, 46%) as yellowish solid.  
Rf = 0.7 (hexane/EtOAc 6:4, UV, KMnO4, PAA). 1H NMR (400 MHz, CDCl3) δ 8.53 (t, J = 2.1 Hz, 1H), 8.14 
(dd, J = 7.8, 1.2 Hz, 1H), 7.65 (dtt, J = 7.7, 5.6, 3.1 Hz, 5H), 7.48 (td, J = 7.6, 1.3 Hz, 1H), 7.33-7.27 (m, 
1H), 7.19-7.08 (m, 2H), 7.03 (dd, J = 7.7, 1.2 Hz, 1H), 6.86 (d, J = 9.1 Hz, 1H), 4.98 (s, 2H), 3.68 ppm (s, 
3H).13C NMR (101 MHz, CDCl3) δ 155.1, 152.6, 147.9, 143.1, 138.2, 137.2, 133.0, 131.0, 130.3, 130.1, 
130.1, 129.0, 128.9, 128.4, 128.2, 127.9, 127.1, 124.8, 123.3, 116.4, 112.1, 111.5, 72.8, 55.8 ppm. LRMS 
(DEP/EI-Orbitrap): m/z (%): 502.1 (100), 421.1 (95), 391.1 (30). HRMS (EI-Orbitrap): m/z: [M]+ Calcd 
for C26H18N2O7S+: 502.0835; found: 502.0838. IR (Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 1548 (s), 1533 (m), 1510 
(m), 1469 (w), 1360 (m), 1343 (s), 1309 (s), 1266 (s), 1246 (m), 1184 (m), 1174 (s), 1158 (m), 1138 (s), 
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1120 (m), 1104 (m), 1072 (s), 1048 (w), 1028 (m), 996 (w), 965 (w), 920 (w), 912 (m), 895 (w), 884 (w), 
858 (w), 815 (s), 783 (m), 775 cm-1 (s).  Melting point: 270 (±2) °C. 
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13.3 Macrocyclic Thiete Dioxides 
General procedure: C-H Macrocyclization of 2H-thiete 1,1- dioxides 
 
A pressure tube was charged with 2H-thiete 1,1- dioxides derivative 3.18 (0.2 mmol, 1 equiv.) and 2 mL 
toluene was added. Subsequently, K2CO3 (55 mg, 0.4 mmol, 2.0 equiv.), Pd(OAc)2 (1.8 mg, 8 μmol, 
4 mol%), tricyclohexylphosphane (PCy3) (4.5 mg, 16 μmol, 8 mol%) and a few drops of pivalic acid 
(~7 μL, 30 mol%) were added. The mixture was stirred at 100 °C in the sealed pressure tube until TLC 
showed consumption of the starting 2H-thiete 1,1- dioxides (approx. 16 hours). After cooling to 
ambient temperature, the tube was opened and a 1:1 mixture of H2O:CH2Cl2 (4 mL) was added. The 
aqueous phase was extracted with CH2Cl2 (3 x 20 mL). The combined organic phases were dried over 
magnesium sulfate, filtrated, concentrated in vacuo and purified by flash-column chromatography on 
silica gel with the appropriate solvent mixture to obtain pure 3.30. 
 
tri-Cyclo-3-phenyl-2H-thiete 1,1-dioxide (3.30-a) 
Using 4-(3-bromophenyl)-2H-thiete 1,1-dioxide according to general procedure, provided 3.30-a 
(40 mg, 0.07 mmol, 37%) as yellowish solid.  
Rf = 0.2 (hexane/EtOAc 5:5, UV, KMnO4). 1H NMR (400 MHz, CDCl3) δ 7.82 (d, J = 7.9 Hz, 1H), 7.71-7.59 
(m, 1H), 7.41 (d, J = 7.9 Hz, 1H), 4.86 ppm (s, 1H). 13C NMR (101 MHz, CDCl3) δ 150.5, 139.7, 131.1, 
131.0, 130.9, 129.9, 127.8, 126.6, 72.1 ppm. HRMS (ESI-Quadrupole): m/z: [M+-H] Calcd for 
C27H17O6S3+: 533.0187; found: 533.0191. IR (Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 2925 (m), 2851 (w), 1295 (s), 
1261 (m), 1192 (s), 1159 (m), 1127 (vs), 1041 (m), 1020 (m), 890 (m), 856 (m), 798 cm-1 (s).  Melting 
point: 245 (±2) °C decomposition.  
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tri-Cyclo-3-(3-methoxyphenyl)-2H-thiete 1,1-dioxide (3.30-b) 
Using 3-(3-bromo-5-methoxyphenyl)-2H-thiete 1,1-dioxide according to general procedure, provided 
3.30-b (2.14 g, 3.43 mmol, 42%) as yellowish solid.  
Rf = 0.2 (hexane/EtOAc 5:5, UV, KMnO4). 1H NMR (400 MHz, CDCl3) δ 7.27 (s, 3H), 7.22-7.20 (m, 3H), 
6.89-6.87 (m, 3H), 4.83 (s, 6H), 3.89 ppm (s, 9H). 13C NMR (101 MHz, CDCl3) δ 160.8, 150.6, 139.7, 
132.1, 128.8, 119.0, 116.7, 114.7, 72.1, 56.0 ppm. HRMS (ESI-Quadrupole): m/z: [M+-H] Calcd for 
C30H23O9S3+: 623.0504; found: 623.0507. IR (Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 1585 (m), 1362 (m), 1291 (s), 
1261 (s), 1226 (s), 1182 (s), 1156 (m), 1129 (vs), 1064 (s), 1050 (s), 1017 (m), 1000 (s), 985 (s), 861 (m), 
822 (m), 806 (m), 800 (m), 736 cm-1 (m).  Melting point: 265 (±2) °C decomposition. 
 
tri-Cyclo-3-(3-fluorophenyl)-2H-thiete 1,1-dioxide (3.30-c) 
Using 3-(3-bromo-5-fluorophenyl)-2H-thiete 1,1-dioxide according to general procedure, provided 
3.30-c (53 mg, 0.09 mmol, 45%) as yellowish solid.  
Rf = 0.65 (hexane/EtOAc 5:5, UV, KMnO4). 1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 8.3 Hz, 3H), 7.36 (s, 
3H), 7.22 (d, J = 8.5 Hz, 3H), 4.90 ppm (s, 6H). 13C NMR (101 MHz, CDCl3) δ 163.4 (d, J = 253.2 Hz), 
138.94, 132.95, 123.2-123.1 (m), 119.03, 118.80, 117.83, 117.59, 71.43 ppm. HRMS (ESI-Quadrupole): 
m/z: [M+-H] Calcd for C27H14F3O6S3+: 586.9905; found: 586.9912. IR (Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 1589 
(m), 1347 (m), 1308 (s), 1201 (m), 1185 (vs), 1132 (vs), 870 cm-1 (m).  Melting point: 250 (±2) °C 
decomposition. 
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tri-Cyclo-3-(naphthalen-2-yl)-2H-thiete 1,1-dioxide (3.30-d) 
Using 3-(7-bromonaphthalen-2-yl)-2H-thiete 1,1-dioxide according to general procedure, provided 
3.30-d (27 mg, 0.04 mmol, 20%) as brownish solid.  
Rf = 0.8 (CH2Cl2/MeOH 96:4, UV, KMnO4). 1H NMR (400 MHz, CDCl3) δ 8.28 (s, 3H), 8.14 (s, 3H), 8.01 (d, 
J = 8.6 Hz, 6H), 7.93 (dd, J = 8.5, 1.5 Hz, 3H), 7.46 (dd, J = 8.5, 1.6 Hz, 3H), 4.97 ppm (s, 6H). 13C NMR 
(101 MHz, CDCl3) δ 150.7, 139.5, 134.9, 132.5, 129.8, 129.6, 128.8, 128.0, 127.8, 126.9, 126.2, 126.0, 
71.9 ppm. HRMS (ESI-Quadrupole): m/z: [M+-H] Calcd for C39H23O6S3+: 683.0657; found: 683.0665. IR 
(Diamond-ATR, neat) 𝜈𝑚𝑎𝑥: 1302 (vs), 1183 (vs), 1126 (vs), 1120 (vs), 917 (m), 911 (m), 847 (s), 813 
(m), 729 cm-1 (m).  Melting point: 290 (±2) °C decomposition. 
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 3.19-b 
net formula C23H16O2S 
Mr/g mol−1 356.42 
crystal size/mm 0.100 × 0.060 × 0.030 
T/K 293.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system triclinic 
space group 'P -1' 
a/Å 8.0586(5) 
b/Å 13.8610(8) 
c/Å 16.3574(11) 
α/° 89.714(2) 
β/° 78.891(3) 
γ/° 89.717(2) 
V/Å3 1792.85(19) 
Z 4 
calc. density/g cm−3 1.320 
μ/mm−1 0.194 
absorption correction Multi-Scan 
transmission factor range 0.71–0.99 
refls. measured 6116 
Rint 0.0603 
mean σ(I)/I 0.0823 
θ range 3.197–25.027 
observed refls. 4010 
x, y (weighting scheme) 0.1008, 0.2422 
hydrogen refinement constr 
refls in refinement 6116 
parameters 470 
restraints 0 
R(Fobs) 0.0728 
Rw(F2) 0.1926 
S 1.064 
shift/errormax 0.001 
max electron density/e Å−3 0.302 
min electron density/e Å−3 −0.301 
  
194 
 Part A - Chapter IV 
 
 
 3.19-d 
net formula C27H18O2S 
Mr/g mol−1 406.47 
crystal size/mm 0.100 × 0.050 × 0.040 
T/K 103.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system monoclinic 
space group 'P 1 21/c 1' 
a/Å 9.8504(4) 
b/Å 18.7839(6) 
c/Å 10.5297(4) 
α/° 90 
β/° 99.0900(10) 
γ/° 90 
V/Å3 1923.83(12) 
Z 4 
calc. density/g cm−3 1.403 
μ/mm−1 0.191 
absorption correction Multi-Scan 
transmission factor range 0.95–0.99 
refls. measured 19079 
Rint 0.0414 
mean σ(I)/I 0.0352 
θ range 3.271–27.099 
observed refls. 3467 
x, y (weighting scheme) 0.0426, 2.6914 
hydrogen refinement constr 
refls in refinement 4231 
parameters 271 
restraints 0 
R(Fobs) 0.0505 
Rw(F2) 0.1262 
S 1.041 
shift/errormax 0.001 
max electron density/e Å−3 0.848 
min electron density/e Å−3 −0.492 
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  3.19-e 
net formula C24H17NO2S 
Mr/g mol−1 383.44 
crystal size/mm 0.100 × 0.060 × 0.050 
T/K 100.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system triclinic 
space group 'P -1' 
a/Å 8.6496(4) 
b/Å 10.5111(5) 
c/Å 11.7560(6) 
α/° 84.633(2) 
β/° 70.467(2) 
γ/° 68.127(2) 
V/Å3 934.20(8) 
Z 2 
calc. density/g cm−3 1.363 
μ/mm−1 0.193 
absorption correction Multi-Scan 
transmission factor range 0.93–0.99 
refls. measured 9803 
Rint 0.0194 
mean σ(I)/I 0.0256 
θ range 3.680–27.103 
observed refls. 3702 
x, y (weighting scheme) 0.0376, 0.5497 
hydrogen refinement constr 
refls in refinement 4084 
parameters 253 
restraints 0 
R(Fobs) 0.0328 
Rw(F2) 0.0858 
S 1.024 
shift/errormax 0.001 
max electron density/e Å−3 0.392 
min electron density/e Å−3 −0.414 
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 3.19-f 
net formula C26H18O3S 
Mr/g mol−1 410.46 
crystal size/mm 0.090 × 0.070 × 0.050 
T/K 299.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system monoclinic 
space group 'P 1 21/c 1' 
a/Å 9.6180(11) 
b/Å 14.8477(16) 
c/Å 15.1188(11) 
α/° 90 
β/° 107.960(3) 
γ/° 90 
V/Å3 2053.8(4) 
Z 4 
calc. density/g cm−3 1.327 
μ/mm−1 0.183 
absorption correction Multi-Scan 
transmission factor range 0.95–0.99 
refls. measured 18827 
Rint 0.0478 
mean σ(I)/I 0.0380 
θ range 3.148–25.349 
observed refls. 2888 
x, y (weighting scheme) 0.0342, 1.1300 
hydrogen refinement constr 
refls in refinement 3751 
parameters 271 
restraints 0 
R(Fobs) 0.0430 
Rw(F2) 0.1017 
S 1.024 
shift/errormax 0.001 
max electron density/e Å−3 0.236 
min electron density/e Å−3 −0.380 
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 3.19-i 
net formula C23H21NO2S 
Mr/g mol−1 375.47 
crystal size/mm 0.080 × 0.060 × 0.050 
T/K 100.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system monoclinic 
space group 'P 1 21/c 1' 
a/Å 9.2628(3) 
b/Å 18.3007(5) 
c/Å 11.2957(4) 
α/° 90 
β/° 97.6550(10) 
γ/° 90 
V/Å3 1897.73(10) 
Z 4 
calc. density/g cm−3 1.314 
μ/mm−1 0.188 
absorption correction Multi-Scan 
transmission factor range 0.93–0.99 
refls. measured 20040 
Rint 0.0306 
mean σ(I)/I 0.0254 
θ range 3.143–27.484 
observed refls. 3759 
x, y (weighting scheme) 0.0400, 1.1560 
hydrogen refinement constr 
refls in refinement 4334 
parameters 247 
restraints 0 
R(Fobs) 0.0367 
Rw(F2) 0.0927 
S 1.034 
shift/errormax 0.001 
max electron density/e Å−3 0.338 
min electron density/e Å−3 −0.433 
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 3.19-k 
net formula C23H21NO5S 
Mr/g mol−1 423.47 
crystal size/mm 0.100 × 0.070 × 0.050 
T/K 100.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system monoclinic 
space group 'P 1 21/n 1' 
a/Å 11.9000(4) 
b/Å 10.8787(3) 
c/Å 17.0090(5) 
α/° 90 
β/° 110.1320(10) 
γ/° 90 
V/Å3 2067.39(11) 
Z 4 
calc. density/g cm−3 1.361 
μ/mm−1 0.192 
absorption correction Multi-Scan 
transmission factor range 0.92–0.99 
refls. measured 18208 
Rint 0.0300 
mean σ(I)/I 0.0276 
θ range 3.165–27.102 
observed refls. 3796 
x, y (weighting scheme) 0.0397, 0.9523 
hydrogen refinement constr 
refls in refinement 4540 
parameters 274 
restraints 0 
R(Fobs) 0.0339 
Rw(F2) 0.0890 
S 1.017 
shift/errormax 0.001 
max electron density/e Å−3 0.270 
min electron density/e Å−3 −0.406 
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 3.19-l 
net formula C21H16O2S 
Mr/g mol−1 332.40 
crystal size/mm 0.362 × 0.278 × 0.221 
T/K 143(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system monoclinic 
space group 'P 21/n' 
a/Å 9.6709(8) 
b/Å 10.5272(7) 
c/Å 16.3722(13) 
α/° 90 
β/° 94.907(7) 
γ/° 90 
V/Å3 1660.7(2) 
Z 4 
calc. density/g cm−3 1.329 
μ/mm−1 0.204 
absorption correction multi-scan 
transmission factor range 0.88636–1.00000 
refls. measured 9249 
Rint 0.0368 
mean σ(I)/I 0.0399 
θ range 4.218–24.995 
observed refls. 2271 
x, y (weighting scheme) 0.0398, 0.6296 
hydrogen refinement constr 
refls in refinement 2916 
parameters 217 
restraints 0 
R(Fobs) 0.0398 
Rw(F2) 0.1047 
S 1.041 
shift/errormax 0.001 
max electron density/e Å−3 0.310 
min electron density/e Å−3 −0.325 
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 3.19-m 
net formula C22H18O3S 
Mr/g mol−1 362.42 
crystal size/mm 0.296 × 0.242 × 0.103 
T/K 143(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system monoclinic 
space group 'C c' 
a/Å 20.6412(17) 
b/Å 5.4509(3) 
c/Å 17.8630(12) 
α/° 90 
β/° 114.456(9) 
γ/° 90 
V/Å3 1829.5(2) 
Z 4 
calc. density/g cm−3 1.316 
μ/mm−1 0.195 
absorption correction multi-scan 
transmission factor range 0.85807–1.00000 
refls. measured 4836 
Rint 0.0318 
mean σ(I)/I 0.0545 
θ range 4.338–27.946 
observed refls. 2912 
x, y (weighting scheme) 0.0440, 0.0390 
hydrogen refinement constr 
Flack parameter −0.02(7) 
refls in refinement 3200 
parameters 236 
restraints 2 
R(Fobs) 0.0399 
Rw(F2) 0.0965 
S 1.063 
shift/errormax 0.001 
max electron density/e Å−3 0.257 
min electron density/e Å−3 −0.274 
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 3.19-q 
net formula C26H19NO2S 
Mr/g mol−1 409.48 
crystal size/mm 0.090 × 0.070 × 0.040 
T/K 100.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system monoclinic 
space group 'C 1 2/c 1' 
a/Å 22.6159(5) 
b/Å 8.5749(2) 
c/Å 21.2839(5) 
α/° 90 
β/° 91.8770(10) 
γ/° 90 
V/Å3 4125.35(16) 
Z 8 
calc. density/g cm−3 1.319 
μ/mm−1 0.180 
absorption correction Multi-Scan 
transmission factor range 0.94–0.99 
refls. measured 20750 
Rint 0.0358 
mean σ(I)/I 0.0283 
θ range 3.164–26.372 
observed refls. 3580 
x, y (weighting scheme) 0.0310, 5.1208 
hydrogen refinement constr 
refls in refinement 4202 
parameters 271 
restraints 0 
R(Fobs) 0.0364 
Rw(F2) 0.0850 
S 1.044 
shift/errormax 0.001 
max electron density/e Å−3 0.361 
min electron density/e Å−3 −0.404 
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 3.19-u 
net formula C27H21NO3S 
Mr/g mol−1 439.51 
crystal size/mm 0.080 × 0.070 × 0.040 
T/K 100.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system monoclinic 
space group 'P 1 21/n 1' 
a/Å 8.9875(2) 
b/Å 13.8360(4) 
c/Å 17.3172(4) 
α/° 90 
β/° 100.4190(10) 
γ/° 90 
V/Å3 2117.91(9) 
Z 4 
calc. density/g cm−3 1.378 
μ/mm−1 0.184 
absorption correction Multi-Scan 
transmission factor range 0.95–0.99 
refls. measured 22311 
Rint 0.0304 
mean σ(I)/I 0.0246 
θ range 3.147–27.102 
observed refls. 4056 
x, y (weighting scheme) 0.0352, 1.3894 
hydrogen refinement constr 
refls in refinement 4666 
parameters 290 
restraints 0 
R(Fobs) 0.0354 
Rw(F2) 0.0902 
S 1.034 
shift/errormax 0.001 
max electron density/e Å−3 0.314 
min electron density/e Å−3 −0.461 
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 3.19-v 
net formula C25H19NO3S 
Mr/g mol−1 413.47 
crystal size/mm 0.080 × 0.060 × 0.050 
T/K 298.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system monoclinic 
space group 'P 1 21/n 1' 
a/Å 11.0210(7) 
b/Å 15.2877(9) 
c/Å 12.5569(6) 
α/° 90 
β/° 94.216(2) 
γ/° 90 
V/Å3 2109.9(2) 
Z 4 
calc. density/g cm−3 1.302 
μ/mm−1 0.180 
absorption correction Multi-Scan 
transmission factor range 0.94–0.99 
refls. measured 21700 
Rint 0.0405 
mean σ(I)/I 0.0302 
θ range 3.246–26.371 
observed refls. 3096 
x, y (weighting scheme) 0.0529, 1.5771 
hydrogen refinement constr 
refls in refinement 4300 
parameters 261 
restraints 0 
R(Fobs) 0.0534 
Rw(F2) 0.1458 
S 1.032 
shift/errormax 0.001 
max electron density/e Å−3 0.277 
min electron density/e Å−3 −0.377 
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 3.19-w 
net formula C26H18N2O7S 
Mr/g mol−1 502.48 
crystal size/mm 0.368 × 0.255 × 0.145 
T/K 143(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system monoclinic 
space group 'P 21/n' 
a/Å 7.8118(4) 
b/Å 35.594(2) 
c/Å 8.7474(5) 
α/° 90 
β/° 110.609(6) 
γ/° 90 
V/Å3 2276.6(2) 
Z 4 
calc. density/g cm−3 1.466 
μ/mm−1 0.195 
absorption correction multi-scan 
transmission factor range 0.93787–1.00000 
refls. measured 12599 
Rint 0.0358 
mean σ(I)/I 0.0466 
θ range 4.242–26.370 
observed refls. 3698 
x, y (weighting scheme) 0.0242, 1.6852 
hydrogen refinement constr 
refls in refinement 4629 
parameters 326 
restraints 0 
R(Fobs) 0.0476 
Rw(F2) 0.0996 
S 1.068 
shift/errormax 0.001 
max electron density/e Å−3 0.315 
min electron density/e Å−3 −0.325 
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 3.30-a 
net formula C27H18O6S3 
Mr/g mol−1 534.59 
crystal size/mm 0.100 × 0.060 × 0.050 
T/K 296.(2) 
radiation MoKα 
diffractometer 'Bruker D8Quest' 
crystal system triclinic 
space group 'P -1' 
a/Å 10.4939(3) 
b/Å 11.1477(3) 
c/Å 12.1923(3) 
α/° 108.6230(10) 
β/° 95.7060(10) 
γ/° 97.9900(10) 
V/Å3 1322.68(6) 
Z 2 
calc. density/g cm−3 1.342 
μ/mm−1 0.319 
absorption correction Multi-Scan 
transmission factor range 0.95–0.98 
refls. measured 25275 
Rint 0.0251 
mean σ(I)/I 0.0246 
θ range 3.292–26.369 
observed refls. 4706 
x, y (weighting scheme) 0.0963, 0.7693 
hydrogen refinement constr 
Flack parameter ? 
refls in refinement 5374 
parameters 325 
restraints 0 
R(Fobs) 0.0498 
Rw(F2) 0.1652 
S 1.086 
shift/errormax 0.001 
max electron density/e Å−3 0.410 
min electron density/e Å−3 −0.503 
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 3.30-b + CHCl3 
net formula C31H25Cl3O9S3  
Mr/g mol−1 744.04 
crystal size/mm 0.100 × 0.090 × 0.080 
T/K 110.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system triclinic 
space group 'P -1' 
a/Å 11.7054(6) 
b/Å 12.3313(7) 
c/Å 14.5166(8) 
α/° 93.996(2) 
β/° 102.009(2) 
γ/° 106.053(2) 
V/Å3 1951.47(19) 
Z 2 
calc. density/g cm−3 1.266 
μ/mm−1 0.440 
absorption correction Multi-Scan 
transmission factor range 0.88–0.97 
refls. measured 21459 
Rint 0.0248 
mean σ(I)/I 0.0392 
θ range 2.460–28.281 
observed refls. 7984 
x, y (weighting scheme) 0.0514, 2.3137 
hydrogen refinement constr 
refls in refinement 9597 
parameters 418 
restraints 0 
R(Fobs) 0.0440 
Rw(F2) 0.1192 
S 1.029 
shift/errormax 0.001 
max electron density/e Å−3 0.623 
min electron density/e Å−3 −0.651 
 
All but one solvent molecule CHCl3 have been SQUEEZED out. 
 
Symmetry code for figure above: i = -x, -y, 1-z. 
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14 Introduction 
An essential category of reaction-class is the olefination, in which two molecules are linked via a double 
bond or a new group is added to a double bond. With a long history the Wittig olefination, discovered 
in 1954, can be seen as the starting point of following successful transformations of various carbonyl 
functions into carbon-carbon double bonds.92 Above all, the synthetically valuable reactions of 
Peterson, Tebbe, Horner-Wadsworth-Emmons, Takai, McMurry and Julia deserve most attention.93 
Despite using different reagents, many of these reactions show clear similarities with respect to the 
mechanism. The Wittig reaction is depicted in Scheme 1.94 Following a nucleophilic addition of ylide 
1.02 to benzaldehyde (1.03), the betaine 1.04 can form a cyclic oxaphosphetane 1.05. Due to the high 
oxophilicity of the phosphorus atom, the oxaphosphetane 1.05 undergoes an elimination to give the 
triphenylphosphine oxide (1.06) and alkene 1.07. 
 
Scheme 1: Wittig olefination of methylenetriphenylphosphorane (1.01) and benzaldehyde (1.02).  
In addition to these meaningful olefination reactions, substituted or functionalized alkenes are a key 
structural motif in naturally occurring compounds (e.g. resveratrol), in drug discovery (e.g. tamoxifen) 
and further transformations such as olefin metathesis.95  
Apart from these classical olefinations, palladium-catalyzed alkenylations can be considered as a 
complementary tool for the synthesis of functionalized olefins.96 As a transition-metal free variant of 
those, the Zweifel reaction/olefination will be described in the following section.  
 
 
 
92 G. Wittig; U. Schöllopf, Chem. Ber. 1954, 87, 1318. R. W. Hoffmann, Angew. Chem. Int. Ed. 2001, 40, 1411. 
93 D. J. Peterson; J. Org. Chem. 1968, 33, 780; F. N. Tebbe; G. W. Parshall; G. S. Reddy, J. Am. Chem. Soc. 1978, 
100, 3611; L. Horner; H. Hoffmann; H. G. Wippel, Chem. Ber. 1958, 91, 61; W. S. Wadsworth; W. D. Emmons, J. 
Am. Chem. Soc. 1961, 83, 1733; K. Takai; K. Nitta; K. Utimoto, J. Am. Chem. Soc. 1986, 108, 7408; J. E. McMurry; 
M. P. Fleming, J. Am. Chem. Soc. 1974, 96, 4708; M. Julia; Y.-M. Paris, Tetrahedron Lett. 1973, 14, 4833. 
94 G. Wittig; W. Haag, Chem. Ber. 1955, 88, 1654. 
95 Resveratrol: M. Takaoka, J. Chem. Soc. Japan 1939, 60, 1090. tamoxifen: Y. Shang, Nat. Rev. Cancer 2006, 6, 
360; For olefin metathesis see: D. Hughes; P. Wheeler; D. Ene, Org. Process Res. Dev. 2017, 21, 1938; O. M. Ogba; 
N. C. Warner; D. J. O`Leary; R. H. Grubbs, Chem. Soc. Rev. 2018, 47, 4510. 
96 E.-I. Negishi; Z. Huang; G. Wang; S. Mohan; C. Wang; H. Hattori, Acc. Chem. Res. 2008, 41, 1474. 
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14.1 Zweifel Olefinations 
In 1967 G. Zweifel and co-workers reported for the first time a stereoselective route towards 
substituted alkenes via a hydroboration/iodination sequence of alkynes (Scheme 2).97 In this first 
example, 1-hexyne (1.09) was treated with dicyclohexylborane (1.08) in THF, followed by the addition 
of sodium hydroxide and iodine.  
 
Scheme 2: First reported Zweifel olefination with dicyclohexylborane (1.08) and 1-hexyne (1.09).   
As a key part of the proposed mechanism, an intermediary iodonium ion (1.13) was observed after the 
addition of iodine (Scheme 3).98 This is followed by a 1,2-metalate rearrangement towards the 
uncharged compound 1.14. For the final elimination step, the bond of the β-iodoboronic ester 1.14 
must rotate in the right position for an anti-periplanar alignment (1.15). Finally, the addition of a base 
results in the formation of the desired olefin 1.11. Notably, this method proceeds without any use of 
transition metals. 
 
Scheme 3: Proposed mechanism of the Zweifel reaction (counter cations have been omitted for simplicity).  
Therefore, in the following decades the Zweifel reaction was successfully applied by several research 
groups, like Negishi, Brown and Evans.99 The Zweifel reaction was used in many total syntheses like the 
one of (-)-filiformin and debromohamigeran E by the groups of Aggarwal and Morken, respectively.100  
More recently, Aggarwal and his group reported a general approach for the functionalization of 
alkenes by a Zweifel mediated strategy.101 In this work, the use of Grignard- and organolithium 
 
97 G. Zweifel; H. Arzoumanian; C. C. Whitney, J. Am. Chem. Soc. 1967, 89, 3652; G. Zweifel; N. L. Polston; C. C. 
Whitney, J. Am. Chem. Soc. 1968, 90, 6243. For a review on Zweifel olefinations see: R. J. Armstrong; V. K. 
Aggarwal, Synthesis 2017, 49, 3323. 
98 R. J. Armstrong; W. Niwetmarin; V. K. Aggarwal, Org. Lett. 2017, 19, 2762. 
99 E.-I. Negishi; G. Lew; T. Yoshida, J. Chem. Soc. Chem. Commun. 1973, 22, 874; D. A. Evans; T. C. Crawford; R. C. 
Thomas; J. A. Walker, J. Org. Chem. 1976, 41, 3947; H. C. Brown; N. G. Bhat, J. Org. Chem. 1988, 53, 6009.  
100 D. J. Blair; C. J. Fletcher; K. M. P. Wheelhouse; V. K. Aggarwal, Angew. Chem. Int. Ed. 2014, 53, 5552; T. P. 
Blaisdell; J. P. Morken, J. Am. Chem. Soc. 2015, 137, 8712. 
101 R. J. Armstrong; W. Niwetmarin; V. K. Aggarwal, Org. Lett. 2017, 19, 2762. 
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reagents (1.16) with commercially available boron pinacol esters (1.17) was described (Scheme 4). A 
wide array of functionalized alkenes was synthesized, wherein chiral-, aryl-, and heteroaryl boron 
pinacol esters (1.17) were used as starting materials. 
 
Scheme 4: Zweifel Olefination of boronic esters with Grignard or organolithium reagents by Aggarwal. 
However, this respectable strategy is currently limited by the availability and price of the boron pinacol 
esters 1.19, which are commonly used for the formation of bisorganoborinates 1.20 (Scheme 5).102  
 
Scheme 5: General formation of bisorganoborinates. 
To address these issues, we developed a general in situ method which combines various 
organometallic species with readily available trialkoxy-organoboronates towards bisorganoborinates.  
  
 
102 J. A. M. Mercer; C. M. Cohen; S. R. Shuken; A. M. Wagner; M. W. Smith; F. R. Moss; M. D. Smith; R. Vahala; A. 
Gonzalez-Martinez; S. G. Boxer; N. Z. Burns, J. Am. Chem. Soc. 2016, 138, 15845; C. Garcia-Ruiz; J. L.-Y. Chen; C. 
Sandford; K. Feeney; P. Lorenzo; G. Berionni; H. Mayr; V. K. Aggarwal, J. Am. Chem. Soc. 2017, 139, 15324; C. Shu; 
A. Noble; V. K. Aggarwal, Angew. Chem. Int. Ed. 2019, 58, 3870; A. Fawcett; T. Biberger; V. K. Aggarwal, Nat. 
Chem. 2019, 11, 117. 
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15 Results 
15.1 Single-Pot Access to Bisorganoborinates: Applications in Zweifel Olefination 
 
Reprinted with permission from A. N. Baumann, A. Music, P. Spieß, N. Hilgert, M. Köllen, D. Didier, Org. 
Lett. 2019, 21, 2189. Copyright© 2019 American Chemical Society. 
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16 Outlook 
With this new method for a general synthesis of bisorganoborinates in hands, combination with an 
unprecedented electrochemical sequence could also lead to a Zweifel-like coupling, but without the 
need for any additives (Scheme 6). 
 
Scheme 6: Proposed electrochemical transformation of bisorganoborinates 1.23 towards coupling products 
1.26 without the use of iodine/base as additive.  
Following an in situ trapping of Grignard reagents as trialkoxy-organoboronates and formation of 
bisorganoborinates 1.23, an electrochemical oxidation step could lead to the oxidized radical zwitter 
ion 1.24. According to a 1,2-metalate rearrangement towards the radical adduct 1.25 and a final 
elimination of the radical *B(OR)2 the desired Zweifel product 1.26 could be obtained.  
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17 Introduction 
Tetraorganoborates are organic compounds of the formula [BR4]-, wherein the residues are 
tetrahedrally bound to boron. One of the most popular tetraorganoborate is sodium tetraphenyl 
borate (2.01), as it is widely used in organic and analytical chemistry (tradename: Kalignost®) (Figure 
1).103 
 
Figure 1: Most used tetraorganoborate in literature: sodium tetraphenyl borate, also known as Kalignost®. 
17.1 Synthesis of Tetraorganoborates  
The first characterized tetraorganoborate was lithium tetraphenyl borate (2.04), which was 
synthesized in 1949 by Wittig and co-workers (Scheme 7).104  Different methods for the formation of 
lithium tetraphenylborate are reported and Wittig described the use of triphenylborane (2.02) and 
phenyllithium (2.03) in ether.  
 
Scheme 7: First reported synthesis of lithium tetraphenylborate by Wittig.  
A few years later, Wittig and Raff came up with another route towards lithium tetraphenylborate. In 
this case, boron trifluoride etherate complex (2.05) was mixed with 4 equivalents of  
 
103 K. Utsumi; L. Packer, Arch. Biochem. Biophys. 1967, 122, 509; P. Abley; J. Halpern, Chem. Commun. 1971, 20, 
1238; P. G. Ciattini; E. Morera; G. Ortar, Tetrahedron Lett. 1992, 33, 4815; N. A. Bumagin; V. V. Bykov, Tetrahedron 
1997, 53, 14437; D. Villemin; M. J. Gómez-Escalonilla; J.-F. Saint-Clair, Tetrahedron Lett. 2001, 42, 635; T. Ohe; S. 
Uemura, Bull. Chem. Soc. Jpn. 2003, 76, 1423; J. Yan; W. Hu; G. Rao, Synthesis 2006, 6, 0943; H. Mizuno; H. 
Sakurai; T. Amaya; T. Hirao, Chem. Commun. 2006, 48, 5042; L. Bai; J.-X. Wang, Adv. Synth. Catal. 2008, 350, 315. 
H. Zeng; R. Hua, J. Org. Chem. 2008, 73, 558; W.-J. Zhou; K.-H. Wang; J.-X. Wang; Z.-R. Gao, Tetrahedron 2010, 
66, 7633; R. B. Bedford: P. B. Brenner; E. Carter; J. Clifton; P. M. Cogswell; N. J. Gower; M. F. Haddow; J. N. Harvey; 
J. A. Kehl; D. M. Murphy; E. C. Neeve; M. L. Neidig; J. Nunn; B. E. R. Snyder; J. Taylor, Organometallics 2014, 33, 
5767; Z. Lu; R. Lavendomme; O. Burghaus; J. R. Nitschke, Angew. Chem. 2019, 131, 9171. 
104 G. Wittig; G. Keicher; A. Rückert; P. Raff, Liebigs Ann. Chem. 1949, 563, 110. 
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phenyllithium (2.03) (Scheme 8).105 Moreover, an analogue method for the preparation of the sodium 
derivative was reported, using phenylmagnesium bromide, followed by treatment with a saturated 
sodium carbonate solution. 
 
Scheme 8: Formation of lithium tetraphenylborate by the treatment of boron trifluoride etherate (2.05) with 
phenyllithium (2.03). 
A special class of tetraorganoborates are the BARF-anions or sometimes called Kobayashi anions. The 
BARF-anions, with the formula [BArF4]-, were synthesized by Kobayashi and his group in 1984, building 
up on the method reported by Wittig (Scheme 9).106 The ArF within the formula indicates the presence 
of fluorinated groups on the tetraorganoborate salt. Beside the work of Kobayashi, it is worth noting 
that the first synthesis of a BARF-Anion, the lithium tetra(pentafluorophenyl)borate (LiBArF20) goes 
back to the work of Massey and Park from 1964.107 
 
Scheme 9: Synthesis towards the BARF-anion BArF24- by the group of Kobayashi. 
In the synthesis reported by Kobayashi, 1-iodo-3,5-bis(trifluoromethyl)benzene (2.06) was used for the 
formation of Grignard species 2.07, followed by a slow addition of boron trifluoride etherate  
(Scheme 9). The sodium salt of the BArF24- anion was finally obtained after workup with sodium 
carbonate in excellent yield. In addition, Bergman and Yakelis reported in 2005 a similar preparation 
of NaBArF24 but with increased safety. In this work isopropylmagnesium chloride and 1-bromo-3,5-
bis(trifluoromethyl)benzene in THF were used, as (trifluoromethyl)aryl Grignards tend to exothermic 
 
105 G. Wittig; P. Raff, Liebigs Ann. Chem. 1951, 573, 195. 
106 H. Nishida; N. Takada; M. Yoshimura; T. Sonoda; H. Kobayashi, Bull. Chem. Soc. Jpn. 1984, 57, 2600. 
107 A. G. Massey; A. J. Park, J. Organometal. Chem. 1964, 2, 245. 
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decomposition in presence of remaining magnesium metal.108 BARF-anions are known to coordinate 
weaker than other commonly used anions, like BF4- or PF6-, and are therefore suitable candidates for 
reactions in which the nature of the anions can influence the outcome.109 
Going a step further to mixed tetraorganoborates, most procedures reported their synthesis by 
treatment of triarylboranes with suitable organometallic species.110 Scheme 10 depicts the first 
reaction of triphenylborane (2.02) with lithium phenylacetylide (2.09) to form the corresponding 
mixed tetraorganoborate 2.10.111  
 
Scheme 10: Formation of the first reported mixed tetraorganoborate by Wittig. 
Another meaningful method for the selective synthesis of mixed tetraorganoborates was reported in 
a Japanese patent from 2016.112 In this straightforward strategy, the commercially available organo-
trifluoroborates (2.11) react with three equivalents of an organometallic reagent (2.12) to generate 
mixed potassium tetraorganoborates (2.13) (Scheme 11).  
 
Scheme 11: Formation of mixed tetraorganoborates using organo-trifluoroborates and different organometallic 
reagents.  
 
108 N. A. Yakelis; R. G. Bergman, Organometallics 2005, 24, 3579; J. L. Leazer; R. Cvetovich; F.-R. Tsay; U. Dolling; 
T. Vickery; D. Bachert, J. Org. Chem. 2003, 68, 3695. 
109 S. G. Weber; D. Zahner: F. Rominger; B. F. Straub, Chem. Commun. 2012, 48, 11325; N. Hafezi; J. M. Holcroft; 
K. J. Hartlieb; E. J. Dale; N. A. Vermeulen; C. L. Stern; A. A. Sarjeant; J. F. Stoddard, Angew. Chem. Int. Ed. 2015, 
54, 456; L. Carreras; L. Rovira; M. Vaquero; I. Mon; E. Martin; J. Benet-Buchholz; A. Vidal-Ferran, RSC Adv. 2017, 
7, 32833; P. Pommerening; J. Mohr; J. Friebel; M. Oestreich, Eur. J. Org. Chem. 2017, 16, 2312. 
110 A. Suzuki; N. Miyaura; S. Abiko; M. Itoh; H. C. Brown; J. A. Sinclair; M. M. Midland, J. Am. Chem. Soc. 1973, 95, 
3080; K. Siegmann, P. S. Pregosin; L. M. Venanzi, Organometallics 1989, 8, 2659; T. Ishikawa; S. Nonaka; A. 
Ogawa; T. Hirao, Chem. Commun. 1998, 1209. J. D. Wilkey; G. B. Schuster, J. Am. Chem. Soc. 1991, 113, 2149; M. 
A. Kropp; M. Baillargeon; K. M. Park; K. Bhamidapaty; G. B. Schuster, J. Am. Chem. Soc. 1991, 113, 2155; J. R. 
Gardinier; P. J. Pellechia; M. D. Smith, J. Am. Chem. Soc. 2005, 127, 12448; M. Asay; B. Donnadieu; T. Amaya; Y. 
Tsukamura; T. Hirao, Adv. Synth. Catal. 2009, 351, 1025; W. W. Schoeller; G. Bertrand, Angew. Chem. Int. Ed. 
2009, 48, 4796. N. Ishida; W. Ikemoto; M. Narumi; M. Murakami, Org. Lett. 2011, 13, 3008;  
111 G. Wittig; P. Raff, Liebigs Ann. Chem. 1951, 573, 195; 
112 S. Atsushi, JP2016150925, 2016. 
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Considering the simplicity of this procedure, we adopted it to access mixed 
alkenyl(hetero)triarylborates 2.14 and their further transformation by oxidative electrochemical 
coupling (Figure 2). 
 
Figure 2: Alkenyl(hetero)triarylborates 2.14. 
17.2 Electrochemical Transformation of Tetraorganoborates 
Tetraorganoborates like tetraphenylborate and particularly the BARF-anion type are well studied with 
respect to electrochemical properties.113 Especially their electrochemical oxidation, first crossed by 
Geske in 1959, has led to unceasing interest over the following decades till now.114 In this reaction 
(Scheme 12), a homo coupling towards biphenyl (2.15) is initiated by an electrochemical oxidation of 
tetraphenylborate (2.14) at a platinum electrode. Geske suggested an intramolecular two electron 
process.115  
 
Scheme 12: Electrochemical oxidation of tetraphenylborate (counter ions have been omitted for more 
simplicity).   
Despite the early proposal on the nature of the mechanism, it is still unclear whether it follows an 
inter- or intramolecular pathway. Recently, Waldvogel and his group have tried to give new 
mechanistical insights and therefore studied the electrochemical stability of different BARF-anions and 
tetraphenylborates under electrochemical conditions.116 Cross-over experiments with two different 
 
113 F. Barrière; W. E. Geiger, J. Am. Chem. Soc. 2006, 128, 3980; W. E. Geiger; F. Barrière, Acc. Chem. Res. 2010, 
43, 1030. 
114 D. H. Geske, J. Phys. Chem. 1959, 63, 1062; W. R. Turner; P. J. Elving, Anal. Chem. 1965, 37, 207; E. E. Bancroft; 
H. N. Blount; E. G. Janzen, J. Am. Chem. Soc. 1979, 101, 3692; J. H. Morris; H. J. Gysling; D. Reed, Chem. Rev. 1985, 
85, 51. S. B. Beil; P. K. Pal; S. Chowdhury; M. G. B. Drew; D. Datta, New J. Chem. 2002, 26, 367; S. B. Beil; S. Möhle; 
P. Enders; S. R. Waldvogel, Chem. Commun. 2018, 54, 6128. 
115 D. H. Geske, J. Phys. Chem. 1962, 66, 1743. 
116 S. B. Beil; S. Möhle; P. Enders; S. R. Waldvogel, Chem. Commun. 2018, 54, 6128. 
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tetraorganoborates exclusively gave the corresponding homo coupling products without a coupling 
between each other, indicating an intramolecular process. 
Building on this finding, we set out to develop a new route towards the formation of 
alkenyl(hetero)triarylborates and further investigate their electrochemical oxidation (Scheme 13). This 
would give more evidence regarding the mechanism, electrochemical stability as well as open a new 
pathway of boron mediated olefinations in contrast to the classical Zweifel olefinations (see Chapter I 
”Zweifel Olefinations”).  
 
Scheme 13: New boron mediated transformations through electrochemical oxidation of tetraorganoborates.   
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18 Results 
18.1 Electrochemical Formation of Functionalized Alkenes using Tetraorganoborates 
As a first goal in the development of an electrochemical approach for the transformation of mixed 
potassium alkenyl(hetero)triarylborates 2.14, these organic salts had to be synthesized in a versatile 
and practical fashion (Scheme 14). Therefore, organometallic species (2.20), like Grignard- and 
organozinc reagents, were engaged with commercially available alkenyl trifluoro borates (2.19).  
 
Scheme 14: Synthesis of mixed potassium alkenyl(hetero)triarylborates.  
Unfortunately, due to the high solvophilicity in polar solvents, precipitation of most of these 
compounds was a major issue. Therefore, a more convenient and feasible two-pot procedure was 
designed (Scheme 15).  
 
Scheme 15: Two-Pot procedure for the functionalization of alkenyl trifluoro borates by an electrochemical 
oxidation.  
Simple workup and solvent switch from tetrahydrofuran to acetonitrile paved the way to an 
electrochemical oxidation step. In the electrification of tetraorganoborates, cheap and reusable glassy 
carbon electrodes were used.  It is worth noting that no inert conditions were necessary, as the 
alkenyl(hetero)triarylborates 2.14 are air and water stable. With this methodology in hands, a small 
library of different functionalized alkenes was accessed (Table 1). The isolated yields vary between 
23% (2.18-j) and 87% (2.18-p) over two steps.     
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Table 1: Functionalized alkenes by a two-pot procedure starting with alkenyl trifluoroborates.  
Entry Electrophile Organometallic reagent Product Yield[a] 
1 
 
  
2.18-a, 41% 
2 
  
 
2.18-b, 52% 
3 
 
 
 
2.18-c, 71% 
4 
 
 
2.18-d, 53% 
5 
 
 
2.18-e, 75% 
6 
 
 
2.18-f, 50% 
7 
 
 
 
2.18-g, 60% 
8 
 
 
2.18-h, 54% 
227 
 Part B - Chapter III 
 
Entry Electrophile Organometallic reagent Product Yield[a] 
9 
 
 
 
2.18-i, 54% 
10 
 
 
2.18-j, 23% 
11 
 
 
2.18-k, 29% 
12 
 
 
 
2.18-l, 77% 
13 
 
 
 
2.18-m, 52% 
14 
 
 
2.18-n, 56% 
15 
 
 
2.18-o, 43% 
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Entry Electrophile Organometallic reagent Product Yield[a] 
16 
 
 
 
2.18-p, 87% 
17 
 
 
2.18q, 40% 
18 
 
 
2.18-r, 86% 
[a] Yield of isolated, analytically pure product. 
In this first scope only strained alkenyl trifluoroborates were chosen as starting material, as there is no 
possibility of obtaining different isomers due the proposed reaction pathway (Scheme 16). In the 
mechanism given below, the reaction of an E-alkenyl(hetero)triarylborate 2.21 is proposed. Following 
an initial anodic oxidation on the alkene moiety, the generated radical cation 2.22/23 can then be 
attacked by one of the phenyl residues attached to the boron atom, leading to an intermediary 
zwitterionic structure 2.24.  
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Scheme 16: Proposed intramolecular mechanism of the electrochemical oxidation of tetraorganoborates.  
By regenerating the aromaticity of the zwitterionic structure 2.24, the radical 2.25 is formed. After a 
second anodic oxidation, the cation 2.26 can then be attacked by a nucleophile such as water, leading 
to the coupled product (2.27). It should be noted that during the transformation, the double bond of 
the starting alkene (2.21) no longer exists. If the C-C bond rotation has time to happen, two different 
stereoisomers with a Z- or E-configuration can be obtained. To gain further evidence for this proposed 
mechanism, a second library was synthesized using Z- or E-alkenyl trifluoroborates (Table 2). Again, a 
two-pot procedure was conducted (Scheme 17). 
 
Scheme 17: Two-Pot procedure for the functionalization of Z- or E-alkenyl trifluoroborates by an 
electrochemical oxidation. 
As expected, starting with E-alkenyl trifluoroborates, only the E-isomer (2.27-a-l) was obtained (up to 
99:1 E/Z selectivity). Starting with Z-alkenyl trifluoroborates, the sterically favoured E-isomer should 
be formed. With lower ratios of selectivity (2.27-m-o) the E-isomers were in fact the major product, 
supporting the previously proposed mechanism. In contrast to the Zweifel reaction, in which a 
stereoinversion is usually observed the electrochemical variant strongly depends on which alkenyl 
trifluoroborates are used and can therefore be regarded as stereoconvergent. Furthermore, due to no 
coupling products between the alkenyl groups of two alkenyl(hetero)triarylborates an intermolecular 
reaction can be ruled out.   
For sensitive functional groups such as nitriles, esters or pyridines the use of the corresponding 
organozinc species was required, but lower yields were obtained (2.27-b/l). Nevertheless, the use of 
organozinc compounds is necessary, since alkenyl trifluoroborates can be implemented, which carry 
more sensitive functional groups. As an application, this new method was applied for the late stage 
functionalization of dehydroepiandrosterone (DHEA) (2.27-p) and the synthesis of the naturally 
occurring pinosylvin (2.27-f).  
In summary, this stereoconvergent and intramolecular transformation of alkenyl(hetero)triarylborates 
provided further insight into the mechanism and presents a novel route for a catalyst- and transition-
metal-free coupling of alkenes with aromatic ring systems.  
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Table 2: Functionalized alkenes by a two-pot procedure starting with Z- or E-alkenyl trifluoroborates.  
Entry Electrophile 
Organometallic 
reagent 
Product Yield[a] 
1 
 
 
 
 
 
2.27-a, 69% 
E/Z = 99:1[b] 
2 
 
 
2.27-b, 29% 
E/Z = 99:1[b] 
3 
 
 
2.27-c, 74% 
E/Z = 99:1[b] 
4 
 
 
2.27-d, 63% 
E/Z = 99:1[b] 
5 
 
 
2.27-e, 57% 
E/Z = 99:1[b] 
6 
 
 
pinosylvin 
2.27-f[c], 
42% 
E/Z = 99:1[b] 
231 
 Part B - Chapter III 
 
Entry Electrophile 
Organometallic 
reagent 
Product Yield[a] 
7 
  
 
2.27-g, 68% 
E/Z = 99:1[b] 
8 
 
 
 
2.27-h, 70% 
E/Z = 99:1[b] 
9 
 
 
 
2.27-i, 71% 
E/Z = 99:1[b] 
10 
 
 
 
2.27-j, 55% 
E/Z = 99:1[b] 
11 
 
 
2.27-k, 68% 
E/Z = 99:1[b] 
12 
  
 
2.27-l, 25% 
E/Z = 95:5[b] 
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Entry Electrophile 
Organometallic 
reagent 
Product Yield[a] 
13 
 
 
 
2.27-m, 
65% 
E/Z = 
90:10[b] 
14 
 
 
2.27-n, 57% 
E/Z = 93:7[b] 
15 
 
 
 
2.27-o, 57% 
E/Z = 
84:16[b] 
16 
  
 
DHEA-derivative 
2.27-p, 57% 
[a] Yield of isolated, analytically pure product. [b] Determined by GC. [c] coupled product was treated with BBr3 
in DCM for the formation of unprotected OH-groups.  
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19 Outlook 
According to the successful electrochemical Zweifel olefination of alkenyl(hetero)triarylborates, a 
biaryl coupling of tetraarylborates would be conceivable. This would lead to a scalable and catalyst 
free strategy (Scheme 18), which would open an alternative way of thinking about coupling reactions 
in general.  
 
Scheme 18: Possible electrochemical oxidation of mixed tetraarylborates towards the hetero coupled biaryls.    
Going a step further, a hetero coupling of tetraarylborates with a suitable dummy system would avoid 
the excess of organometallic reagent (Scheme 19). In this strategy, the easily accessible borate 
template 2.31 would be treated successively with the two organometallic species to be linked in the 
electrochemical step.117 The mixed tetraorganoborate 2.32 would then be coupled and the remaining 
borinic nitrile 2.33 could be recovered by treatment with potassium bifluoride and used for another 
coupling step.  
 
Scheme 19: Possible electrochemical oxidation of tetraorganoborate 2.32 by designing a reusable template.   
 
 
 
 
117 J. A. Sprenger; J. Landmann; M. Drisch; N. Ignat´ev; M. Finze, Inorg. Chem. 2015, 54, 7, 3403. 
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Part B, Chapter II, contains typical experimental procedures and selected examples for each topic 
discussed in this part. The full supporting information can be downloaded free of charge on the 
corresponding website of the publishing company. 
20 General Considerations 
For general considerations see Part A - Chapter IV “General Consideration”. Electrochemical 
oxidations on scales smaller than 1.0 mmol were performed on the IKA ElectraSyn 2.0. All used 
electrodes were purchased from IKA, except the RVC (reticulated vitreous carbon) electrodes which 
were obtained from Goodfellow (Carbon – Vitreous – 3000C Foam, Thickness: 6.35 mm, Bulk density: 
0.05 g/cm3, Porosity: 96.5%, Pores/cm: 24). Electrochemical oxidations on a scale greater than 
1.0 mmol were performed on an Atlas 0931 Potentiostat – Galvanostat using a two-electrode 
undivided cell setup. 
21 Experimental for Chapter I 
21.1 Single-Pot Access to Bisorganoborinates: Applications in Zweifel Olefination 
Mg-insertion/Ligand exchange with alkenyllithium reagents/Zweifel olefination sequence 
 
A reaction tube was charged with lithium chloride (1.1 mmol, 1.1 equiv.) and magnesium turnings 
(1.6 mmol, 1.6 equiv.). Lithium chloride was dried in vacuo using a heat gun (600 °C, 5 min). After 
addition of THF/Dioxane (9:1, 1 M) and 1,2-dibromoethane (1 drop), the mixture was heated to boil 
with a heat gun to activate the magnesium, before tributylborate (1.0 mmol, 1.0 equiv.) was added at 
once. Heteroaryl/aryl bromide 3.01 (1.0 mmol, 1.0 equiv.) was dissolved in THF (1 M) and added to the 
activated magnesium suspension at room temperature dropwise (to hold approx. 23 °C a water bath 
was used). The mixture was then stirred for one hour at approx. 23 °C to yield a THF-solution of the 
magnesium organoboronate 3.02. The solution was cooled to -78 °C, before the solution of 
alkenyllithium reagent 3.03 (1.0 - 2.0 mmol, 1.0 - 2.0 equiv.) was added dropwise. After half an hour, 
the reaction was warmed to 0 °C and let stir for 1 h. After the solution was cooled down again to -78 °C, 
iodine (3.0 mmol, 3.0 equiv.), dissolved in THF (1.5 M), was added dropwise. After 20 min, a suspension 
of sodium methoxide (5.0 mmol, 5.0 equiv.) in methanol (2.5 M) was added at once. After reaching 
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room temperature the reaction is completed. The reaction was then treated by the addition of a 
saturated solution of sodium thiosulfate and extracted with diethyl ether (3 x 20 mL). The combined 
organic phases were dried over magnesium sulfate, filtered and concentrated under reduced pressure. 
The crude product was purified by flash column chromatography with appropriate solvent mixtures to 
afford the desired coupling product 3.04. 
 
2-Chloro-4-(1-ethoxyvinyl)-1-fluorobenzene (selected example) 
Using 4-bromo-2-chloro-1-fluorobenzene provided the product (0.58 mmol, 116 mg, 58%) as 
colourless oil.  
Rf = 0.41 (hexane, UV, PAA, KMnO4). 1H NMR (400 MHz, Benzene-d6) δ 7.72 (dd, J = 7.2, 2.2 Hz, 1H), 
7.19 (dq, J = 6.4, 2.3 Hz, 2H), 6.61 (t, J = 8.7 Hz, 1H), 4.38 (d, J = 2.9 Hz, 1H), 3.95 (d, J = 2.9 Hz, 1H), 3.43 
(q, J = 7.0 Hz, 2H), 1.03 ppm (t, J = 7.0 Hz, 3H).13C NMR (101 MHz, Benzene-d6) δ 158.46 (d, J = 249.8 
Hz), 158.05 (d), 134.31 (d, J = 3.9 Hz), 125.5, 125.4, 121.2 (d, J = 18.0 Hz), 116.3 (d, J = 21.2 Hz), 82.9 (d, 
J = 1.4 Hz), 63.5, 14.3 ppm. LRMS (DEP/EI-Orbitrap): m/z [%]: 200.0 (7), 174.0 (14), 172.0 (19), 159.0 
(33), 158.0 (7), 157.0 (100), 156 (11), 130.0 (11), 129.0 (35). HRMS (EI-Orbitrap): m/z: [M+] Calcd for 
C10H10ClFO: 200.0404; found: 200.0396. IR (Diamond-ATR, neat) ?̃?max: 2976 (w), 2279 (w), 1692 (w), 
1593 cm-1 (w).  
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1H NMR (400 MHz, benzene-d6)  
 
13C NMR (101 MHz, benzene-d6) 
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Mg-insertion/Ligand exchange with alkenylmagnesium reagents/Zweifel olefination sequence 
 
A reaction tube was charged with lithium chloride (1.1 mmol, 1.1 equiv.) and magnesium turnings 
(1.6 mmol, 1.6 equiv.). Lithium chloride was dried in vacuo using a heat gun (600 °C, 5 min). After 
addition of THF/Dioxane (9:1, 1 M) and 1,2-dibromoethane (1 drop), the mixture was heated to boil 
with a heat gun to activate the magnesium, before tributylborate (1.0 mmol, 1.0 equiv.) was added at 
once. Heteroaryl/aryl bromide 3.01 (1.0 mmol, 1.0 equiv.) was dissolved in THF (1 M) and added to the 
activated magnesium suspension at room temperature dropwise (to hold approx. 23 °C a water bath 
was used). The mixture was then stirred for one hour at approx. 23 °C to yield a THF-solution of the 
magnesium organoboronate 3.02. After that a solution of alkenylmagnesium reagent 3.05 (3.0 mmol, 
3.0 equiv.) was added dropwise at 0 °C and stirred for another 1 h at 0 °C. After the solution was cooled 
down again to -78 °C, iodine (3.0 mmol, 3.0 equiv.), dissolved in THF (1.5 M), was added dropwise. After 
20 min a suspension of sodium methoxide (5.0 mmol, 5.0 equiv.) in methanol (2.5 M) was added at 
once. After reaching room temperature the reaction is completed. The reaction was then treated by 
the addition of saturated solution of sodium thiosulfate and extracted with diethyl ether (3 x 20 mL). 
The combined organic phases were dried over magnesium sulfate, filtered and concentrated under 
reduced pressure. The crude product was purified by flash column chromatography with appropriate 
solvent mixtures to afford the desired coupling product 3.06. 
 
1-Bromo-3-methoxy-5-(prop-1-en-2-yl)benzene (selected example) 
Using 1,3-dibromo-5-(prop-1-en-2-yl)benzene provided the product (0.34 mmol, 154 mg, 34%) as 
colourless oil. 
Rf = 0.59 (hexane/EtOAc 98:2, UV, PAA, KMnO4). 1H NMR (400 MHz, CDCl3) δ 7.17 (t, J = 1.6 Hz, 1H), 
6.94 (t, J = 2.0 Hz, 1H), 6.89 (t, J = 1.9 Hz, 1H), 5.34 (s, 1H), 5.09 (s, 1H), 3.79 (s, 3H), 2.09 ppm (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 160.3, 144.4, 142.1, 122.8, 121.4, 115.7, 114.0, 111.0, 55.6, 21.9 ppm. 
LRMS (DEP/EI-Orbitrap): m/z [%]: 229.0 (11), 228.0 (98), 227.0 (11), 226 (100), 188.0 (15), 186.0 (15). 
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HRMS (EI-Orbitrap): m/z: [M+] Calcd for C10H10ClFO: 200.0404; found: 200.0396. IR (Diamond-ATR, 
neat) ?̃?max: 2938 (br/w), 1599 (m), 1557 (vs), 1560 cm-1 (s). 
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1H NMR (400 MHz, CDCl3)  
 
13C NMR (101 MHz, CDCl3) 
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22 Experimental for Chapter II 
22.1 Electrochemical Formation of Functionalized Alkenes using Tetraorganoborates 
General Procedure: Two-pot Procedure for the synthesis of functionalized alkenes starting from 
potassium alkenyl trifluoroborate salts 
 
A 25 mL Schlenk flask was charged with the corresponding potassium trifluoroborate salt 2.19/2.21 
(0.4 mmol, 1.0 equiv.) and 2 mL of THF were added. The mixture was cooled to 0 °C and the aryl-
Grignard reagent (1.2 mmol, 3.0 equiv.) was added dropwise over 30 minutes via syringe pump. After 
addition, the reaction mixture was allowed to stir for further 10 min at 0 °C and was then quenched 
with 5 mL of H2O and extracted with EtOAc (3 x 40 mL). If no phase separation was observed, 5 mL of 
aqueous saturated K2CO3 solution was added. The combined organic phases were filtered and 
concentrated under reduced pressure. The crude tetraorganoborate 2.14 was then dissolved in 8 mL 
of HPLC grade MeCN and transferred into a 10 mL IKA glass vial. The reaction was started using the IKA 
ElectraSyn 2.0 with GCE (glassy carbon electrodes) as working and counter electrode (5 mA, 3.0 F, 
1.3 mA/cm2, 700 rpm stirring). The crude was then treated with water and extracted with diethyl ether 
(3 x 15 mL). The combined organic phases were dried over magnesium sulfate, filtered, concentrated 
under reduced pressure and purified by flash-column chromatography on silica gel with the 
appropriate solvent mixture to obtain pure 2.18/2.27. 
Adaptation for the use of arylzinc reagents 
After addition of the arylzinc instead of the aryl-Grignard reagent via syringe pump, the reaction was 
heated to 40 °C for 16 hours to ensure full conversion of the potassium trifluoroborate salt into the 
desired salt 2.14. General procedure was then followed to give products 2.18/2.27. 
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1-Methoxy-4-(prop-1-en-2-yl)benzene (2.18-a) 
Using potassium trifluoro(prop-1-en-2-yl)borate and (4-methoxyphenyl)magnesium bromide 
according to general procedure, provided 2.18-a (0.16 mmol, 24 mg, 41%) as colourless oil. 
1H NMR (400 MHz, CDCl3) δ 7.45-7.37 (m, 2H), 6.91-6.82 (m, 2H), 5.29 (dd, J = 1.6, 0.8 Hz, 1H), 5.04-
4.96 (m, 1H), 3.82 (s, 3H), 2.13 ppm (dd, J = 1.5, 0.8 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 158.5, 142.7, 
133.9, 126.7, 113.7, 111.3, 56.1, 22.1 ppm. Analytical data in accordance to literature.118 
 
1-(Cyclopent-1-en-1-yl)-3,5-bis(trifluoromethyl)benzene (2.18-b) (selected example) 
Using potassium cyclopent-1-en-1-yltrifluoroborate and (3,5-bis(trifluoromethyl)phenyl)magnesium 
bromide according to general procedure, provided 2.18-b (0.21 mmol, 58 mg, 52%) as colourless oil. 
Rf = 0.6 (hexane, UV, PAA). 1H NMR (400 MHz, CDCl3) δ 7.81 (s, 2H), 7.70 (s, 1H), 6.39 (td, J = 2.7, 1.4 
Hz, 1H), 2.78-2.71 (m, 2H), 2.62-2.56 (m, 2H), 2.08 ppm (p, J = 7.6 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 
140.3, 138.9, 131.6 (q, J = 32.9 Hz), 130.7, 125.5, 123.5 (q, J = 272.5 Hz), 120.3 (q, J = 3.9 Hz), 33.7, 33.2, 
23.4 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 280.1 (100), 261.1 (50), 245.1 (40), 211.1 (100), 191.1 (45), 
142.1 (25). HRMS (EI-Orbitrap): m/z: [M+] Calcd. for C13H10F6+: 280.0687; found: 280.0680. 
  
 
118 W. J. Kerr; A. J. Morrison; M. Pazicky; T. Weber, Org. Lett. 2012, 14, 2250. 
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1H NMR (400 MHz, CDCl3)  
 
13C NMR (101 MHz, CDCl3) 
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4'-Methoxy-2,3,4,5-tetrahydro-1,1'-biphenyl (2.18-c) 
Using potassium cyclohex-1-en-1-yltrifluoroborate and (4-methoxyphenyl)magnesium bromide 
according to general procedure, provided 2.18-c (0.28 mmol, 53 mg, 71%) as colourless oil. 
1H NMR (400 MHz, CDCl3) δ 7.36-7.29 (m, 2H), 6.90-6.82 (m, 2H), 6.03 (tt, J = 3.9, 1.7 Hz, 1H), 3.81 (s, 
3H), 2.38 (dtd, J = 6.1, 3.2, 2.6, 1.4 Hz, 2H), 2.19 (dddd, J = 8.7, 6.3, 4.4, 2.5 Hz, 2H), 1.82-1.72 (m, 2H), 
1.68-1.61 ppm (m, 2H). 13C NMR (101 MHz, CDCl3) δ 158.5, 136.0, 135.5, 126.0, 123.3, 113.6, 55.4, 
27.6, 26.0, 23.2, 22.3 ppm. Analytical data in accordance to literature.119 
  
3',4'-Dichloro-2,3,4,5-tetrahydro-1,1'-biphenyl (2.18-d) 
Using potassium cyclohex-1-en-1-yltrifluoroborate and (3,4-dichlorophenyl)magnesium bromide 
according to general procedure, provided 2.18-d (0.21 mmol, 48 mg, 53%) as colourless oil. 
Rf = 0.80 (hexane, UV, PAA, KMnO4). 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 2.2 Hz, 1H), 7.35 (d, J = 8.4 
Hz, 1H), 7.20 (dd, J = 8.4, 2.2 Hz, 1H), 6.13 (td, J = 4.0, 1.9 Hz, 1H), 2.33 (tdd, J = 6.2, 2.5, 1.7 Hz, 2H), 
2.20 (dddd, J = 9.2, 6.7, 4.7, 2.7 Hz, 2H), 1.82-1.72 (m, 2H), 1.70-1.58 ppm (m, 2H). 13C NMR (101 MHz, 
CDCl3) δ 142.0, 134.8, 132.3, 130.2, 130.1, 127.0, 126.7, 123.5, 27.3, 26.0, 23.0, 22.0 ppm. LRMS 
(DEP/EI-Orbitrap): m/z (%): 226.0 (70), 211.0 (20), 191.0 (60), 163.0 (100). HRMS (EI-Orbitrap): m/z: 
[M+] Calcd. for C12H12Cl2+: 226.0316; found: 226.0309. 
 
 
 
119 M. O. Ganiu; A- H. Cleveland; J. L. Paul; R. Kartika, Org. Lett. 2019, 21, 5611. 
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4'-Fluoro-2,3,4,5-tetrahydro-1,1'-biphenyl (2.18-e) 
Using potassium cyclohex-1-en-1-yltrifluoroborate and (4-fluorophenyl)magnesium bromide 
according to general procedure, provided 2.18-e (0.30 mmol, 53 mg, 75%) as colourless oil. 
1H NMR (400 MHz, CDCl3) δ 7.41-7.29 (m, 2H), 7.03-6.92 (m, 2H), 6.06 (tt, J = 3.9, 1.8 Hz, 1H), 2.37 (ddq, 
J = 6.3, 4.3, 2.2 Hz, 2H), 2.20 (dtt, J = 8.8, 6.1, 2.6 Hz, 2H), 1.85-1.74 (m, 2H), 1.70-1.60 ppm (m, 2H). 13C 
NMR (101 MHz, CDCl3) δ 161.75 (d, J = 244.9 Hz), 138.8, 135.6, 126.37 (d, J = 7.7 Hz), 124.7, 114.88 (d, 
J = 21.2 Hz).,27.5, 25.8, 23.0, 22.1 ppm. Analytical data in accordance to literature.120 
 
4'-Fluoro-2,3,4,5-tetrahydro-1,1'-biphenyl (2.18-f) 
Using potassium cyclohex-1-en-1-yltrifluoroborate and (4-(dimethylamino)phenyl)magnesium 
bromide according to general procedure, provided 2.18-f (0.20 mmol, 40 mg, 70%) as colourless oil. 
1H NMR (400 MHz, CDCl3) δ 7.34-7.27 (m, 2H), 6.74-6.65 (m, 2H), 6.00 (tt, J = 4.0, 1.7 Hz, 1H), 2.38 (ddt, 
J = 6.2, 3.9, 2.0 Hz, 2H), 2.19 (dtd, J = 8.2, 4.0, 2.2 Hz, 2H), 1.82-1.72 (m, 2H), 1.69-1.59 ppm (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 149.6, 136.1, 131.3, 125.7, 121.7, 112.6, 40.9, 27.5, 26.0, 23.3, 22.5 ppm. 
Analytical data in accordance to literature.121 
 
 
 
 
120 K. Ishizuka; H. Seike; T. Hatakeyama; M. Nakamura, J. Am. Chem. Soc. 2010, 132, 13117. 
121 W. D. Oosterbaan; P. C. M. van Gerven; C. A. van Walree; M. Koeberg; J. J. Piet; R. W. A. Havenith; J. W. 
Zwikker; L. W. Jenneskens; R. Gleiter, Eur. J. Org. Chem. 2003, 3117. 
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4-Phenyl-3,6-dihydro-2H-pyran (2.18-g) 
Using potassium (3,6-dihydro-2H-pyran-4-yl)trifluoroborate and phenylmagnesium bromide according 
to general procedure, provided 2.18-g (0.24 mmol, 38 mg, 60%) as colourless oil. 
1H NMR (400 MHz, CDCl3) δ 7.42-7.38 (m, 2H), 7.37-7.32 (m, 2H), 7.30-7.24 (m, 1H), 6.13 (tt, J = 3.0, 
1.6 Hz, 1H), 4.33 (q, J = 2.8 Hz, 2H), 3.94 (t, J = 5.5 Hz, 2H), 2.74-2.34 ppm (m, 2H). 13C NMR (101 MHz, 
CDCl3) δ 140.4, 134.2, 128.6, 127.4, 124.8, 122.6, 66.0, 64.6, 27.3 ppm. Analytical data in accordance 
to literature.122 
 
4-(3,5-Bis(trifluoromethyl)phenyl)-3,6-dihydro-2H-pyran (2.18-h) 
Using potassium (3,6-dihydro-2H-pyran-4-yl)trifluoroborate and (3,5-bis(trifluoromethyl)phenyl) 
magnesium bromide according to general procedure, provided R2.04-h (0.22 mmol, 64 mg, 54%) as 
colourless oil. 
Rf = 0.3 (hexane/EtOAc 9:1, UV, PAA, KMnO4). 1H NMR (400 MHz, CDCl3) δ 7.80 (s, 2H), 7.76 (s, 1H), 
6.31 (tt, J = 3.0, 1.6 Hz, 1H), 4.36 (q, J = 2.9 Hz, 2H), 3.96 (t, J = 5.4 Hz, 2H), 2.59-2.51 ppm (m, 2H). 13C 
NMR (101 MHz, CDCl3) δ 142.3, 132.3, 131.89 (q, J = 33.1 Hz), 126.3, 125.05-124.76 (m), 123.51 (d, J = 
271.9 Hz), 121.09-120.83 (m), 65.8, 64.2, 27.1 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 296.1 (100), 
278.1 (70), 267.1 (80), 254.1 (20). HRMS (EI-Orbitrap): m/z: [M+] Calcd. for C13H10F6+: 296.0636; found: 
296.0628. 
 
 
 
122 B. Guo; G. Schwarzwalder; J. T. Njardarson, Angew. Chem. Int. Ed. 2012, 51, 5675. 
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4-(3,5-Dimethylphenyl)-3,6-dihydro-2H-pyran (2.18-i) 
Using potassium (3,6-dihydro-2H-pyran-4-yl)trifluoroborate and (3,5-dimethylphenyl)magnesium 
bromide according to general procedure, provided R2.04-i (0.22 mmol, 64 mg, 54%) as colourless oil. 
Rf = 0.35 (hexane/EtOAc 98:2, UV, KMnO4). 1H NMR (400 MHz, CDCl3) δ 7.02 (s, 2H), 6.92 (s, 1H), 6.09 
(tt, J = 3.1, 1.6 Hz, 1H), 4.32 (q, J = 2.8 Hz, 2H), 3.93 (t, J = 5.5 Hz, 2H), 2.54-2.48 (m, 2H), 2.33 ppm (s, 
6H). 13C NMR (101 MHz, CDCl3) δ 140.5, 138.0, 134.4, 129.1, 122.8, 122.2, 66.0, 64.7, 27.5, 21.5 ppm. 
LRMS (DEP/EI-Orbitrap): m/z (%): 188.1 (100), 173.1 (90), 159.1 (35), 145.1 (100). 
 
4-(Benzo[b]thiophen-5-yl)-3,6-dihydro-2H-pyran (2.18-j) 
Using potassium (3,6-dihydro-2H-pyran-4-yl)trifluoroborate and benzo[b]thiophen-5-ylmagnesium 
bromide according to general procedure, provided 2.18-j (0.09 mmol, 20 mg, 23%) as colourless oil. 
Rf = 0.60 (hexane/EtOAc 98:2, UV, PAA, KMnO4). 1H NMR (400 MHz, CDCl3) δ 7.74-7.68 (m, 2H), 7.37-
7.29 (m, 2H), 7.23 (d, J = 5.5 Hz, 1H), 6.09 (tt, J = 3.0, 1.6 Hz, 1H), 4.26 (q, J = 2.8 Hz, 2H), 3.88 (t, J = 5.5 
Hz, 2H), 2.59-2.46 ppm (m, 2H). 13C NMR (101 MHz, CDCl3) δ 140.0, 138.7, 136.9, 134.3, 124.2, 122.6, 
122.4, 121.7, 119.7, 66.1, 64.7, 27.7 ppm. HRMS (EI-Orbitrap): m/z: [M+] Calcd. for C13H12OS+: 
216.0609; found: 216.0604. 
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5-(3,6-Dihydro-2H-pyran-4-yl)-2,2-difluorobenzo[d][1,3]dioxole (2.18-k) 
Using potassium (3,6-dihydro-2H-pyran-4-yl)trifluoroborate and (2,2-difluorobenzo[d][1,3]dioxol-5-
yl)magnesium bromide according to general procedure, provided 2.18-k (0.12 mmol, 27 mg, 29%) as 
colourless oil. 
Rf = 0.30 (hexane/EtOAc 98:2, UV, PAA). 1H NMR (400 MHz, CDCl3) δ 7.11-7.06 (m, 2H), 7.03-6.99 (m, 
1H), 6.06 (tt, J = 3.0, 1.6 Hz, 1H), 4.31 (q, J = 2.8 Hz, 2H), 3.93 (t, J = 5.4 Hz, 2H), 2.47 ppm (ttd, J = 5.5, 
2.7, 1.6 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 143.63 (d, J = 120.1 Hz), 143.0, 137.1, 132.8, 131.8 (t, J = 
255.1 Hz), 123.3, 120.1, 109.3, 106.3, 65.9, 64.5, 27.6 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 240.0 
(70), 222.0 (20), 196.9 (25), 158.0 (50). HRMS (EI-Orbitrap): m/z: [M+] Calcd. for C12H10F2O3+: 240.0598; 
found: 240.0592. 
 
4-(4-Methoxyphenyl)-3,6-dihydro-2H-thiopyran (2.18-l) 
Using potassium (3,6-dihydro-2H-thiopyran-4-yl)trifluoroborate and (4-methoxyphenyl)magnesium 
bromide according to general procedure, provided 2.18-l (0.31 mmol, 63 mg, 77%) as colourless oil. 
Rf = 0.5 (hexane/EtOAc 98:2, UV, PAA). 1H NMR (400 MHz, CDCl3) δ 7.30-7.25 (m, 2H), 6.89-6.84 (m, 
2H), 6.12-6.08 (m, 1H), 3.81 (s, 3H), 3.33 (dt, J = 4.5, 2.3 Hz, 2H), 2.88 (t, J = 5.8 Hz, 2H), 2.70-2.64 ppm 
(m, 2H). 13C NMR (101 MHz, CDCl3) δ 159.0, 137.7, 135.6, 126.7, 120.3, 113.8, 55.4, 28.8, 26.4, 
25.3 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 206.1 (100), 191.0 (5), 177.0 (60), 147.1 (75). 
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tert-Butyl 4-(4-methoxyphenyl)-3,6-dihydropyridine-1(2H)-carboxylate (2.18-m) 
Using potassium (1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridin-4-yl)trifluoroborate and (4-
methoxyphenyl)magnesium bromide according to general procedure, provided 2.18-m (0.21 mmol, 
60 mg, 52%) as colourless oil. 
1H NMR (400 MHz, CDCl3) δ 7.35-7.29 (m, 2H), 6.93-6.83 (m, 2H), 5.94 (s, 1H), 4.05 (s, 2H), 3.81 (s, 3H), 
3.63 (t, J = 5.7 Hz, 2H), 2.50 (s, 2H), 1.49 ppm (s, 9H). 13C NMR (101 MHz, CDCl3) δ 159.0, 133.4, 131.8, 
127.8, 126.1, 113.9, 79.8, 55.4, 43.6, 40.7, 39.2, 28.6 ppm. Analytical data in accordance to 
literature.123 
 
tert-Butyl 4-(4-fluorophenyl)-3,6-dihydropyridine-1(2H)-carboxylate (2.18-n) 
Using potassium (1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridin-4-yl)trifluoroborate and (4-
fluorophenyl)magnesium bromide according to general procedure, provided 2.18-n (0.22 mmol, 
62 mg, 56%) as colourless oil. 
1H NMR (400 MHz, CDCl3) δ 7.37-7.29 (m, 2H), 7.06-6.98 (m, 2H), 5.97 (s, 1H), 4.09-4.02 (m, 2H), 3.63 
(t, J = 5.7 Hz, 2H), 2.49 (s, 2H), 1.49 ppm (s, 9H). 13C NMR (101 MHz, CDCl3) δ 162.23 (d, J = 246.2 Hz), 
155.0, 136.9, 134.8, 126.60 (d, J = 7.9 Hz), 115.35 (d, J = 21.3 Hz), 113.0, 79.9, 43.8, 39.9, 28.6, 27.7 ppm. 
Analytical data in accordance to literature.124 
 
 
123 A. Music; C. Hoarau; N. Hilgert; F. Zischka; D. Didier, Angew. Chem. Int. Ed. 2019, 58, 1188. 
124 D.J. Wustrow; L. D. Wise, Synthesis 1991, 11, 993. 
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tert-Butyl 4-(4-(trifluoromethyl)phenyl)-3,6-dihydropyridine-1(2H)-carboxylate (2.18-o) 
Using potassium (1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridin-4-yl)trifluoroborate and (4-
(trifluoromethyl)phenyl)magnesium bromide according to general procedure, provided 2.18-o 
(0.17 mmol, 56 mg, 43%) as colourless oil. 
1H NMR (400 MHz, CDCl3) δ 7.58 (d, J = 8.7 Hz, 2H), 7.46 (d, J = 8.1 Hz, 2H), 6.12 (s, 1H), 4.15-4.00 (m, 
2H), 3.65 (t, J = 5.7 Hz, 2H), 2.53 (s, 2H), 1.49 ppm (s, 9H). 13C NMR (101 MHz, CDCl3) δ 154.9, 144.2, 
134.7, 129.27 (q, J = 32.6 Hz), 126.77 (q, J = 129.9 Hz), 125.51 (q, J = 3.8 Hz), 125.3, 123.0, 80.0, 44.0, 
39.8, 28.6, 27.4 ppm. Analytical data in accordance to literature.125 
 
8-(4-Methoxyphenyl)-1,4-dioxaspiro[4.5]dec-7-ene (2.18-p) 
Using potassium trifluoro(1,4-dioxaspiro[4.5]dec-7-en-8-yl)borate and (4-methoxyphenyl)magnesium 
bromide according to general procedure, provided 2.18-p (0.35 mmol, 86 mg, 87%) as colourless oil. 
1H NMR (400 MHz, CDCl3) δ 7.35-7.31 (m, 2H), 6.88-6.81 (m, 2H), 5.90 (td, J = 3.9, 2.0 Hz, 1H), 4.02 (s, 
4H), 3.80 (s, 3H), 2.66-2.60 (m, 2H), 2.51-2.42 (m, 2H), 1.92 ppm (t, J = 6.5 Hz, 2H). 13C NMR (101 MHz, 
CDCl3) δ 158.7, 135.7, 134.2, 126.4, 120.0, 113.6, 108.0, 64.6, 55.4, 36.2, 31.5, 27.0 ppm. Analytical 
data in accordance to literature.126 
 
 
125 Merck & Co., US6303593, 2001, B1. 
126 A. J. Pearson; I. C. Richards; D. V. Gardner, J. Org. Chem. 1984, 49, 3887. 
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8-(3,5-Difluorophenyl)-1,4-dioxaspiro[4.5]dec-7-ene (2.18-q) 
Using potassium trifluoro(1,4-dioxaspiro[4.5]dec-7-en-8-yl)borate and (3,5-
difluorophenyl)magnesium bromide according to general procedure, provided 2.18-q (0.16 mmol, 
40 mg, 40%) as colourless oil. 
Rf = 0.10 (hexane/EtOAc 98:2, UV, PAA). 1H NMR (400 MHz, CDCl3) δ 6.95-6.85 (m, 2H), 6.66 (tt, J = 8.8, 
2.3 Hz, 1H), 6.05 (tt, J = 4.0, 1.6 Hz, 1H), 4.02 (s, 4H), 2.63-2.56 (m, 2H), 2.49-2.44 (m, 2H), 1.91 ppm (t, 
J = 6.6 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 163.1 (dd, J = 246.8, 13.3 Hz), 144.9 (t, J = 9.2 Hz), 134.6 (t, 
J = 2.6 Hz), 124.0, 108.3-107.9 (m), 107.6, 102.1 (t, J = 25.6 Hz), 64.7, 36.2, 31.3, 26.6 ppm. LRMS 
(DEP/EI-Orbitrap): m/z (%): 252.1 (35), 237.0 (5) 164.0 (15), 151.0 (15), 86.0 (100). HRMS (EI-Orbitrap): 
m/z: [M+] Calcd. for C14H14F2O2+: 252.0962; found: 252.0956. 
 
8-(4-Fluorophenyl)-1,4-dioxaspiro[4.5]dec-7-ene (2.18-r) 
Using potassium trifluoro(1,4-dioxaspiro[4.5]dec-7-en-8-yl)borate and (4-fluorophenyl)magnesium 
bromide according to general procedure, provided 2.18-r (0.34 mmol, 80 mg, 86%) as colourless oil. 
Rf = 0.15 (hexane/EtOAc 98:2, UV, PAA). 1H NMR (400 MHz, CDCl3) δ 7.38-7.31 (m, 2H), 7.02-6.95 (m, 
2H), 5.93 (tt, J = 3.9, 1.6 Hz, 1H), 4.02 (s, 4H), 2.63 (tq, J = 6.4, 2.1 Hz, 2H), 2.48-2.44 (m, 2H), 1.92 ppm 
(t, J = 6.5 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 162.1 (d, J = 245.4 Hz), 137.7 (d, J = 3.2 Hz), 135.5, 126.8 
(d, J = 7.8 Hz), 121.6 (d, J = 1.4 Hz), 115.1 (d, J = 21.2 Hz), 107.8, 64.6, 36.2, 31.4, 27.1 ppm. LRMS 
(DEP/EI-Orbitrap): m/z (%): 234.1 (25), 219.1 (5), 146.0 (20), 133.0 (20), 86.0 (100). HRMS (EI-Orbitrap): 
m/z: [M+] Calcd. for C14H15FO2+: 234.1056; found: 234.1049. 
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(E)-1-Styryl-4-(trifluoromethyl)benzene (2.27-a) 
Using potassium (E)-trifluoro(styryl)borate and (4-(trifluoromethyl)phenyl)magnesium bromide 
according to general procedure, provided 2.27-a (0.28 mmol, 68 mg, 69%, E/Z = 99:1) as white solid. 
1H NMR (400 MHz, CDCl3) δ 7.61 (s, 4H), 7.56-7.52 (m, 2H), 7.43-7.37 (m, 2H), 7.33-7.27 (m, 1H), 7.20 
(d, J = 16.4 Hz, 1H), 7.12 ppm (d, J = 16.4 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 140.9, 136.7, 131.3, 
129.36 (q, J = 32.4 Hz), 128.9, 128.4, 127.2, 126.9, 126.7, 125.77 (q, J = 3.9 Hz), 123.0 ppm. Analytical 
data in accordance to literature.127 
 
(E)-4-Styrylbenzonitrile (2.27-b) 
Using potassium (E)-trifluoro(styryl)borate and (4-cyanophenyl)zinc(II) iodide according to general 
procedure, provided 2.27-b (0.12 mmol, 24 mg, 29%, E/Z = 99:1) as white solid. 
1H NMR (400 MHz, CDCl3) δ 7.69-7.61 (m, 2H), 7.61-7.57 (m, 2H), 7.56-7.52 (m, 2H), 7.43-7.37 (m, 2H), 
7.36-7.29 (m, 1H), 7.22 (d, J = 16.3 Hz, 1H), 7.09 ppm (d, J = 16.3 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 
141.9, 136.4, 132.6, 132.5, 129.0, 128.8, 127.0, 127.0, 126.8, 119.2, 110.7 ppm. Analytical data in 
accordance to literature.128 
 
 
127 S. W. Youn; B. S. Kim; A. R. Jagdale, J. Am. Chem. Soc. 2012, 134, 11308. 
128 H. Li; J. Lü; J. Lin; Y. Huang; M. Cao; R. Cao, Chem. Eur. J. 2013, 19, 15661. 
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(E)-1-Styrylnaphthalene (2.27-c) 
Using potassium (E)-trifluoro(styryl)borate and naphthalen-1-ylmagnesium bromide according to 
general procedure, provided 2.27-c (0.30 mmol, 68 mg, 74%, E/Z = 99:1) as white solid. 
1H NMR (400 MHz, CDCl3) δ 8.23 (d, J = 8.0 Hz, 1H), 7.93-7.86 (m, 2H), 7.82 (d, J = 8.2 Hz, 1H), 7.76 (d, 
J = 6.1 Hz, 1H), 7.65-7.60 (m, 2H), 7.58-7.48 (m, 3H), 7.42 (t, J = 7.7 Hz, 2H), 7.34-7.29 (m, 1H), 7.17 ppm 
(d, J = 16.0 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 137.7, 135.1, 133.8, 131.9, 131.5, 128.9, 128.8, 128.2, 
127.9, 126.8, 126.2, 126.0, 125.9, 125.8, 123.9, 123.8 ppm. Analytical data in accordance to 
literature.129 
 
(E)-5-Styrylbenzofuran (2.27-d) 
Using potassium (E)-trifluoro(styryl)borate and benzofuran-5-ylmagnesium bromide according to 
general procedure, provided 2.27-d (0.25 mmol, 55 mg, 63%, E/Z = 99:1) as white solid. 
Rf = 0.3 (hexane, UV, PAA, KMnO4). 1H NMR (400 MHz, CDCl3) δ 7.72 (s, 1H), 7.62 (d, J = 2.2 Hz, 1H), 
7.55-7.47 (m, 4H), 7.37 (t, J = 7.7 Hz, 2H), 7.31-7.19 (m, 2H), 7.10 (d, J = 16.3 Hz, 1H), 6.78 ppm (d, J = 
2.2 Hz, 1H).  13C NMR (101 MHz, CDCl3) δ 154.8, 145.7, 137.6, 132.6, 129.1, 128.8, 128.0, 127.8, 127.5, 
126.5, 123.1, 119.4, 111.7, 106.8 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 220.0 (100), 204.9 (10), 191.0 
(60).  HRMS (EI-Orbitrap): m/z: [M+] Calcd. for C16H12O+: 220.0888; found: 220.0882. 
 
129 M. Das; D. F. O´Shea, Org. Lett. 2016, 18, 336. 
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(E)-2-Styryldibenzo[b,d]furan (2.27-e) 
Using potassium (E)-trifluoro(styryl)borate and dibenzo[b,d]furan-2-ylmagnesium bromide according 
to general procedure, provided 2.27-e (0.23 mmol, 62 mg, 57%, E/Z = 99:1) as white solid. 
1H NMR (400 MHz, CDCl3) δ 8.09 (d, J = 1.8 Hz, 1H), 7.99 (dd, J = 7.8, 1.3 Hz, 1H), 7.64 (dd, J = 8.5, 1.8 
Hz, 1H), 7.61-7.53 (m, 4H), 7.48 (ddd, J = 8.4, 7.3, 1.4 Hz, 1H), 7.43-7.35 (m, 3H), 7.32-7.25 (m, 2H), 
7.17 ppm (d, J = 16.3 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 156.8, 156.0, 137.5, 132.6, 128.9, 128.7, 
128.1, 127.6, 127.5, 126.5, 126.1, 124.8, 124.2, 123.0, 120.9, 118.6, 111.9, 111.9 ppm. Analytical data 
in accordance to literature.130 
 
(E)-5-Styrylbenzene-1,3-diol (pinosylvin) (2.27-f) 
Using potassium (E)-trifluoro(styryl)borate and (3,5-dimethoxyphenyl)magnesium bromide according 
to general procedure, provided (E)-1,3-dimethoxy-5-styrylbenzene. For removal of the methyl groups, 
the crude compound, after electrochemical oxidation, was dissolved in CH2Cl2 (4 mL), cooled down to 
-20 °C and treated with a solution of BBr3 (1.6 mmol, 4 equiv.) dissolved in 1 mL CH2Cl2. The reaction 
was let warm to room temperature. After completion, the reaction was treated with water and 
extracted with dichloromethane (3 × 10 mL) and washed with a solution of saturated aqueous sodium 
chlorid (1 × 10 mL). The combined organic phases were dried over magnesium sulfate, filtered and 
concentrated in vacuo. The crude was purified by flash column chromatography with appropriate 
solvent mixture to provide 2.27-f (0.23 mmol, 62 mg, 57%, E/Z = 99:1) as white solid. 
1H NMR (400 MHz, CDCl3) δ 7.51-7.46 (m, 2H), 7.39-7.33 (m, 2H), 7.29-7.26 (m, 1H), 7.05 (d, J = 16.3 
Hz, 1H), 6.96 (d, J = 16.3 Hz, 1H), 6.58 (d, J = 2.2 Hz, 2H), 6.28 (t, J = 2.2 Hz, 1H), 4.76 ppm (s, 2H). 13C 
 
130 C. Wang; I. Piel; F. Glorius, J. Am. Chem. Soc. 2009, 131, 4194. 
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NMR (101 MHz, CDCl3) δ 156.9, 140.0, 136.8, 129.6, 128.7, 127.9, 127.1, 126.6, 126.3, 106.2, 
102.2 ppm. Analytical data in accordance to literature.131 
 
(E)-1-Fluoro-4-styrylbenzene (2.27-g) 
Using potassium (E)-trifluoro(styryl)borate and (4-fluorophenyl)magnesium bromide according to 
general procedure, provided 2.27-g (0.27 mmol, 54 mg, 68%, E/Z = 99:1) as white solid. 
1H NMR (400 MHz, CDCl3) δ 7.46-7.35 (m, 4H), 7.27 (t, J = 7.7 Hz, 2H), 7.21-7.13 (m, 1H), 7.03-6.92 ppm 
(m, 4H). 13C NMR (101 MHz, CDCl3) δ 162.34 (d, J = 247.2 Hz), 137.2, 133.51 (d, J = 3.3 Hz), 128.7, 128.49 
(d, J = 2.5 Hz), 128.01 (d, J = 8.0 Hz), 127.7, 127.5, 126.5, 115.65 ppm (d, J = 21.6 Hz). Analytical data in 
accordance to literature.132 
 
(E)-1,3-Difluoro-5-(2-phenylprop-1-en-1-yl)benzene (2.27-h) 
Using potassium (E)-trifluoro(2-phenylprop-1-en-1-yl)borate and (3,5-difluorophenyl)magnesium 
bromide according to general procedure, provided 2.27-h (0.28 mmol, 64 mg, 70%, E/Z = 99:1) as white 
solid. 
Rf = 0.6 (hexane, UV, PAA, KMnO4). 1H NMR (400 MHz, CDCl3) δ 7.56-7.46 (m, 2H), 7.43-7.36 (m, 2H), 
7.35-7.29 (m, 1H), 6.94-6.83 (m, 2H), 6.74-6.66 (m, 2H), 2.28 (d, J = 1.4 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 162.97 (dd, J = 247.4, 13.2 Hz), 143.4, 141.62 (t, J = 9.7 Hz), 140.1, 128.6, 127.9, 126.2, 125.80 
(t, J = 2.6 Hz), 112.21-111.70 (m), 102.01 (t, J = 25.5 Hz), 17.8 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 
230.1 (100), 215.1 (80), 195.1 (20). HRMS (EI-Orbitrap): m/z: [M+] Calcd. for C14H15FO2+: 230.0907; 
found: 230.0896. 
 
131 J. Yang; C. Wang; Y. Sun; X. Man; Y. Li; F. Sun, Chem. Commun. 2019, 13, 1903. 
132 A. L. Isfahani; I. Mohammadpoor-Baltork; V. Mirkhani; A. R. Khosropour; M. Moghadam; S. Tangestaninejad; 
R. Kia, Adv. Synth. Catal. 2013, 355, 957. 
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(E)-4-(4-Fluorostyryl)-1,1'-biphenyl (2.27-i) 
Using potassium (E)-(2-([1,1'-biphenyl]-4-yl)vinyl)trifluoroborate and (4-fluorophenyl)magnesium 
bromide according to general procedure, provided 2.27-i (0.28 mmol, 78 mg, 71%, E/Z = 99:1) as white 
solid. 
1H NMR (400 MHz, CDCl3) δ 7.69-7.55 (m, 6H), 7.55-7.42 (m, 4H), 7.40-7.31 (m, 1H), 7.15-7.00 ppm (m, 
4H). 13C NMR (101 MHz, CDCl3) δ 162.35 (d, J = 247.2 Hz), 140.6, 140.4, 136.2, 133.50 (d, J = 3.3 Hz), 
128.8, 128.1, 128.0, 127.5, 127.4, 126.9, 126.9, 115.67 ppm (d, J = 21.6 Hz). Analytical data in 
accordance to literature.133 
 
(E)-2-Chloro-1-fluoro-4-(4-fluorostyryl)benzene (2.27-j) 
Using potassium (E)-trifluoro(4-fluorostyryl)borate and (3-chloro-4-fluorophenyl)magnesium bromide 
according to general procedure, provided 2.27-j (0.22 mmol, 55 mg, 55%, E/Z = 99:1) as white solid. 
Rf = 0.40 (hexane, UV, KMnO4). 1H NMR (400 MHz, CDCl3) δ 7.53 (dd, J = 7.0, 2.2 Hz, 1H), 7.48-7.43 (m, 
2H), 7.33 (ddd, J = 8.6, 4.6, 2.2 Hz, 1H), 7.12 (t, J = 8.7 Hz, 1H), 7.06 (t, J = 8.7 Hz, 2H), 6.99 (d, J = 16.3 
Hz, 1H), 6.90 ppm (d, J = 16.3 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 162.7 (d, J = 247.8 Hz), 157.6 (d, J = 
249.8 Hz), 134.7 (d, J = 3.9 Hz), 133.0 (d, J = 3.4 Hz), 128.7 (d, J = 2.4 Hz), 128.3, 128.2, 126.2 (d, J = 7.0 
Hz), 126.1 (t, J = 2.1 Hz), 121.5 (d, J = 18.1 Hz), 116.9 (d, J = 21.5 Hz), 115.9 ppm (d, J = 21.7 Hz). LRMS 
(DEP/EI-Orbitrap): m/z (%): 250.0 (95), 235.0 (15), 214.1 (100), 195.1 (30). 
 
133 Y. Liu; P. Liu; Y. Wei, Chin. J. Chem. 2017, 35, 1141. 
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(E)-2-(4-Fluorostyryl)dibenzo[b,d]furan (2.27-k) 
Using potassium (E)-trifluoro(4-fluorostyryl)borate and dibenzo[b,d]furan-2-ylmagnesium bromide 
according to general procedure, provided 2.27-k (0.27 mmol, 78 mg, 68%, E/Z = 99:1) as white solid. 
Rf = 0.30 (hexane, UV, PAA, KMnO4). 1H NMR (400 MHz, CDCl3) δ 8.07 (d, J = 1.8 Hz, 1H), 7.98 (d, J = 6.9 
Hz, 1H), 7.62 (dd, J = 8.6, 1.8 Hz, 1H), 7.60-7.45 (m, 5H), 7.37 (td, J = 7.5, 1.0 Hz, 1H), 7.18 (d, J = 16.3 
Hz, 1H), 7.14-7.05 ppm (m, 3H). 13C NMR (101 MHz, CDCl3) δ 162.40 (d, J = 246.9 Hz), 156.8, 156.0, 
133.74 (d, J = 3.3 Hz), 132.4, 128.53 (d, J = 2.5 Hz), 128.00 (d, J = 7.8 Hz), 127.5, 126.9, 126.0, 124.9, 
124.2, 123.0, 120.8, 118.5, 115.9, 115.7, 111.95 ppm (d, J = 4.4 Hz). LRMS (DEP/EI-Orbitrap): m/z (%): 
288.1 (100), 273.0 (5), 257.1 (30). HRMS (EI-Orbitrap): m/z: [M+] Calcd. for C20H13FO+: 288.0950; found: 
288.0945. 
 
Ethyl (E)-3-(pyridin-3-yl)acrylate (2.27-l) 
Using potassium (E)-(3-ethoxy-3-oxoprop-1-en-1-yl)trifluoroborate and pyridin-3-ylzinc(II) iodide 
according to general procedure, provided 2.27-l (0.10 mmol, 18 mg, 25%, E/Z = 99:1) as colourless oil. 
Rf = 0.25 (hexane/EtOAc 6:4, UV, PAA). 1H NMR (400 MHz, CDCl3) δ 8.75 (d, J = 2.2 Hz, 1H), 8.61 (dd, J 
= 4.8, 1.6 Hz, 1H), 7.84 (dt, J = 7.9, 2.0 Hz, 1H), 7.67 (d, J = 16.1 Hz, 1H), 7.37-7.31 (m, 1H), 6.51 (d, J = 
16.1 Hz, 1H), 4.28 (q, J = 7.1 Hz, 2H), 1.35 ppm (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 166.5, 
151.1, 149.9, 141.0, 134.3, 130.4, 123.9, 120.6, 61.0, 14.4 ppm. HRMS (EI-Orbitrap): m/z: [M+] Calcd. 
for C10H11NO2+: 177.0790; found: 177.0782. 
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(E)-1,3-difluoro-5-styrylbenzene (2.27-m) 
Using potassium (Z)-trifluoro(styryl)borate and (3,5-difluorophenyl)magnesium bromide according to 
general procedure, provided 2.27-m (0.26 mmol, 56 mg, 65%, E/Z = 90:10) as white solid. 
1H NMR (400 MHz, CDCl3) δ 7.56-7.48 (m, 2H), 7.43-7.35 (m, 2H), 7.35-7.28 (m, 1H), 7.11 (d, J = 16.2 
Hz, 1H), 7.05-6.97 (m, 3H), 6.71 ppm (tt, J = 8.8, 2.3 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 163.41 (dd, J 
= 247.5, 13.2 Hz), 140.88 (t, J = 9.6 Hz), 136.4, 131.4, 129.0, 128.5, 126.9, 126.62 (t, J = 2.9 Hz), 109.46-
108.89 (m), 102.85 ppm (t, J = 25.7 Hz). Analytical data in accordance to literature.134 
 
(E)-1-Styrylnaphthalene (2.27-n) 
Using potassium (Z)-trifluoro(styryl)borate and naphthalen-1-ylmagnesium bromide according to 
general procedure, provided 2.27-n (0.17 mmol, 37 mg, 43%, E/Z = 93:7) as white solid. 
1H NMR (400 MHz, CDCl3) δ 8.23 (d, J = 8.0 Hz, 1H), 7.93-7.86 (m, 2H), 7.82 (d, J = 8.2 Hz, 1H), 7.76 (d, 
J = 6.1 Hz, 1H), 7.65-7.60 (m, 2H), 7.58-7.48 (m, 3H), 7.42 (t, J = 7.7 Hz, 2H), 7.34-7.29 (m, 1H), 7.17 ppm 
(d, J = 16.0 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 137.7, 135.1, 133.8, 131.9, 131.5, 128.9, 128.8, 128.2, 
127.9, 126.8, 126.2, 126.0, 125.9, 125.8, 123.9, 123.8 ppm. Analytical data in accordance to 
literature.135 
 
134 T. Ismail; S. Shafi; J. Srinivas; D. Sarkar; Y. Qurishi; J. Khazir; M. S. Alam; H. M. S. Kumar, Bioorg. Chem. 2016, 
64, 97. 
135 M. Das; D. F. O´Shea, Org. Lett. 2016, 18, 336. 
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(E)-2-(3,5-Bis(trifluoromethyl)styryl)-6-methoxynaphthalene (2.27-o) 
Using potassium (Z)-trifluoro(2-(6-methoxynaphthalen-2-yl)vinyl)borate and (3,5-
bis(trifluoromethyl)phenyl) magnesium bromide according to general procedure, provided 2.27-o 
(0.22 mmol, 89 mg, 56%, E/Z = 84:16) as colourless oil. 
Rf = 0.25 (hexane, UV, PAA, KMnO4). 1H NMR (400 MHz, CDCl3) δ 7.94 (s, 2H), 7.85 (s, 1H), 7.77-7.68 
(m, 4H), 7.38 (d, J = 16.3 Hz, 1H), 7.24 (d, J = 15.1 Hz, 1H), 7.19-7.12 (m, 2H), 3.94 ppm (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 158.4, 139.8, 134.9, 132.8, 132.13 (q, J = 33.1 Hz), 131.5, 129.9, 129.1, 127.8, 127.6, 
126.2, 124.8, 123.9, 122.2, 120.81-120.57 (m), 119.5, 106.1 ppm. LRMS (DEP/EI-Orbitrap): m/z (%): 
396.1 (100), 381.0 (5), 353.0 (10), 333.0 (5). HRMS (EI-Orbitrap): m/z: [M+] Calcd. for C21H14F6O2+: 
396.0949; found: 396.0949. 
 
tert-Butyl(((3S,8R,9S,10R,13S,14S)-17-(4-fluorophenyl)-10,13-dimethyl-
2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)dimethylsilane 
(2.27-p) 
Using potassium ((3S,8S,9S,10R,13S,14S)-3-((tert-butyldimethylsilyl)oxy)-10,13-dimethyl-
2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)trifluoroborate and 
(4-fluorophenyl)magnesium bromide according to general procedure, provided 2.27-p (0.25 mmol, 
121mg, 63%) as colourless oil. 
Rf = 0.2 (hexane/EtOAc 98:2, UV, PAA, KMnO4). 1H NMR (400 MHz, CDCl3) δ 7.32 (dd, J = 8.7, 5.5 Hz, 
2H), 7.01-6.95 (m, 2H), 5.85 (dd, J = 3.4, 1.8 Hz, 1H), 5.38-5.33 (m, 1H), 3.50 (tt, J = 11.0, 4.7 Hz, 1H), 
2.34-2.15 (m, 3H), 2.09-1.96 (m, 3H), 1.85-1.41 (m, 10H), 1.33-1.20 (m, 1H), 1.06 (s, 3H), 1.03 (s, 3H), 
0.90 (s, 9H), 0.07 ppm (s, 6H). 13C NMR (101 MHz, CDCl3) δ 161.9 (d, J = 245.4 Hz), 153.8, 141.9, 133.4 
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(d, J = 3.5 Hz), 128.2 (d, J = 7.7 Hz), 127.1, 120.9, 114.9 (d, J = 21.0 Hz), 72.6, 57.7, 50.5, 50.4, 47.2, 42.9, 
37.3, 36.8, 35.4, 32.1, 31.6, 30.5, 26.0, 20.9, 19.4, 18.3, 16.6, −4.6 ppm. 
 
